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Glucocorticoids are the most effective anti -inflammatory agents currently available, but a variety of adverse effects limit their clinical 
usefulness. This work explores further two facets of the interaction between glucocorticoids and the skin, with the aim of identifying means 
of reducing glucocorticoid toxicity. 
(a) Metabolism of glucocorticoids by skin: Human skin is active in the terminal metabolism of cortisol to cortisone, but the biological 
implications of this process in skin are uncertain. Because there are technical difficulties in dealing with human skin, an animal model, the 
nude mouse, has been evaluated for its suitability to the study of the metabolism of corticosterone to 11B- dehydrocorticosterone (the 
homologous reaction in rodents of cortisol to cortisone conversion in man); a process mediated by 1 l ß- hydroxysteroid dehydrogenase. The 
skin of the nude mouse has previously been shown to be appropriate for pharmacokinetic and phannacodynamic studies of glucocorticoids. 
In this model, skin 11B- hydroxysteroid dehydrogenase had an apparent Km for corticosterone of 37 p.M. Skin 11B- hydroxysteroid 
dehydrogenase was up- regulated, in -vivo, by active glucocorticoids and was NADP dependent. By comparison, kidney 1 Iß- hydroxysteroid 
dehydrogenasé had a higher apparent Km (120 µM) for corticosterone, used NAD and NADP with equal facility and was not regulated in- 
vivo by glucocorticoids. These data suggest that the skin may possess an isoform distinct from that of the kidney. Immunohistochemical 
studies demonstrated that 11ß -hydroxysteroid dehydrogenase was most abundant in the epidermis. In- vitro, this enzyme was markedly 
inhibited by glycyrrhetinic acid, the active principle in liquorice. Using the classic bioassay of glucocorticoid activity (skin vasoconstrictor 
assay), it was found that co- application of glycyrrhetinic acid and hydrocortisone resulted in potentiation of skin vasoconstrictor activity 
of hydrocortisone. This suggests that inhibition of hydrocortisone metabolism might explain the long recognised but poorly understood anti - 
inflammatory action of liquorice and its congeners and may represent a novel means of targeting glucocorticoid therapy. 
(b) Skin vasoconstrictor response (blanching) to topical glucocorticoids: Glucocorticoids applied topically to human skin produce 
vasoconstriction in dermal vessels, the degree of which correlates closely with the potency and clinically efficacy of these compounds. 
Although previous workers had noted heterogeneity in blanching responses to glucocorticoids, this was never systematically studied. In 
qualitative studies, it was shown that skin blanching was inducible by RU- 28362, a specific glucocorticoid receptor (type II) agonist and 
blocked by RU- 38486, a glucocorticoid antagonist. Moreover, aldosterone (type I receptor agonist) failed to produce blanching. In addition 
blanching was observed in an individual with clinical and biochemical features of aldosterone receptor deficiency. These data therefore 
suggest that blanching is a glucocorticoid specific phenomenon mediated via the classical glucocorticoid receptor. To test whether skin 
vasoconstrictor response might reflect glucocorticoid sensitivity, blanching responses was tested in a clinical model of glucocorticoid 
resistance. In patients with glucocorticoid resistant asthma, skin responsiveness was also found to be diminished. Responsiveness was also 
somewhat diminished in a cohort of asthmatics on long term prednisolone. Skin vasoconstrictor responsiveness might therefore reflect 
systemic sensitivity to glucocorticoids and previous glucocorticoid use might reduce skin responsiveness. When tested against other parameter 
indicating systemic glucocorticoid effects, acute systemic glucocorticoid exposure over 10 days did not affect skin responsiveness. It is possible 
that resistance to the anti -inflammatory effects of glucocorticoids might accrue from long term exposure and it might therefore be possible 
to use the skin vasoconstrictor assay a marker for glucocorticoid sensitivity - a novel purpose for this long used assay. 
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AIMS AND OBJECTIVES 
6 
CHAPTER 1.1: GLUCOCORTICOIDS 
1.1a GENERAL: 
Cortisol and corticosterone are steroid hormones derived from the adrenal 
cortex. One of the earliest understood and demonstrable actions was a profound 
influence upon glucose metabolism (Melby, 1974; Bowes et al., 1991) and hence the term 
glucocorticoid is used to describe these compounds and their congeners. Cortisol is the 
principal naturally occurring glucocorticoid in man. In some lower species e.g. rodents, 
corticosterone is the homologue. 
Glucocorticoids have a variety of effects and because glucocorticoid receptors 
are ubiquitous (Ballard, etal.,1974; LaPointe and Baxter, 1989) they influence virtually 
all tissues. The physiologic effects vary depending on the target tissue and may be 
anabolic or catabolic. Catabolic actions are predominant in lymphoid tissues whereas 
in the liver the overall effects are anabolic. Other effects include maintenance of blood 
pressure, salt and water balance, and interactions with other hormones (La Pointe and 
Baxter, 1989). These influences are crucial to normal homeostasis. Under periods of 
stress or illness their value in this regard becomes obvious such that when there is 
glucocorticoid deficiency, simple illness can become life -threatening. There are also 
7 
important effects on foetal growth (Reinisch, el al., 1978) and tissue differentiation 
(Torday, 1980; Murphy, 1981). In the foetal lung for example glucocorticoids are 
crucial to maturational processes (Torday, 1980). Effects on growth persist long after 
delivery (Loeb, 1976). 
The effects of glucocorticoids on intermediary metabolism are complex. In 
respect of glucose metabolism, the net effect of glucocorticoid (action) is 
"glucose- sparing" i.e. reduced glucose uptake by peripheral tissues as a result of insulin 
antagonism, increased hepatic glycogenolysis as well as increased gluconeogenesis 
(Baxter and Tyrrell, 1986). There are other important effects upon intermediary 
metabolism. Thus protein catabolism is affected by their action releasing amino acids 
that can be channelled into gluconeogenesis (Baxter and Tyrrell, 1986). The effects 
upon lipids are site dependent such that although lipolysis is the dominant feature, there 
is the tendency for centripetal deposition of fat. This occurs because glucocorticoids 
sensitize subcutaneous tissue in the arms and legs to the lipolytic effects of 
catecholamines (Melby 1974). On the other hand, subcutaneous tissue of the trunk 
exhibit lipogenesis in response to glucocorticoids (Melby, 1974). 
It is the anti -inflammatory and immunomodulatory properties of these 
8 
compounds, however, that make them important therapeutically. In response to 
physical, chemical or immunologic stimuli the host mounts an inflammatory response. 
Glucocorticoids act at almost all phases (Tsurufuji and Ohuchi, 1989) to muffle the 
inflammatory response which if left unchecked could itself threaten homeostasis 
(Munck et al, 1984). In this regard glucocorticoids have been shown to alter the white 
cell count (Parrillo and Fauci, 1979), to stabilize lysosomal membranes, reduce capillary 
permeability, and decrease phagocytosis (Fauci and Dale, 1974; Fauci et al., 1976). In 
addition, they suppress synthesis of pro -inflammatory proteins e.g. interleukin 2 
(Goodwin et al, 1986) as well as stimulate other proteins (lipocortins) which are 
inhibitory to pro -inflammatory eicosanoids (Peers and Flower, 1990). 
Glucocorticoids are today vital weapons in our therapeutic armamentarium. 
They are by far the most effective anti- inflammatory agents in current use and a diverse 
range of human diseases is amenable to treatment with them. Millions of prescriptions 
are written for them annually in the United States alone (Christy, 1971). Yet as recently 
as forty five years ago the benefits of this group of drugs were unknown. 
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1_lb I-IISTORICAL: 
Although the adrenals were recognized anatomically as far back as the 
Renaissance (Murray, 1989), their physiological role remained obscure for four 
centuries. It was the observations of Thomas Addison that were to spark interest in this 
area. In 1855 Addison recorded that disease of the "suprarenal capsules" was associated 
with weakness, fatigue, hyperpigmentation, anaemia, feeble heart action, hypotension, 
and gastrointestinal irritability; a symptom -complex which today bears his name 
(Thorn, 1949). Soon thereafter, Brown - Sequard demonstrated the deleterious effects 
of bilateral adrenalectomy in experimental animals (Murray, 1989), establishing the 
crucial physiological role of the adrenals. Almost another hundred years were to elapse 
before the pharmacologic effects of extracts of the adrenal cortex were appreciated. The 
discovery that was to revolutionize scientific therapeutics was the consequence of 
perseverance, scientific collaboration and mere chance (Kendall, 1949). 
The symptoms of rheumatoid disease as well as asthma and psoriasis were 
known to be ameliorated in some patients by concurrence of pregnancy or the 
appearance of jaundice, a marker of liver disease. Hench, a clinician and 
rheumatologist, surmised that bile, bilirubin, or steroids might have a therapeutic role 
10 
in these diseases. Bile and bilirubin proved ineffective (Hench et al., 1949). In the 
meantime, Reichstein and Kendall (reviewed in Kendall, 1949) had devised means of 
synthesizing adrenal steroids, interestingly enough, from bile acids. The stage was set 
for a revolutionary discovery. 
On September 21, 1948, Hench prescribed the first dose of Kendall's Substance 
E (cortisone) (Hench et al., 1949). Days later, patients who were virtually crippled by 
rheumatoid arthritis had displayed a dramatic response to this new treatment. The era 
of glucocorticoid therapy for inflammatory disease had begun. Following this 
discovery, glucocorticoid therapy was applied to any disease in which inflammation was 
known to or be suspected of playing a role in the pathogenesis. Current uses of 
glucocorticoids are summarized in Table 1.1, according to Thomas and Keenan, (1986). 
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Table 1.1: Therapeutic uses of Glucocorticoids (Thomas and Keenan, 1986) 
Replacement therapy: adrenocortical insufficiency: 
Addison's disease 
Adrenalectomy 
Congenital adrenal hyperplasia 
Palliative therapy: anti -inflammatory and immune suppression: 
Arthritis and tendinitis 








Collagen vascular disorders 
Neuromuscular disorders (myasthenia gravis) 
Specialized therapy: 
Fetal respiratory distress syndrome 
Idiopathic nephrotic syndrome 
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1.1c ADVERSE EFFECTS: 
It was not long after the introduction of glucocorticoids to therapeutics that the 
two -edged nature of this form of therapy was revealed. Undesirable effects of cortisone 
were soon described (Boland and Headley, 1950). Hench himself had reported signs of 
mild hypercortisolism eg. water retention and weight gain and in a few cases more 
marked clinical features of Cushing's syndrome (Hench et al., 1949). Soon thereafter, 
Fraser et al., (1952) reported adrenal atrophy and irreversible shock in a patient with 
rheumatoid arthritis who had been on cortisone treatment for eight months. Adrenal 
insufficiency still remains a feared complication for those on long term therapy. Other 
effects also soon became apparent. Harvey Cushing had noted a tendency for bony 
fracture in his description of the state of endogenous glucocorticoid excess (Cushing, 
1932). Likewise, Curtess (et al., 1954) were among the first to recognize that exogenous 
glucocorticoids had similar deleterious effects upon the skeleton. The adverse effects 
of glucocorticoids are numerous but broadly, they can be classified into two categories. 
(A) Withdrawal effects associated with sudden cessation of prolonged therapy with 
glucocorticoids can be associated with: - 
(i) Fever, myalgia, arthralgia and malaise which may simulate 
symptoms of the actual condition being treated e.g. rheumatoid 
disease or rheumatic fever; 
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(ii) Pseudotumour -cerebri; 
(iii) Secondary adrenal insufficiency: This depends on 
duration and dose of treatment. Recovery of the 
hypothalamic- pituitary- adrenal axis can be protracted 
(Streck and Lockwood, 1979; Harrison et al., 1982) and 
incomplete for many ensuing months (Graber etal.,1965). 
Adrenal insufficiency may be precipitated by intercurrent 
illness up to twelve months after discontinuing therapy, 
even if supra- physiological dosages of glucocorticoids 
were administered for only a period of weeks (Melby, 
1974; Axelrod 1989). 
(B) The adverse effects that accrue from prolonged therapy especially if used in high 
dosage are numerous and are summarized in the Table 1.2 (according to 
Axelrod, 1989). There does not appear to be any particular complication of 
glucocorticoid therapy that is unique to any one agent and all have potential for 
similar adverse effects. However, the more potent glucocorticoids (and usually 
the more efficacious) are more likely to produce such unwanted effects. 
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Table 1.2: Adverse effects of glucocorticoids (Axelrod 1989) 
Ophthalmic 
Posterior subeapsular cataracts, increased intraocular pressure and glaucoma, exophthalmos 
Cardiovascular 
Hypertension 
Congestive heart failure in predisposed patients 
Gastrointestinal 
Peptic ulcer disease, pancreatitis 
Endocrine-metabolic 
Truncal obesity, moon fades, supraclavicular fat deposition, posterior cervical fat deposition 
(buffalo hump), mediastinal widening (lipomatosis), hepatomegaly due to fatty liver (rare) 
Acne, hirstitism or virilism, impotence, menstrual irregularities 
Suppression of growth in children 
Hyperglycemia; diabetic ketoacidosis; hyperosmolar, nonketotic diabetic coma; 
hyperlipoproteinemia 
Negative balance of nitrogen, potassium, and calcium 
Sodium retention, hypokalemia metabolic alkalosis 
Secondary adrenal insufficiency 
Musculoskeletal 
Myopathy 
Osteoporosis, vertebral compression fractures, spontaneous fractures 
Aseptic necrosis of femoral and humeral heads and other bones. 
Neuropsychiatrie 
Convulsions 
Benign intracranial hypertension (psendotumorcerebri) 
Alterations in mood or behavior, such as euphoria, insomnia, increased appetite, depression 
Psychosis 
Dermatologie 
Facial erythema; thin, fragile skin; petechiae and ecchymoses; violaceous striae; impaired 
wound healing 
Panniculitis (following withdrawal) 
Immune, infectious 
Suppression of delayed hypersensitivity 
Neu trophilia, monocytopenia, lymphoeytopenia, decreased inflammatory responses 
Susceptibility to infections. 
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Whereas the magnitude of adverse effects is related to total dose and 
duration of therapy (Messer et al., 1983), some patients respond to and develop side 
effects from glucocorticoids more readily than others when comparable doses are used 
(Axelrod, 1989). Differences in pharmacokinetic handling of drugs among individuals 
(Kozower et al., 1974) might be responsible in part for heterogeneity in propensity to 
adverse effects but inherent differences in sensitivity mediated by cellular mechanisms 
(Becker 1965; Bigger et al, 1972; Becker et al, 1973, 1976) might also contribute to this. 
This has been a relatively ignored area and further work along these lines might reap 
rich rewards. 
The dilemma remains to separate the anti -inflammatory /immunosuppressive 
(desirable) effects of glucocorticoid therapy from its adverse effects. The initial 
approach to this problem put reliance upon manipulation of structure - function 
relationship of the steroid molecule. 
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1.1d CI- IEMISTRY: 
The chemical structure of cortisol is depicted in Figure 1.1. Biological activity 
is dependent upon the presence of the C -4, 5- double bond and a ketone group at C -3. 
The presence of the OH group at C -11 is crucial for glucocorticoid (anti -inflammatory) 
activity. This conclusion was drawn after years of study by several laboratories 
including those of Liddle and Bush (Brownie, 1992), stalwarts in the early studies of 
glucocorticoids. In fact, this conclusion might have been deduced from the observation 
that cortisone was devoid of anti -inflammatory effects on the skin despite appreciable 
absorption, whereas cortisol was highly effective when used in this way (Sulzberger and 
Witten, 1952). This was probably the earliest (overlooked!) lesson that the skin might 
be targeted/protected with regard to glucocorticoid action. Cortisone (chemical 
structure shown in Figure 1.2) differs from cortisol in having a keto group ( =0) instead 
of an hydroxyl ( -OH) at C -11. The conversion of cortisol to cortisone is a biological 
process with which many mammalian tissues, including skin, are empowered (Monder 
and White, 1992) via the enzyme complex, 11B- hydroxysteroid dehydrogenase. If this 
enzyme system can be modulated locally then it might be possible to target 
glucocorticoid therapy with the potential of reducing the risks commonly associated 
with systemic glucocorticoid exposure. Exploring this novel path is worthwhile because 
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o 
Figure 1.1: Chemical Structure of Cortisol 
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Figure 1.2: Chemical Structure of Cortisone 
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1.1e OPTIMIZING GLUCOCORTICOID ACTION: 
Modification of the basic cortisol molecule (Figure 1.3) has resulted in an array 
of glucocorticoid agents with widely varying properties and clinical efficacy. Early 
studies were focussed on improving the anti -inflammatory effects i.e. glucocorticoid 
activity of the endogenous hormone, cortisol (hydrocortisone). Such modifications 
involved both the ring structure and the side -chains as indicated in Figure 1.3 (Thalen 
etal,1989). Thus the insertion ofa double bond at the C -1,2- position yielded predniso- 
lone with four times the potency of cortisol. The introduction of fluorine atom at the 
C -9 -a position of cortisol produced fludrocortisone with ten times the glucocorticoid 
potency of the parent compound as well as a profoundly enhanced (x 125) 
mineralocorticoid action (Szefler, 1989). Methyl substitution at the C- 16- position of 
fludrocortisone largely eliminated mineralocorticoid activity resulting in dexamethasone 
(C -16 -a) or betamethasone (C -16 -ß) both of which have twenty five times the 
glucocorticoid potency of cortisol (Szefler, 1989). There was still, however, no real 
separation of anti -inflammatory activity from the undesirable effects of glucocorticoids. 
Adrenal suppression, osteoporosis, and propensity to infection can be serious 














































































































































































































































































































































The next advance was topical application to the site of disease and it seemed 
reasonable that such an approach might limit unwanted systemic effects. Sulzberger 
and Witten (1952) had already introduced this concept when hydrocortisone was used 
topically to treat skin disease. Indeed the introduction of topical hydrocortisone 
therapy to skin represented a major step towards overcoming the problem of systemic 
toxicity. Such effects have not been described with topical hydrocortisone except in the 
very young with severe skin disease (Turpeinen et al, 1986; Turpeinen, 1988). Although 
topical hydrocortisone proved an enormous breakthrough, its relatively low potency 
and poor transcutaneous bioavailability limited its clinical usefulness. The subsequent 
use of derivatives with enhanced lipophilicity resulted in increased topical efficacy. 
Thus masking the -OH groups in the C -16a -, C -17a- and C- 21- positions produced 
compounds which were highly efficacious (Phillips, 1976; Brattsand et al., 1981). 
Unfortunately, the bogey of adverse systemic effects remains a problem even within 
recommended dosages (Staughton and August, 1975; Himathongkam et al., 1978) but 
especially when used injudiciously (Teelucksingh et al., 1993). 
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Subsequent work showed, however, that better topical to systemic activity 
therapeutic ratios might yet be achieved. Such studies demonstrated that the 
introduction of C -16 -, C- 17- acetal substitutions was superior to C -6- and C -9- position 
halogenation in this regard (Dahlberg etal.,1983). Beclomethasone dipropionate is the 
prototype of the former and its introduction made topical therapy applicable to the lung 
i.e. inhaled glucocorticoid for asthma (Brown et al., 1972; Gaddie et al., 1973 a, b). 
Previous attempts to treat asthma with aerosolized glucocorticoid proved disappointing. 
Hydrocortisone was not sufficiently potent (Gelfand, 1951) and its more potent 
congeners e.g. dexamethasone, though effective, provided little advantage over oral 
treatment because the dose required for equivalent control of symptoms was similar by 
both routes (Linder, 1963). Undoubtedly, beclomethasone dipropionate and more 
recently budesonide, have been a major advance in reducing the risk benefit ratio of 
topical therapy (Thalen et al., 1989). Nevertheless, systemic exposure does occur with 
this form of therapy (Toogood el al, 1977; Toogood, 1989, 1990; Ali et al., 1991) 
although whether enough to be clinically relevant is still debatable (Reid et al., 1986; 
Hollman and Allen, 1988, Littlewood etal., 1988; Stead and Cooke, 1989; Capewell et 
al., 1990; Meeran et al., 1991; Pouw et al., 1991; Toogood, 1990; Wolthers, 1991). 
Herein lies the challenge with glucocorticoid therapy; the need to dissociate the 
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anti -inflammatory/immunomodulatory effects of glucocorticoids from their undesirable 
effects. Current clinical approaches to minimize adverse effects of glucocorticoids 
include: - 
1. Use in diseases only where they are known to be of benefit 
2. Use of minimum maintenance doses for the shortest possible time 
3. Use of topical therapy where possible 
4. Use of alternate -day therapy (Bengtsson and Malmvall, 1981; Axelrod, 
1989). 
More recent elucidation of the mechanism of action of these compounds have 
opened up some exciting possibilities with respect to enhancing therapeutic index 
(Flower, 1988 a, b). 
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1.1f MECHANISM OF ACTION: 
Despite the diverse and apparently contradictory effects of glucocorticoids on 
different tissues a unifying hypothesis for such manifold effects has long been considered 
(Selye, 1946; Ingle, 1952; Schayer, 1964, 1967). The permissive action upon homeostasis 
ofbasal glucocorticoid production was recognised (Ingle, 1952) but the role ofincreased 
levels of circulating glucocorticoids accompanying stress (Selye, 1946) would not be 
accommodated by this hypothesis. The microcirculatory hypothesis as proposed by 
Schayer (1964, 1967) suggested that glucocorticoids induced vasoconstriction by 
antagonism of a putative vasodilator of the microcirculation. The latter would not have 
explained the contrasting effects of enhanced protein synthesis in liver with 
simultaneous lympholytic effects. 
The unifying hypothesis came not from debates regarding the observed functions 
and effects of glucocorticoids but from a search for their mechanism of action. 
Karlson's hypothesis that hormones may act at the level of gene transcription (Karlson, 
1963) together with Edelman's observation of the accumulation of radio -labelled 
aldosterone in the nuclear and perinuclear areas of epithelial cells in the toad bladder 
(quoted in Cope, 1972) set the scene for what was later elucidated about glucocorticoid 
action. 
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Glucocorticoids enter target cells by passive diffusion and bind to specific 
receptors. This steroid -receptor complex then translocates to the nucleus and binds to 
glucocorticoid responsive elements of specific genes. In so doing, a change in 
transcription rate ensues resulting in altered messenger RNA production and ultimately 
protein synthesis (reviewed in Moudgil, 1985). 
With the discovery of the glucocorticoid receptor came the understanding and 
the final unifying concept that the diverse effects of glucocorticoids emerge from a single 
molecular mechanism (Munck et al., 1984; Munck and Guyre, 1989). It was an earlier 
(and erroneous) concept that repression or depression of genetic material was 
responsible solely for the 'physiological actions' of glucocorticoids, and the anti - 
inflammatory effect (pharmacological action) of glucocorticoids was a peculiarity 
associated with high doses, the effects of which did not accrue from gene activation (in 
Munck et al., 1984). Evidence from a number of quarters however, emerged to dispel 
this hypothesis. The anti -inflammatory actions of glucocorticoids were clearly shown 
to require de -novo protein synthesis implying that gene expression was also crucial to 
anti -inflammatory actions (Tsurufuji and Ohuchi, 1989). 
Weissmann and Thomas had proposed that the anti -inflammatory actions of 
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glucocorticoids arose out of the ability to stabilize lysosomal membranes (Stevenson, 
1977). However, pharmacologic concentrations of glucocorticoids failed to produce 
such an effect in purified preparations of lysosomes indicating that stabilisation of 
lysosomal membranes was not a direct action but necessitated a second messenger 
(Stevenson, 1977). The search for and discovery of such a mediator was achieved 
almost simultaneously by three independent groups of workers (Flower, 1988 b). 
Following the discovery that aspirin and other non -steroidal anti -inflammatory 
drugs mediated their action via inhibition of the cyclo -oxygenase enzyme (and hence 
prostaglandin synthesis) the possibility that glucocorticoids (with their known anti - 
inflammatory action) might also be involved in prostaglandin metabolism was pursued 
(Flower, 1988 b). Whereas there was no apparent direct effect of glucocorticoids on 
cyclo -oxygenase, hydrocortisone and dexamethasone were shown to prevent 
prostaglandin generation in a variety of systems (reviewed in Flower 1988 b). Using the 
guinea -pig isolated perfused lung in connection with bioassays sensitive to 
prostaglandin endoperoxides and thromboxane A2 a series of experiments by Flower's 
group elucidated this area. Thus, the site of activity of glucocorticoids in this pathway 
was localized to inhibition of arachidonic acid release from membrane phospholipids 
(Nijkamp et al, 1976), presumably by an effect on phospholipase A2. Subsequent work 
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showed that glucocorticoid- induced phospholipase inhibition was mediated by the 
classic steroid pathway involving protein biosynthesis (Flower and Blackwell, 1979; 
Russo -Marie et al., 1979). Extracts containing such a glucocorticoid- induced product 
were shown to possess anti -inflammatory effects in a model of acute inflammation 
(Blackwell et al., 1982). 
Many of the anti -inflammatory effects of glucocorticoids have now been shown 
to be mediated by this family of proteins, the lipocortins (or annexins) (Duncan et al., 
1993). Increased levels of lipocortin 1 have been demonstrated both in vitro (Hirata, 
1989) and in vivo (Goulding et al, 1990) following treatment with glucocorticoids. The 
sequencing of the amino acid structure of this protein, cloning of the gene and 
expression of the recombinant protein (Wanner et al., 1986) provided further evidence 
for its role in glucocorticoid action. Human recombinant lipocortin 1 has been shown 
to mimic the activity of glucocorticoids in inhibiting thromboxane release in the guinea- 
pig isolated perfused lung bioassay system (Cirino et al, 1987) and this protein or an 
N- terminal peptide fragment has been shown to have anti -inflammatory effects in many 
models of acute inflammation (Cirino et al., 1989, 1993). In addition the anti - 
inflammatory action of dexamethasone can be reversed by anti -serum to lipocortin -1 
(Duncan et al., 1993). 
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If lipocortins are the "second messenger" for the anti -inflammatory signals 
(alone) then there must be great optimism about the future of anti -inflammatory 
therapy. However, lipocortins may have effects outside of their recognized 
anti -inflammatory role. Thus lipocortin -1 has been shown to have potential for effects 
on the hypothalamic -pituitary- adrenal axis (Taylor et al., 1993) as well as growth and 
differentiation (Croxtall and Flower, 1992; Croxtall et al, 1993 a,b). This implies that 
analogues of this protein might well retain these properties (and lead to unwanted side 
effects) when used therapeutically. 
A common mechanism for both 'physiologic' and 'pharmacologic' effects of 
glucocorticoids would therefore explain the difficulty in separating the benefits of 
glucocorticoids from their adverse effects. Indeed, the distinction between 
pharmacologic and physiologic dosages is quite arbitrary, since it has been found that 
supra -physiologic replacement dosages of glucocorticoids offer no benefit over 
'physiologic' replacement dosages in adrenalectomized primates undergoing surgical 
stress (Udelsman et al., 1986). 
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Separating the benefits of glucocorticoids from their side effects therefore 
continues to be a clinical and pharmacological challenge. This work turns attention to 
what further lessons the skin may yet reveal with respect to glucocorticoid therapy. 
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1.2 SKIN AND GLUCOCORTICOID: 
1.2a SKIN: GENERAL 
Skin is the major interface between the body and the environment and is 
well- adapted to offering protection against physical, chemical, and microbiological 
assault. Its appearance, texture, and smell are important elements in social and sexual 
communication. The receipt of signals by it from the outside world can critically alter 
behaviour leading to actions that can defend the internal milieu. The reverse is also 
true. An endless variety of lesions on its surface may give clues to significant internal 
turmoil. A classic example is that of vitiligo, especially in the setting of adjacent 
increasing pigmentation, which might suggest disease as remote as the adrenal gland e.g. 
Addison's disease. Can the skin reveal deeper secrets ofadrenal /glucocorticoid activity? 
This work aims to answer just this question. 
1.2b SKIN: STRUCTURE AND FUNCTION 
The skin is arguably the largest and, perhaps, heaviest organ in the body. The 
average surface area in an adult is 1.5 - 2.0 square metres and has an estimated weight 
of 20 kg (Nasemann el a1., 1983). The epidermis and its appendages (hair, sebaceous 
glands, and sweat glands) are derived from ectoderm. Together they account for only 
about 0.5 kg and represent the outer horny layer. The underlying dermis is derived 
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from mesoderm and averages 3.5 kg (Nasemann et al, 1983). The balance is made up 
of subcutaneous fat. The epidermis is avascular and must depend for its nutrition on 
the underlying dermis which has a rich vascular supply. Homeothermia is advantageous 
in that metabolic processes can function independent of ambient temperature. The skin 
plays a major role in thermoregulation, facilitated by its dermal vasculature and 
subcutaneous insulating fat. 
Skin is compressible as well as distensible providing a flexible coat ready to 
accommodate physical stresses. Because the skin is at the front line of defences it is a 
veritable immunologic organ equipped with antigen -processing Langerhan's cells and 
keratinocytes with the capacity to secrete a variety of immunoinodulatory cytokines 
(Shimada and Katz, 1988). Unfortunately this can sometimes work against it and the 
skin can frequently be the site of immunologically -mediated disease e.g. eczema, 
pemphigoid, and erythema multiforme. 
Skin is not just a simple, passive protective coat. Indeed it exhibits high 
metabolic activity (Lorincz and Stoughton, 1958) and is well furnished with a repertoire 
of enzymes (Ellis, 1964) to support its many important functions. Its role in lipid 
synthesis has been long recognized (Hsia et al., 1970). Indeed, the elaboration of 
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cholecalciferol from 7- dehydrocholesterol represents a unique photoendocrine system 
(Holick, 1981). Another important and perhaps overlooked function is the ability to 
biotransform various endogenous and exogenous substrates which are traditionally the 
domain of liver and kidney; for example, the skin has been shown to participate in the 
metabolism of a variety of drugs (Bickers et al., 1982 a, b; Bickers, 1983). 
The skin is the target for a wide range of hormones. The effects of steroid 
hormones, in particular, have long been of interest. Hippocrates, for example, noted 
that eunuchs never developed secondary sexual characteristics (Medvei, 1982). Indeed 
it is now clear that several human skin disorders are related to abnormalities in the 
terminal metabolism of androgens (Price, 1975). These include acne vulgaris, 
hidradenitis suppurativa, and male- pattern alopecia. Importantly, the skin is not a 
passive recipient but actively participates in the activation of androgens (Wotiz et al., 
1956; Jenkins and Ash, 1971) and oestrogens (Weinstein et al., 1968) via a network of 
enzymes which have been extensively studied (Berliner el al, 1968; Berliner, 1972; 
Longcope, 1980). The role of skin 5a- reductase, for example, in defining secondary 
sexual differentiation is perhaps the best known (Imperato- McGinley et al., 1974). 
The metabolism of glucocorticoids by skin has been less well studied. 
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1.2c SKIN - A GLUCOCORTICOID TARGET TISSUE: 
Glucocorticoid receptors have only recently been demonstrated in skin of both 
man (Ponec et ai, 1980; Epstein, 1983) and rodents (Epstein and Munderloh, 1981; 
Smith and Shuster, 1984). In man, these receptors have been demonstrated in cultured 
fibroblasts (Ponec et al, 1980), cultured keratinocytes (Ponec et al, 1981), as well as 
homogenates ofseparated dermis (Smith and Shuster, 1987) and epidermis (Epstein and 
Bonifas, 1982; Smith and Shuster, 1987). The presence of glucocorticoid receptors in 
skin might have been deduced on clinical grounds alone. Dermatological features e.g. 
skin thinning and purpura have long been recognized and are common in patients with 
Cushing's syndrome (Ross and Linch, 1982; Walker and Edwards, 1992) and occur 
early in the course of treatment with glucocorticoids (Singleton et ai, 1979). 
There is considerable data to support a physiologic role for glucocorticoids in 
skin. In human keratinocyte cultures, for example, the absence of hydrocortisone from 
the culture medium results in poor proliferation and terminal maturation which can be 
prevented by the addition of hydrocortisone (Ponec et al, 1988). Similar effects had 
previously been demonstrated, in vivo, in both birds and rodents (Robertson and 
Maibach, 1989). Keratinization and inhibition of collagenase and gelatinase activity are 
processes intimately associated with normal skin integrity. These processes have also 
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been shown to be under glucocorticoid influence (Robertson and Maibach, 1989). 
These physiological effects may have all been overlooked were it not for the 
responsiveness of dermatological disease to glucocorticoid therapy. Soon after Hench 
et al., (1949) introduced cortisone into the therapy of rheumatoid disease, 
dermatologists were quick to pick up the trail. Cortisone proved useless but when 
hydrocortisone became available, its value to treat skin pathology was immediately 
obvious (Sulzberger and Witten, 1952). Today, glucocorticoids remain the single most 
important therapeutic option in a variety of dermatoses (Garden and Freinkel, 1986). 
1.2d METABOLISM OF GLUCOCORTICOIDS BY SKIN: 
Malkinson et al., (1959) were the first to demonstrate that human skin could 
metabolize hydrocortisone. Incubation of human skin slices with cortisol produced 
cortisone as indicated by the chromatographic evidence. Hsia (Hsia et al., 1964; Hsia 
and Hao, 1966; Hsia, 1971) later confirmed and extended this work in a series of in vitro 
experiments. Both the epidermis and dermis were shown to be capable of this 
conversion. Although other substances were identified cortisone accounted for > 80% 
35 
of the products (Hsia et al., 1964). The reverse reaction, cortisone to cortisol, was also 
demonstrated (Hsia and Hao, 1967). At the same time, Berliner and Ruhmann, (1966) 
not only demonstrated cortisol -cortisone conversion in skin connective tissue but also 
highlighted the contrasting effects of cortisol and cortisone on fibroblast growth in 
culture; cortisol suppressed growth whereas cortisone was without effect. This led 
Berliner and Ruhmann, (1966) to speculate that cortisol to cortisone conversion might 
be of biological significance in influencing growth and maturation of skin elements. As 
is the case with the sex steroids, it therefore seems that the terminal metabolism of 
cortisol might be important in normal skin physiology. The conversion of cortisol to 
cortisone is mediated by the enzyme 11B- hydroxysteroid dehydrogenase (11B -HSD). 
This enzyme is ubiquitous in mammalian tissues (Table 1.3 modi lied from Monder and 
White, 1992). 
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Table 1.3: Distribution of 11 ß- hydroxysteroid dehydrogenase activity in mammalian tissues 
(Modified from Monder and White 1992) 
Tissue or organ 11 B-dchydrogenase 11 -oxoreductase 
Liver 1,2,3,4,5,6,7,9,11 2,3,4,5,7,11 
Kidney 1,2,3,4,5,6 1,2,110 
Lung 2,3,4,5,6 1,2,3,4,5o 
Spleen 3,5,6 3 
Heart 2 
Blood Vessels 4 4 
Lymphocytes 2,3 2 
Thymocytes 2,3 3 
Testes 2,3,4,7,11 2 
Ovary 2o 70 
Uterus 1 1 
Amniotic membrane 1 1 
Chorion 1 1 
Placenta 1,2,8 1,8 
Diaphragm 2,6 
Brain 2,3,6,8 2 
Pituitary 2 
Stomach 2 
Small intestine 1,2 
Large intestine 2 
Skeletal muscle 2,3,7 2o,7o 
Adrenal Cortex 1,2,4,6,9,10,12 10 
Adipose tissue 1 10 
Gingival tissue 1 
Mammary gland 1,2 2o 
Salivary gland 2 
Dermis 1 
Skin fibroblasts 1 1 
Whole skin 1 
1, Human; 2, rat; 3, mouse; 4, rabbit; 5, guinea pig; 6, dog; 7, cattle; 8, baboon; 9, sheep; 10, 
meadow vole, 11, pig; 12, cat; o, none detected in designated tissue. 
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Important physiologic roles have been defined for 1113- hydroxysteroid 
dehydrogenase in many organs in which this has been studied. In the kidney for 
example, l 1ß- hydroxysteroid dehydrogenase has been shown to protect the non -specific 
mineralocorticoid receptor from occupancy by physiologic glucocorticoids (Stewart et 
al 1987, 1988, 1991, Edwards et al., 1988). Likewise, placental 11B- hydroxysteroid 
dehydrogenase provides a barrier to the transfer of maternal glucocorticoids to the 
foetus (Monder and White, 1992) and in the foetal lung (Abramovitz et al, 1982, 1984) 
and gastrointestinal tract (Smith et al., 1981) changes in the activity of this enzyme 
crucially influence glucocorticoid- dependent maturation. The role of this enzyme in 
skin is speculative but from a pharmacological viewpoint, if it was possible to inhibit 
skin 11ß- hydroxysteroid dehydrogenase this might potentiate the action of cortisol. 
Cortisol is itself a weak glucocorticoid if systematically absorbed (Turpeinen et al., 
1988) so that local inhibition of metabolism might confer site -specific action. 
1113- hydroxysteroid dehydrogenase has received much attention in other organs 
but has been somewhat overlooked in the skin. 
1.2e SKIN - A MARKER OF GLUCOCORTICOID ACTIVITY: 
Skin has proved to be an excellent window for evaluating glucocorticoid activity. 
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Thirty years ago, it was observed that in the course of treating skin diseases with topical 
glucocorticoids, pallor of the surrounding skin occurred (McKenzie and Stoughton, 
1962). It was hypothesized that vasoconstriction in the dermal vascular bed was 
responsible for this phenomenon and that this might serve as an index of potency of the 
glucocorticoid agent. Early studies confirmed that this was indeed the case. Thus the 
physical measure of plastic occlusion, which is known to enhance percutaneous 
absorption, was shown to result in increased vasoconstrictor responses, verifying the 
hypothesis (McKenzie and Stoughton, 1962). Later on, it was shown that this bioassay 
could reflect intrinsic activity of glucocorticoids, a conclusion drawn on the basis of 
penetration studies. Thus agents that exhibited far less penetration than others were 
capable of inducing greater vasoconstrictor responses (Stoughton, 1969), implying 
greater inherent glucocorticoid activity. Stoughton went on further to demonstrate that 
apart from predicting potency of glucocorticoids, skin vasoconstriction was an accurate 
predictor of likely clinical efficacy (Cornell and Stoughton, 1985). Thus agents that 
produce intense pallor were likely to be more efficacious in clinical practice. The skin 
vasoconstrictor bioassay therefore became an important screening tool for testing new 
glucocorticoid agents allowing potency standardization of such agents. After thirty 
years of use, there is still no other bioassay for glucocorticoids that is simpler or cheaper 
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and which has the reliability and predictability for detecting such potential for clinical 
efficacy (Stoughton, 1992). 
Previous authors have noted that responsiveness to topically applied 
glucocorticoids is heterogeneous (Burdick, 1974; Barry and Woodford, 1978; 
Stoughton, 1992). There are those individuals who respond with an intense degree of 
pallor and others who only barely do so or not at all. Indeed for the purposes intended, 
subjects were screened and then used in experiments to evaluate glucocorticoids only if 
they were found to be good responders (Burdick, 1974). These experiments were 
designed to ascertain the potency of glucocorticoids and the significance of skin 
unresponsiveness in individuals was not explored. 
A negative response could presumably arise as a result of poor bioavailability 
across the skin barrier. It is also possible that individuals who do not demonstrate a 
skin response to highly bioavailable topically applied glucocorticoid may be exhibiting 
some form of glucocorticoid resistance. In clinical practice, it is well recognized that 
there is heterogeneity in systemic responsiveness to glucocorticoids administered in 
equivalent doses (Axelrod, 1989). The question that arises therefore is whether the skin 
could be used as a marker of glucocorticoid sensitivity. 
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1.3 AIMS AND OBJECTIVES: 
HYPOTHESIS 1: 
The skin is involved in the terminal metabolism of the natural glucocorticoids 
and that inhibition of this metabolic process could have pharmacologic 
potential. 
AIMS: 
(a) To demonstrate the presence or absence of the enzyme(s) that inactivate 
cortisol /corticosterone in skin. 
(b) To define an inhibitor for this enzyme system in skin. 
(c) To demonstrate that inhibition of this enzyme system in skin could lead to 
potentiation of glucocorticoid action with consequent therapeutic possibilities. 
HYPOTI -IESIS 2: 




(a) To evaluate skin vasoconstrictor responsiveness /unresponsiveness 
longitudinally in a group of subjects and the effects of glucocorticoid agonists 
and antagonists. 
(b) To compare skin vasoconstrictor responsiveness in individuals with known 
sensitivity to glucocorticoids. 
In so doing it is hoped that such information might provide a means of reducing 
systemic and /or local toxicity associated with glucocorticoid therapy. 
42 
CHAPTER 2 
MATERIALS AND GENERAL METI -TODS 
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CHAPTER 2: MATERIALS AND METHODS 
CHEMICALS: 
[1,2,6,7- 3H]- corticosterone (sp.act. 86 Ci/mmol), iodinated insulin 125I (Cat No: IM38), 
iodinated cortisol (Cat No: IM 129): Amersham International Plc. Lincoln Place, Green 
End, Aylesbury, Buckinghamshire. HP20 2TP. 
Bovine serum albumin (Miles, fraction V, reagent grade): ICN Flow (formerly ICN 
Biochemicals), Eagle House, Peregrine Business Park, Gomm Road, High Wycombe, 
Buckinghamshire, HP13 7DL. 
Reagent grade salts, analytical grade solvents, Cocktail T "Scintran" scintillation fluid, 
Merck (5553) thin -layer chromatography plates, high vacuum silicone grease. Merck 
Limited (formerly BDH), Burnefield Avenue, Thorneback, Glasgow G46 7TP. 
Bio -Rad protein assay kit: Biorad Laboratories Ltd., Maylands Avenue, Hemel 
Hempstead, Herts. HP2 7TD. 
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Aldosterone, hydrocortisone acetate, hydrocortisone: NAD, NADP, Tris: Sigma 
London Co. Ltd., Fancy Road, Poole, Dorset BH17 7NH. 
Beclomethasone dipropionate: Steraloids Ltd., 31 Radcliffe Road, Croydon, Surrey. 
Beclomethasone dipropionate metered dose inhaler: Allen and Hanburys Ltd., 
Horsenden House, Oldfield Land North, Greenford, Middlesex UB6 OHE. 
RU -28362 and RU- 38486: Gifts from Roussel Uclaf, France. 
B- glycyrrhetinic acid: Aldrich Chemical Co, Ltd., The Old Brickyard, New Road, 
Gillingham, Dorset SP8 4JL. 
Antiserum to 11B- hydroxysteroid dehydrogenase - a gift from Dr. Carl Monder. 
(Population Council, N.Y.). 
OTHER MATERIALS: 
Polyester film (Melinex, 12 am), DPX: ICI, U.K. 
Tubigrip: Seton Healthcare Group, Oldham, England. 
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Double -sided adhesive tape (Scotch TM): 3M. 
7 x 7 nun square rubber stamp: Thomas H. Peck Ltd., York Place, Edinburgh EH 1. 
Tissue homogenizer: Ystral homogenizer, Scottish Scientific Instruments Centre, 
Limited. 
Double -beam spectrophotometer: Shimadzu UV -210A. 
Radioactivity counter: Packard 4430 series beta counter. 
BUFFER S: 
Glass distilled deionized water was used for all aqueous solutions. 
Krebs- Ringer bicarbonate buffer (gassed with 95% 02 and 5% CO2 for 1 hour) had the 
following composition: 
118 mM NaC1 
3.8 mM KC1 
1.19 mM KH2 PO4 
2.54 mM Ca C12. 2H20 
25 mM NaHCO3 
Glucose and bovine serum albumin (final concentrations of 0.2% w /vol) were added 
prior to use. 
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Tris -HC1 buffer (pH 8.5) had the following composition: 
0.1 M -tris 50 ml 
0.1 M -HCI 14.7 ml 
H2O 35.3 ml 
ANIMAL STUDIES: 
These studies were performed under an Animal Licence obtained from the Home Office 
and had the approval of the Animal Research Studies Ethics Committee. 
EXPERIMENTAL ANIMALS: 
(1) Hairless mice strain MF1- hr /Ola /Hsd. Harlan Olac, Oxon, U.K. 
(2) Nude mice (nu /nu, mixed genetic background), Imperial Cancer Research Fund. 
HUMAN STUDIES: 
Subjects were recruited either from; 
(1) hospital personnel (volunteers) or 
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(2) hospital clinics (patients) for asthma study 
All studies in humans had the approval of the Local Ethics Committee. For 
studies involving the use of systemic drugs, the conduct of experiments were in keeping 
with the declaration of Helsinki as to the recommendations guiding medical doctors in 
treatment involving human subjects (Appendix 1). 
GENERAL METHODS: 
OSTEOCALCIN: Plasma osteocalcin was measured by an in -house 
radioimmunoassay set up as described by Price and Nishimoto (1980), using antiserum, 
raised in rabbits, against purified bovine osteocalcin. Purified bovine osteocalcin was 
also used to prepare the tracer (12I- labelled osteocalcin) and the standards. 
Precipitated second antibody was used in the separation system. Intra and inter -assay 
coefficients of variation were 5% and 12% respectively. The reference range was up to 
12 µg /L. (This assay was performed by Dr. Laila Tibi, Department of Clinical 
Chemistry, Royal Infirmary, Edinburgh). 
PLASMA GLUCOSE: This was measured on Beckman CX3 autoanalyser using a 
glucose oxidase specific electrode. Intra and inter -assay coefficients of variation were 
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<1% and 2.2% respectively over the reference range (4.2 -6.2 mmol /L). 
PLASMA INSULIN: An in -house single antibody radioimmunoassay was used to 
measure plasma insulin. Bound and unbound fractions were separated with charcoal. 
Antibody to porcine insulin, raised in guinea pig, was obtained from Scottish Antibody 
Production Unit (Lanarkshire, Scotland) and 125I insulin from Amersham International 
(Aylesbury, Bucks, England). Standards were prepared from human insulin (1st 
International Rf Prep.) obtained from National Biological Standards Board (Potters 
Bar, Herts, England). Intra and inter -assay coefficients of variation were < 10% 
throughout the range. 
PLASMA C- PEPTIDE: This was measured by radioimmunoassay using reagents 
obtained from Navo Biolabs. Intra and inter -assay coefficients of variation were < 10% 
throughout the range. 
PLASMA CORTICOSTERONE AND CORTISOL: These were measured by in- 
house radio immunoassays (courtesy of Dr. Brent Williams, Department of Medicine, 
Western General Hospital, Edinburgh) employing a double antibody precipitation 
technique to separate bound from free glucocorticoid. The intra- and inter -assay 
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coefficients of variation were < 10 %. 
PLASMA 11- DEOXYCORTISOL: This was measured using the method of Perry 
(Perry et al., 1982). 
PLASMA TRIGLYCERIDES AND CHOLESTEROL: These were measured using 
standard enzymatic procedures (Kodak Ektachem). Intra and inter -assay coefficients 
of variation were < 2% throughout the ranges of these assays. 




SKIN VASOCONSTRICTOR ASSAY 
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CHAPTER 3: SKIN VASOCONSTRICTOR BIOASSAY 
3.1 INTRODUCTION: 
This bio -assay evolved from a simple clinical observation. The treatment of 
human skin with topical corticosteroids was shown to result in pallor (McKenzie and 
Stoughton, 1962), which was presumed to occur on the basis of vasoconstriction in the 
dermal vascular bed. This led to the idea that the visible cutaneous effect of a 
glucocorticoid might be a reflection of its potency. Early work verified this and the 
human skin vasoconstrictor assay evolved. The assay was found to be robust and could 
predict penetrability and activity of new corticosteroid agents (McKenzie, 1962, 
McKenzie and Atkinson. 1964). Later on, studies demonstrated excellent correlation 
between the vasoconstrictor assay and clinical efficacy (Barry and Woodford, 1976, 
1978; Gibson etal., 1984; Cornell and Stoughton, 1985). This made it appropriate and 
relevant to clinical practice through the predictable relationship between a 
glucocorticoid's vasoconstrictor ability and its clinical efficacy and it has been the 
standard method of testing new glucocorticoid agents for clinical use (Stou ghton, 1992). 
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3.1a CURRENT USES OF SKIN VASOCONSTRICTOR BIOASSAY: 
(i) Screening new synthetic glucocorticoids: 
The initial use of the skin vasoconstrictor bioassay was to evaluate percutaneous 
absorption and later, potency of glucocorticoids. This bioassay has fulfilled its role so 
well and for so long that it is now the basis on which new agents are tested and ranked 
for potency. 
(ii) Development of topical formulations: 
In the initial stages potency of different agents in the same base was evaluated. 
Its use has since been extended to compare the effects of different vehicle formulations 
of the same drug. It was on this basis, for example, that foams were found to be 
superior to ointment, gel or cream (Barry and Woodford, 1986). 
(iii) Study of penetration enhancers: 
Using blanching as an end -point it has been possible to study the effects of 
substances that could increase drug delivery across the skin e.g. propylene glycol. 
(iv) Determining dose and time regimens: 
The application of dermatological formulations in the past has been largely 
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empiric with respect to both frequency and dosing. The repetitive application of topical 
glucocorticoid can lead to attenuation of blanching responses. Blanching in response 
to potent agents will disappear within 48 hours if applied twice a day (Du Vivier and 
Stoughton, 1975). The response will return in 3 -4 days if there is no intervening 
exposure. When less potent glucocorticoids are used, more frequent application is 
necessary to induce this tachyphylactic response (Du Vivier and Stoughton, 1975; Du 
Vivier, 1976). In this way it may be possible to design therapeutic regimens for any 
given agent. 
A great value of this assay is its simplicity and low cost. With thirty years 
experience of its use, the following points regarding its precision have emerged. 
3.1b FACTORS AFFECTING PRECISION OF ASSAY 
(i) Occlusion: In some cases investigators have performed the assay without 
polythene occlusion (Christie and Moore- Robinson, 1970; Coldman et al., 1971). The 
effect of occlusion, by its hydrating effect on the epidermis is to enhance penetration 
(Robertson and Maibach, 1989). This effect could mask intrinsic differences that exist 
among different agents (Burdick, 1974). Without occlusion, however, lower blanching 
scores and greater intra- and inter- subject variation can be expected (Barry and 
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Woodford, 1978). 
(ii) Site: The human forearm has been the traditional site for skin testing although 
the back has also been used (Burdick, 1974). The accessibility of the forearm is an 
obvious advantage. The disadvantages are that blanching is inconsistent in volunteers 
with very narrow or very short forearms (Burdick, 1974, Barry and Woodford, 1978). 
Inconsistent blanching scores also occur if application sites are too near the elbow or 
wrist (Burdick, 1974). In individuals who during the period of application indulge in 
activities involving sustained action of the forearm muscles (Barry and Woodford 1978; 
Burdick, 1974) blanching can also prove erratic. 
(iii) Duration of occlusion: The duration ofocclusion has also been a variable with 
considerable influence on results. It is known that a period of about 6 hours exposure 
is required before blanching becomes obvious (Barry and Woodford, 1978). Some 
studies have utilized this period of exposure and yet others have allowed exposure for 
up to 72 hours. In evaluating the effect of duration of exposure upon blanching scores, 
Barry and Woodford, (1978) measured blanching at intervals ranging from 6 to 96 
hours after application. They found that blanching scores increased with duration of 
application up to a maximum at 18 hours and decreased exponentially after this time. 
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Most workers will therefore now utilize a period of exposure of 16 to 18 hours before 
assessing the blanching response. 
(iv) Single or multiple readings? The use of a single or multiple readings across 
an assay provides yet another variable. The precision of the assay is undoubtedly 
improved by multiple measurements (Gibson etal., 1984). Here a series of readings are 
taken over a specified time and a time- response curve plotted from which the area under 
the blanching curve can be determined. Nonetheless, it has been found that a single 
reading technique yields substantial information (Gibson et al., 1984). Using a single 
reading after 16 h exposure, the blanching produced by a series of agents was known to 
correlate closely with the known clinical efficacy of such agents (Cornell and Stoughton, 
1985). 
(v) Scoring blanching: The method of assessing the response has also been 
variable. Originally, although different patterns /intensities of blanching were observed, 
no attempt was made to grade these and response was expressed qualitatively, as 
"present" or "absent" (McKenzie, 1962). It was not long before the mathematical 
advantage of assigning a numeric value to the blanching response became evident (Place 
et al, 1970). This amounted to no more than a visual analogue scale where normal skin 
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in relation to test sites served as a negative control and was rated "0 ". Depending on the 
intensity of blanching for any given test -substance a scale of 0 - 3 or 0 -4 could then be 
employed. 
(vi) Scoring by instrumentation: The evaluation of responses by the human eye has 
been the time- honoured means of assessing the skin vasoconstrictor response to 
topically applied glucocorticoids. A considerable amount of work has gone into 
utilizing more objective means of evaluating this response. Laser -doppler velocimetry 
(Amantea et al, 1983, Bisgaard et al, 1986), reflectance spectrophotometry (Feather et 
al., 1982), surface thermography and xenon wash -out methods have all been employed 
and are still under investigation (Shah et al., 1989). Initial results with some of these 
have been disappointing (Amantea et al., 1983). Many of the biophysical principles 
while excellent for measuring increases in cutaneous blood flow e.g. erythema appear 
not to be sensitive to reduced blood flow. Blanching readily discerned by the eye may, 
therefore, not be detected using biophysical methods (Amantea et al., 1983). Thus the 
human eye is currently the most sensitive and versatile tool for evaluating the 
vasoconstrictor response and continues to be the preferred method in the current 
literature (Stoughton, 1992). 
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(vii) Lighting: Appropriate lighting is crucial to proper interpretation of responses. 
Direct or bright sunlight attenuates visual assessment of blanching responses (Barry and 
Woodford, 1978). Responses are best read in artificial light provided by fluorescent 
tubes (Barry and Woodford, 1978). 
3.2 METHODOLOGY 1: COMPARISON OF TEST SUBSTANCES 
WITHIN A GROUP OF SUBJECTS. 
When the aim of the study was to examine the efficacy of various test -substances, 
the Stoughton -McKenzie vasoconstrictor assay as modified by Place et al (1970) was 
used. Here a rubber stamp imprinted with the design of 7 x 7 mm squares in 4 vertical 
columns and 9 horizontal rows was used. The print surface was lightly coated with 
silicone grease and when impressed upon the mid- forearm served as a template for 
test -sites. The columns were oriented in the long axis of the forearm (Plate 3.1). This 
made best use of the skin area of the forearm and avoided getting too close to the elbow 
or wrist where blanching tends to be erratic. 
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PLATE 3.1 
Rubber stamp template of 7 x 7 mm squares 
oriented in long axis of forearm 
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It was important to use the minimum of silicone grease as excessive amounts 
smudged and obscured the symmetry of the outline. Moreover the aim was to outline 
the margins of the squares and not to coat the area of the square with the grease. The 
latter can influence bioavailability of test -substances and prejudice outcome. In practice 
best results were achieved by lightly coating grease- proof paper with the silicone grease, 
applying the rubber stamp on to the paper and then to apply the stamp on to the 
subject's forearm. The square -pattern reduced the problem of recognition of test sites 
(Place et al., 1970). The grid- pattern was marked with indelible ink to assist in the 
identification of individual sites when these were subsequently being scored. Plate 3.2 
shows the typical appearance of a grid -pattern blanching test using this methodology. 
Using this grid -system it was possible to assess up to 36 test -substances 
simultaneously. Test -substances were assigned positions on the grid at random and 
using a pipette 10 µl aliquots were transferred to their designated sites. With the 
forearm kept horizontal the test solution remained confined to its site by the borders of 
silicone grease. Test -substances were made up in a vehicle of 95% ethanol. When the 
alcohol evaporated the test -substance was left deposited in its ascribed test -site. 
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PLATE 3.2 
Typical appearance of a grid -pattern blanching test 
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After evaporation of the alcohol was complete, usually within 3 -5 minutes, the 
sites were occluded with polythene. This was kept in place by tape and further secured 
by covering with tubular gauze. 
3.3 METHODOLOGY 2: COMPARISON OF SUBJECTS ACCORDING 
TO CLINICAL GROUPS. 
Where qualitative differences were sought or in evaluating the effects of a limited 
range of test -substances the skin vasoconstrictor test was performed using a technique 
similar to that originally described (McKenzie and Stoughton, 1962). Here 
double -sided adhesive tape was used as the template. A cork -borer was used to cut the 
outline of a circle of 2 cm diameter. Up to 5 such circles could be cut upon a strip of 
double -sided adhesive tape. Such a strip was readily accommodated by most forearms. 
Having applied the template, test -solutions were spread via a pipette with circular 
movements over the surface of the skin. In this way test -substances were distributed 
uniformly across the test -areas. Sites were occluded with polythene after the alcohol 
had evaporated. The sticky nature of the upper surface of the tape facilitated polythene 
occlusion without need for further dressing (Plate 3.3). Using this methodology, 
dose -response relations for up to 5 concentrations of a particular substance could be 
evaluated. The use of a larger area of application facilitated recognition and scoring of 
blanching. Plate 3.4 shows the typical appearance of a blanching test using this 
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PLATE 3.3 
Double -sided adhesive tape method 
fog skin vasoconstrictor assay 
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PLATE 3.4 
Typical appearance of skin blanching 
using the adhesive tape method 
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methodology. 
For both methods, test- substances were applied between 1600 h and 1700 h, 
occluded overnight and all dressings removed the following morning at 0800 h (about 
16 h occlusion). Removal of the occlusive dressing revealed hÿperaemia of the 
underlying skin due to the adhesive tape. This was allowed to resolve and usually did 
so within an hour. Only then was any attempt made to read the results. Using such a 
protocol one took advantage of the observation that 16 -18 h application time yielded 
maximal blanching responses (Barry and Woodford, 1978; Stoughton, 1992). 
3.4 SCORING OF SKIN VASOCONSTRICTOR RESPONSE: 
The ease of reading of skin vasoconstrictor responses was critically dependent 
upon ambient lighting. Direct sunlight attenuated the intensity of the response. 
Responses were best observed in artificial light. For all experiments responses were read 
under fluorescent lighting. Sites were first evaluated for the presence or absence of 
blanching. Absent blanching implied that the skin at the test site was similar to 
contiguous normal skin and was scored '0'. When blanching was present this was rated 
according to intensity as '3', '2' or '1', where: - 
3 = intense blanching 
2 = definite blanching 
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1 = mild blanching 
Where the double -sided adhesive tape method (method 2) was used, four 
categories of blanching could be recognized:- 
4 = intense blanching extending beyond the area of application 
of test substance 
3 = intense blanching 
2 = definite blanching 
1 = mild blanching 
3.5 PREPARATION OF TEST SUBSTANCES: 
Steroids obtained as pure dried compounds from their manufacturers were 
dissolved in 95% ethanol. Strength of solutions is indicated for each experiment and 
expressed as weight of substance per unit volume of solvent (e.g. ,ug/ml). In situations 
where glycyrrhetinic acid had been added to steroid preparations, final concentrations 
are indicated. 
Solutions were stored in light -tight containers between 2 - 8 °C and utilized 
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within two weeks. When glycyrrhetinic acid was added these solutions were used within 
24 hours. 
The skin vasoconstrictor bioassay will be referred to in further chapters of this 
work. It will be used in the traditional role of defining glucocorticoid efficacy. It was 
also evaluated for a novel purpose - to define glucocorticoid sensitivity. 
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CHAPTER 4 
AN ANIMAL MODEL FOR STUDY 
OF 
11B- HYDROXYSTEROID DEHYDROGENASE IN SKIN 
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CI- IAPTER 4 
AN ANIMAL MODEL FOR STUDY 
OF 
liB- HYDROXYSTEROID DEHYDROGENASE IN SKIN: 
4.1 THE ENZYME: 11B- HYDROXYSTEROID DEHYDROGENASE: 
The enzyme 11 B- hydroxysteroid dehydrogenase catalyses the conversion of the 
native glucocorticoid in man (cortisol) and rodents (corticosterone) to their 
metabolically inactive metabolites cortisone and 11- dehydrocorticosterone, respectively. 
The presence of this enzyme was first described in tissues in the 1950s (Arelung 
et al., 1953; Ganis et al., 1955). Enzyme from the liver received most of the early 
attention and has been extensively investigated and characterized. Its subcellular 
localization was found to reside in the microsomal fractions (Hurlock and Talalay, 
1959; Bush et al., 1968). Purification of the enzyme from rat liver was eventually 
achieved and it was found to be a glycoprotein with molecular weight 34 KD and 
NADP -dependent (Lakshmi and Monder, 1985a, 1988). Initial studies indicated that 
this might be an enzyme complex comprising two enzymes facilitating opposite 
reactions; an 11- dehydrogenase converting cortisol (and corticosterone) to cortisone 
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(and 11- dehydrocorticosterone) with the second enzyme, an 11- oxoreductase, mediating 
the reverse reaction (Lakshmi and Monder, 1985 b). This was further supported when 
the purified enzyme was found to exhibit dehydrogenase but no significant reductase 
activity (Lakshmi and Monder, 1988). Later work with the cloned enzyme, however, 
expressed in transfected chinese hamster ovary cells and osteosarcoma cells 
demonstrated that both dehydrogenase and reductase activities could be detected 
(Agarwal etal., 1989). The latter group (Agarwal etal..,1990) showed subsequently that 
the predominant direction of the enzyme could be influenced both by redox state of 
coenzymes and by the extent of post -translational processing (level of glycosylation). 
11ß- hydroxysteroid dehydrogenase can be found in most mammalian tissues 
though both the level of activity and direction (dehydrogenase or reductase) can vary 
greatly (Monder and White, 1992). Whereas experimental conditions do undoubtedly 
influence the direction of the reaction (Monder and Shackleton, 1984) net 
dehydrogenation or reduction is, for some part, tissue dependent. For example, the 
kidney is largely a site of dehydrogenation (11f3-HSD2) whereas in the liver reductase 
activity (11B -HSD,) is dominant (Rundle etal., 1989; Walker etal., 1992 b). There is 
also great variation in the properties of the enzyme between species and even in the same 
species (and same organ) properties differed depending on the stage of the life cycle 
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(Monder and Shackleton, 1984). Moreover, the relative direction of metabolism in an 
organ can change during development (Monder and Shackleton, 1984). The factors 
regulating such transformation in net direction of metabolism are complex and 
probably hormonally related (Zumoff et ai, 1983; Koerner and Hellman, 1964; Pepe 
et al., 1988; Tye and Burton, 1980). 
Recent data, however, suggest that the existence of different proteins might 
explain the known biological and biochemical differences among tissues. The evidence 
in favour of different isoenzymes include the following. Firstly, kinetically distinct 
forms in the liver (Monder and Lakshmi, 1989) as well as differing species of messenger 
RNA for 11 B- hydroxysteroid dehydrogenase could be identified in the kidney 
(Krozowski et al., 1990). In addition, immunohistochemical studies using an antibody 
raised against liver -type protein failed to demonstrate staining for enzyme in some 
tissues although in these tissues enzyme activity could be readily demonstrated 
(Edwards el ai, 1988; Brown et ai, 1993). Moreover, defects in a gene encoding a 
protein with 11ß -hydroxysteroid dehydrogenase activity could not be detected in 
patients exhibiting clinical biochemical features of diseases known to be associated with 
either 11- dehydrogenase or 11- oxoreductase activity (Nikkila et ai, 1993). All the 
foregoing with the latter, in particular, indicated that at least another gene (and perhaps 
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other /several proteins) encodes for 11B- hydroxysteroid dehydrogenase activity. Studies 
involving coenzyme preferences further support this view. Thus NA D- dependent 11 ß- 
hydroxysteroid dehydrogenase activity (cf NADP- dependent liver isoform) has been 
identified in placenta (Brown et al., 1993) and renal cortical distal convoluted tubule 
(Mercer and Krozowski, 1992). 
Current knowledge favours the existence of at least two isoforms of the enzyme 
of which the liver isoform designated (11 ß -HSD,) and placental isoform (11 B -H SD) are 
prototypes (Brown el al., 1993). 1lß -HSD, is NAD- preferring, has an apparent 
molecular weight of 40 KD, has ahigher affinity for glucocorticoids than 11B-HS DI and 
acts predominantly as a dehydrogenase. By comparison 11B -HSD, is NADP 
dependent, has a molecular weight of 34 KD, and acts predominantly as a reductase. 
Whether the NAD- dependent activity detectable in the distal nephron represents yet 
another isoform is not yet clear. 
Knowledge of the high degree ofconservation and broad tissue distribution have 
long suggested that the enzyme might have some important physiologic role. Evidence 
to support this has only recently been forthcoming. 
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The crucial role that this enzyme plays in the kidney has now been elucidated. 
Here this enzyme has been shown to protect the non -specific distal tubular 
mineralocorticoid receptor from glucocorticoids. This conclusion has been drawn from 
a series of studies involving a patient with congenital deficiency of the enzyme (Stewart 
et al., 1988) and in metabolic- balance studies in subjects exposed to liquorice, an 
inhibitor of the enzyme (Stewart et al., 1987). These studies explained the following 
paradox. In vitro, both the purified (Krozowski and Funder, 1983) and cloned 
mineralocorticoid receptor expressed in a cell line (Arriza et al, 1987; Arriza, 1991) were 
non -specific and bound aldosterone, cortisol and corticosterone with similar affinity. 
Yet, in vivo, despite the fact that circulating free cortisol levels may be as much as 
100 -fold higher than those of aldosterone, renal mineralocorticoid receptors will 
selectively bind aldosterone (Edwards, 1990). By converting cortisol to cortisone (which 
has no affinity for the mineralocorticoid receptor) the enzyme therefore allows the 
preferential access of aldosterone (which is not metabolized by the enzyme (Edwards 
and Hayman, 1991), to the mineralocorticoid receptor. Thus when the enzyme is either 
congenitally absent or there is acquired deficiency secondary to liquorice or 
carbenoxolone ingestion, aldosterone specificity is lost and mineralocorticoid receptors 
become exposed to physiological levels of cortisol. Because the binding of cortisol to 
the mineralocorticoid receptor results in a sequelae indistinguishable from that when 
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aldosterone interacts with the mineralocorticoid receptor (Cato et al., 1991), the result 
is that there are not only the classical features ofmineralocorticoid excess; hypertension, 
hypokalaemic alkalosis and suppressed plasma renin activity, but also suppressed 
aldosterone levels (Edwards et al., 1988). 
The expression of enzyme activity in tissues without mineralocorticoid receptors 
e.g. liver and testis (Walker et al., 1992b), organs in which glucocorticoid receptors and 
11 B- hydroxysteroid dehydrogenase colocalize (Phillips et al, 1989; Edwards, 1991; 
Monder and White, 1992), suggests that the role of this enzyme extends beyond 
protection of mineralocorticoid receptor and it might also serve to protect tissues from 
glucocorticoid excess. Placental enzyme is thought to play such a role. As normal 
pregnancy progresses both total and free maternal cortisol levels increase exponentially 
(Burke and Roulet, 1970; Rees et al, 1975). Placental enzyme inactivates cortisol 
(Burton and Jeyes, 1968; Pasqualini et al., 1970; Levitz et al., 1978; Waddell et al, 1988) 
thereby protecting the developing foetus from the potentially growth inhibitory and 
teratogenic effects of this hormone. Indeed, the importance of this barrier to the fetus 
may be even more far reaching. Thus the administration of dexamethasone (which is 
not metabolized by the enzyme) to pregnant rats has been shown to adversely affect 
birth weight and predispose to hypertension in adult life (Benediktsson et al, 1993; 
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Edwards et al., 1993). In a similar fashion, the enzyme is present in testis where studies 
on the ontogeny of the enzyme suggest that its temporal expression is closely linked to 
the developmental rise in testosterone at puberty (Phillips et al., 1989). Gl ucoco rticoid 
excess is detrimental to testicular function (Bambino and Hseuh, 1981) and the enzyme 
seems well -placed anatomically and functionally to protect against such deleterious 
effects (Phillips et al, 1989). 
Indeed, wherever the enzyme has been studied it appears to modulate local 
glucocorticoid exposure. This usually impacts positively on some local physiologic 
processes (Monder and White, 1992). 
4.2 11ß- HYDROXYSTEROID DEHYDROGENASE IN SKIN: 
That corticosteroids are actively metabolized by human skin was first shown by 
Malkinson et al., (1959) who demonstrated that slices of human skin converted cortisol 
to cortisone. Subsequent work by Hsia (Hsia et al., 1964; Hsia and Hao, 1966, 1967; 
Hsia, 1971) confirmed and extended these findings. Hsia noted the formation of other 
substances notably C -20 -OH compounds but cortisone accounted for greater than 80% 
of the products. Skin (Hsia and Hao, 1967) or skin fibroblasts (Hammami and Siiteri, 
1991) were also shown to be capable of performing the reverse reaction: cortisone to 
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cortisol. These findings implied that 11 ß- hydroxysteroid dehydrogenase was present 
in skin. 
The earlier studies were essentially qualitative though a number of characteristics 
were determined. Firstly, the direction of the reaction favoured dehydrogenation 
(Malkinson et al., 1959; Hsia et a1,1964). Secondly, NA DP seemed to be the preferred 
co- enzyme (Hsia etal., 1964). More recently, Hammami and Siiteri, (1991) studied this 
enzyme in greater detail using cultured human skin fibroblasts. They established a Km 
value of 200 -300 nM for cortisol using whole cells. They also found that active 
glucocorticoids, cortisol and dexamethasone, increased 11 ß- hydroxysteroid activity 
whereas other steroid hormones had no appreciable effect. Contrary to what had been 
previously reported for whole skin (Hsia et al., 1964) Hammami and Siiteri, (1991) 
found that fibroblasts exhibited greater reductase than dehydrogenase activity and 
concluded that skin was mainly a site of reduction of cortisone. This may have 
however, been an effect of the cell type studied. Fibroblasts from other tissues have also 
been found to exhibit greater reductase activity. Thus, Abramovitz et al., (1982) had 
previously demonstrated that human fetal lung fibroblasts exhibited greater reductase 
activity, whereas lung epithelial elements were superior in ability to perform the reverse 
reaction. The dominance of reductase activity in fibroblasts is, however, not always 
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consistent (Smith and Giroud, 1975). The significance of reductase activity (cortisone 
to cortisol conversion) in human skin remains dubious given the greater metabolic 
activity of epidermal keratinocytes (Ellis, 1964) compared with dermis (where 
fibroblasts are located). As previously discussed experimental conditions (and perhaps 
choice of tissue) do influence the direction of reaction but the most compelling 
indication of the predominant direction of metabolism of cortisol in skin comes from 
clinical observations. Thus, when cortisone is applied to the skin it is well -absorbed 
(Robertson and Maibach, 1989) but without any biological effect (implying lack of 
significant conversion to cortisol in skin). It is for this reason that the thrust of current 
work was to focus upon the dehydrogenase activity (cortisol to cortisone) of skin 11 B- 
hydroxysteroid dehydrogenase. 
Cortisol (and its congeners) produce beneficial and often dramatic therapeutic 
effects in a wide variety of dermatoses. These include not only inflanunatory conditions 
(eg. eczema) where glucocorticoid benefits are self -evident but, in addition, in conditions 
where there are features of abnormal epidermal proliferation and maturation are 
features eg. psoriasis. The latter can probably be explained on what has been observed 
in- vitro. Thus it has been shown in keratinocyte culture, that cortisol promotes terminal 
differentiation (Ponec e1ä1,1988), emphasizing the importance of glucocorticoid in cell 
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maturation. Is the role of 11B- hydroxysteroid dehydrogenase in the skin to modulate 
local glucocorticoid action? Berliner and Ruhmann, (1966) had previously noted that 
cortisol but not cortisone inhibited skin fibroblast proliferation in culture, thus implying 
a potential role for the enzyme in regulating skin differentiation. 
Given the important physiological role defined for this enzyme in other tissues 
and the known benefits of glucocorticoid therapy in skin diseases, it seems plausible that 
the enzyme might also be important in skin. One possible way of defining a role for the 
enzyme in skin includes evaluating the factors influencing its activity (control). Another 
is to study the possible impact of its deficiency. It was the latter situation that led to the 
elucidation of the enzyme's role in the kidney (Stewart et al., 1988). Thus the study of 
this enzyme in skin diseases might define possible pathophysiologic mechanisms of 
particular dermatoses. Finally, there is an obvious therapeutic implication. If this 
enzyme could be inhibited locally then the action of physiologic levels of glucocorticoid 
at that site could be potentiated. Although one of the primary objectives of this thesis 
was the latter, it became necessary to seek out a model that might be suitable for all of 
the above. 
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4.3 THE NEED FOR AN ANIMAL MODEL: 
It was important to find an appropriate animal model For the study of the skin 
enzyme because of some difficulties posed by human skin. Firstly homogenization of 
human skin is extremely difficult (Voigt et al, 1970). Fibrous proteins such as keratin 
and collagen are important for the structural integrity of skin but these very proteins, 
however, make it extremely difficult to homogenize human skin using methods that are 
excellent for visceral organs like liver and kidney. 
Secondly, it was not always possible to obtain readily human skin for study. 
Moreover the use of cultured keratinocytes or skin fibroblasts while representing fair 
surrogates may mislead as to what exists in vivo, because of changes in cell 
characteristics upon culture (Priestley, 1986). Finally, there are some experiments that 
can only be performed in animals. 
4.4 WHY THE HAIRLESS MOUSE? 
Rodents seem a particularly suitable model in which to elucidate the biochemical 
and immunologic effects of glucocorticoids (Spearman and Jarrett, 1975; Back and 
Egelrud, 1985; Cohen, 1989). Hairless mice, in particular, have skin that bears many 
similarities to human skin in physicochemical handling of glucocorticoids and this 
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species has previously been used as a model system for evaluating pharmacodynamies 
and phannacokinetics of topical glucocorticoids (Du Vivier et al., 1978; Marks et al, 
1973). In addition, because they are congenitally athymic, hairless mice have been 
shown to accept skin grafts from several species, including human skin - normal and 
diseased (Briggaman, 1985). Human skin thus transplanted retains its features for 
months without alterations (Reed and Manning, 1973; Lane et al., 1989). The 
characteristics of l 1ß- hydroxysteroid dehydrogenase in the skin of hairless mice was 
therefore investigated. 
4.5 METHODOLOGY: 
4.5a Preparation of a skin homogenate. 
Dorsal skin was obtained from freshly killed hairless mice (usually nu/nu or for 
some experiments as specifically indicated, MF1 -hr /ola/Hsd) and placed immediately 
in universal containers kept on ice. Subcutaneous fat was removed with a pair of 
forceps. Then 1.0 g of skin was weighed out and finely minced with a scalpel. Minced 
tissue was then homogenized in 10 ml Krebs -Ringer buffer using an Ystral homogenizer 
(Scottish Scientific Instruments Ltd) at maximum setting for periods of 20 seconds with 
intervals of 30 seconds for cooling. Four or five cycles of homogenization followed by 
cooling produced a dense suspension with small fragments of residual skin. To prevent 
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excessive rise in temperature, tubes containing the tissue were surrounded in ice during 
the procedure. 
The resulting homogenate was then centrifuged at 750 g for 5 minutes at 4 °C to 
sediment unbroken cells and debris. The supernatant was withdrawn by suction using 
a plastic transfer pipette. 
4.5b Preparation of a kidney homogenate: A positive control for 
11 B- hydroxysteroid dehydrogenase activity. 
Most of the impetus to recent research into 11B- hydroxysteroid dehydrogenase 
came from the important physiologic role defined for the enzyme in kidney. Although 
different isozymes may reside in proximal and distal tubules, the kidney is similar to the 
skin (Malkinson et al., 1959; Hsia et al., 1964) in having dehydrogenation as the 
dominant reaction (Walker et al., 1992 b). It was therefore thought that the kidney 
would be useful for comparative studies with the skin. Kidneys were simultaneously 
removed from animals and kept in ice -cold 0.9% saline. Perinephric fat was peeled 
away with forceps and both kidneys (combined wet weight was usually about 0.5 g) 
minced and homogenized in 10 ml Krebs- Ringer buffer using a Dounce tissue grinder 
(Wheaton Scientific, New Jersey) for about 20 strokes. 
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4.5c Measurement of protein concentration of homogenates. 
This was performed using the Bio -Rad protein assay kit, a dye binding assay 
based on the differential colour change in response to various concentrations of protein. 
The Bio -Rad assay employs an acidic solution of the dye Coomassie Brilliant Blue 
G -250 which when bound to protein shifts its absorbance maximum from 465 nm to 595 
mn ( Biorad Laboratories). A Shimadzu UV -210 -A double beam spectrophotometer 
was used to measure results. Using a range of known concentrations of bovine serum 
albumin a standard curve was produced. Skin homogenate diluted 1:7 and kidney 
homogenate diluted 1:8 with Krebs- Ringer buffer were then assayed and protein 
concentration determined from the standard curve. 
4.5d 11 ß- hydroxysteroid dehydrogenase enzyme assay. 
(i) Incubation Procedure: A volume of homogenate yielding the desired protein 
content (usually 0.5 mg for both skin and kidney) made up to 1 ml with Krebs -Ringer 
buffer (with added 0.2% glucose and 0.2% bovine serum albumin) was incubated with 
10µl (equivalent to 37 KBQ) 3H- corticosterone for a specified time, usually one hour, 
(unless otherwise stated) in a shaking water bath at 37 °C. The final concentration of 
3H- corticosterone in each incubate was 12 nM. Where indicated other substances e.g. 
NAD/NADP or glycyrrhetinic acid were added in volumes of 10 t1 to achieve final 
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concentrations as stated. 
All incubations were performed in triplicate in disposable borosilicate glass 
culture tubes (Corning Glassware, N.Y.). Blank samples comprising buffer and 
3H- corticosterone but no homogenate were run with each experiment. At the end of the 
incubation period tubes were transferred to ice and immediately centrifuged at 1500 g 
for 15 minutes at 4 °C. The supernatant was removed by suction and stored at -70 °C 
until required for steroid extraction and identification. 
(ii) Extraction: Samples were extracted with 2.5 ml ethyl acetate by agitating in a 
motor- driven shaker (Griffin and George, U.K.) for 5 minutes and then allowed to 
stand for 5 minutes to ensure separation of the organic and aqueous phases. With a 
pipette 2 ml of the organic phase (upper) was transferred to glass tubes for drying. This 
was undertaken under air in a sample concentrator (Dri -Block DB 3, Jencons Scientific, 
U.K.). Radioactivity was then reconstituted in 100 Al of ethanol prior to thin -layer 
chromatography. 
(iii) Identification of metabolic product: Separation of substrate and products 
ofthe incubation procedure was performed by thin -layer chromatography. Unlabelled 
83 
corticosterone and 11- dehydrocorticosterone in ethanolic solution (10 µ1, 2mg /m1) were 
admixed with extracted steroids and spotted on silica gel plates [Merck (5553)]. These 
were developed in a solvent system containing chloroform: 95% ethanol (92:8) to a 
distance of 15 cm usually taking 1 hour to do so. Spots corresponding to the added 
standards were identified under an ultraviolet light and scraped into vials. After the 
addition of 4 ml of scintillation fluid (Scintran, BDH Chemicals) radioactivity was 
counted using a Packard 4430 series beta counter. 
(iv) Determining enzyme activity: Using this procedure the substrate 
3H- corticosterone was separated from the product 3H- 11- dehydrocorticosterone. 
Enzyme activity was expressed as the percentage conversion of substrate to product 
which was determined from the radioactivity (counts per minute) corresponding to each. 
i.e. Activity = counts per minute (3H- 11- dehydrocorticosterone) / counts per minute 
(3H- 11- dehydrocorticosterone + 3H- corticosterone). Blank incubations (i.e. tubes not 
containing homogenates) usually showed a percent conversion < 2% and this factor 
would be deducted from the values for actual experimental samples. 
(v) Recovery of radioactivity: Recovery of radioactivity after chromatography 
was compared with analogous aliquots which were mixed with liquid scintillant and 
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subjected to radioactivity counting after the extraction stage. This showed that recovery 
following TLC was always greater than 90 %. The combined counts from 
3H- corticosterone and 3H -11- dehydrocorticosterone accounted for greater than 95% of 
recoverable radioactivity implying that other metabolites of corticosterone were 
relatively unimportant in this animal tissue. 
4.6 RESULTS: 
4.6a Relationship between protein content of homogenates and l l B- 
hydroxysteroid dehydrogenase activity: 
Figure 4.1 depicts the relationship between varying protein content and 
percentage conversion (mean ± SEM) of 3H- corticosterone to 3H dehydrocorticosterone 
for 9 homogenates. For skin homogenates, there was a linear relation up to 0.75 mg 
protein per incubate and percentage conversion. Thereafter the concentration - 
conversion response curve was flat. On the basis of this, protein content of 0.5 mg was 
chosen for incubation in most subsequent experiments. 
For incubations with whole kidney homogenates, the results were similar but 
kidney exhibited higher activity (Figure 4.1). For most subsequent experiments with 
kidney, 0.5 mg protein content was also chosen for incubation. 
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Figure 4.1: The relationship between protein content of homogenates and 
activity of skin () and kidney () 11 beta -hydroxysteroid dehydrogenase. 
Results shown as mean ± SEM, n =3 for both tissues with triplicate 
incubations. 
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4.6b Relationship between incubation time and l l L3- hydroxysteroid 
dehydrogenase activity: 
Figure 4.2 depicts the mean (± SEM) percentage conversion of 3H- corticosterone 
to 3H- dehydrocorticosterone for 0.5 mg protein equivalent of kidney and skin 
homogenates. Over the time range investigated, this relationship was linear. 
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Fig. 4.2: The relationship of 11 beta -hydroxysteroid dehydrogenase 
activity (mean ± SEM, n -3 with triplicate incubations) with time for kidney 
and skin homogenates of nude mouse 
88 
4.6c The effect of coenzymes NADP and NAD on skin 1 113- hydroxysteroid 
dehydrogenase: 
Walker eta', (1992 b) in comparing the utilization of NAD+ and NADP by 11 B- 
hydroxysteroid dehydrogenase in different rat tissues found that NAD preferring 
isoforms of the enzyme exists at sites where aldosterone specific mineralocorticoid 
receptors abound eg. kidney and colon. Given the presence of aldosterone- sensitive 
sweat glands in skin, I was therefore keen to evaluate the preferences of the skin enzyme 
for co- factors. The preference for coenzyme would also give a broad indication of the 
isoform present in skin. Results are shown as mean ( ±SEM). The effect of co- factor 
was assessed by one factor analysis of variance followed by paired Student's t -test with 
significance set at the 5% limit. 
The addition of NAD and NADP both significantly increased activity of kidney 
enzyme (Figure 4.3) and with almost equal facility (p =NS). This was unlike the case 
with skin enzyme (Figure 4.4), where although both NAD and NADP both increased 
enzyme activity, NADP was much more efficient (p <0.05). Using 0.5 mg skin protein, 
concentrations of NADP above 50 pm produced maximum increase in activity i.e. >50 




Figure 4.3: The activity of 11 beta -hydroxysteroid dehydrogenase in 
kidney homogenate (mean ± SEM, n =3) without cofactor, with NAD and NADF 
NAD (100 µ M) NADP (100 µ M) 








Figure 4.4 The activity of skin 11 beta -hydroxysteroid dehydrogenase (mean -± 
SEM, n -3 with triplicate incubations) without co- factor and with NAD and 
NADP. 
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Figure 4.5: The activity of skin 11 ß- hydroxysteroid 
dehydrogenase (mean ± SEM, n =3) with varying 
concentrations of NADP. 
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4.6d ESTABLISHING A KM FOR SKIN 1lß- IIYDROXYSTEROID 
DEI-IYDROGENASE FOR CORTICOSTERONE: 
Previous investigations have determined the Michaelis constants of the enzymes 
in various tissues in rats and a wide range of values have been obtained (Monder and 
Lakshmi, 1989). Hammami and Siiteri (1991) established a Km for human skin 1 lB- 
hydroxysteroid dehydrogenase for cortisol and found this to be of the same order of 
magnitude as the circulating levels of cortisol implying that the enzyme can modulate 
skin exposure to cortisol. 
It was important therefore that the Km for the skin enzyme for corticosterone 
be established in the animal model. While there are dangers and problems involved in 
the study of enzyme activities in crude homogenates, important data have been derived 
from crude extracts of tissues studied in this way (Crabtree et al., 1979). In particular, 
this method has been extremely useful for comparative studies (Crabtree et al., 1979). 
Thus the Km for kidney enzyme in these animals could also be easily established for 
comparison. 
Incubations were performed in tris -HC1 buffer (pH 8.5) with NADP 250 µM at 
37 °C for 10 minutes. Tissue protein concentrations (0.38 mg for kidney, 0.5 mg for 
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skin) were chosen so that reaction velocities were linear with time and percent 
conversion of substrate was < 25 %. 
A fixed amount of 3H- corticosterone (107 AM) was added to each incubate along 
with increasing amounts of cold corticosterone. Substrate concentrations [S] ranged 
from 107 - 1070 µM. From the percentage conversion of 3H- corticosterone to 
3H- dehydrocorticosterone at each substrate concentration the mass of product [V] was 
calculated as depicted in Tables 4.1 and 4.2. The results are the mean of nine 
incubations at each concentration. 
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Table 4.1 : Substrate concentration[S] and 
% conversion of corticosterone by homogenates of mouse skin 
[S] x 10 -4 Conversion ( %) * [V] 1 1 
(mol /L) Mass converted - - 
x 10 -5 (mo1 /1) V S 
(104) (1 03) 
1.07 12.1 1.3 7.7 9.35 
1.20 12.4 1.4 7.0 8.33 
1.50 10.0 1.5 6.7 6.67 
2.10 7.3 1.5 6.7 4.76 
3.60 4.5 1.6 6.3 2.78 
5.40 3.0 1.6 6.3 1.85 
10.70 1.7 1.8 5.6 0.94 
* Mass converted = [S] x % conversion 
Results are the mean of 9 incubations at each concentration. 
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Table 4.2: Substrate concentration[S] and 
% conversion of corticosterone by homogenates of mouse kidney 
[S] x 10-4 Conversion ( %) * [V] 1 1 
(mol /L) Mass converted - - 
x 10 -5 (mol/1) V S 
(104) (103) 
1.07 20.7 2.2 4.5 9.35 
1.20 16.3 1.9 5.3 8.33 
1.50 16.2 2.4 4.2 6.67 
2.10 13.3 2.7 3.7 4.76 
3.60 8.3 2.9 3.4 2.78 
5.40 5.9 3.2 3.1 1.85 
10.70 3.3 3.2 3.1 0.94 
* Mass converted = [S] x % conversion 
Results are the mean of 9 incubations at each concentration. 
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Using the Lineweaver -Burk transformation of the Michaelis -Menten equation 
a plot of 1/[V] versus 1/[S] was then made and Km determined for skin and kidney 11 B- 
hydroxysteroid dehydrogenase for corticosteroid in the mouse. The apparent Km for 
skin enzyme was 37 x 10-6M (Figure 4.6), and that for the kidney enzyme was 120 x 10-6 
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Figure 4.6: Lineweaver -Burk plot for skin 11 ß- hydroxysteroid hydrogenase using 
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Figure 4.7: Lineweaver -Burk plot for kidney 11 ß- hydroxysteroid hydrogenase using 
corticosterone as substrate 
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Conclusions: 
The apparent estimated Michaelis constant for kidney 11 B- hydroxysteroid 
dehydrogenase for corticosterone in this experiment was similar to that described for 
rat kidney enzyme for corticosterone (160 AM) by Stewart (M.D. Thesis, University of 
Edinburgh, 1989). The apparent Km for skin 11B- hydroxysteroid dehydrogenase 
corticosterone has not been previously studied. It is known that there are at least two 
species of enzyme in kidney (11 B -HSD,, in proximal tubule and probably 11 B -HSD2 in 
distal nephron). Experimental conditions in this work favoured dehydrogenase 
(11B-HSD2) activity. Under parallel conditions a lower Km for skin enzyme for 
corticosterone was obtained. 
4.7 REGULATION OF SKIN 1111- IIYDROXYSTEROID 
DEHYDROGENASE 
4.7a Introduction: 
Il ß- hydroxysteroid dehydrogenase is known to be influenced by a number of 
hormones (Monder and Shackleton, 1984). Skin 113- hydroxysteroid dehydrogenase 
was shown to be regulated by glucocorticoids in vitro ( Hammami and Siiteri, 1991). It 
was therefore important to establish the influence of glucocorticoids on the skin 
enzyme in vivo. 
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4.7b METHODS: 
Six week old male hairless mice weighing 20 -25 g were used for this experiment. 
A control group was sham- operated and all other animals underwent bilateral 
adrenalectomy under halothane anaesthesia. Adrenalectomized animals were randomly 
allocated to one of four groups; no replacement, corticosterone replaced (5 µg/g day'), 
dexamethasone replaced (0.5 ,ug/g day -1) (Haigh dal., 1990), aldosterone replaced (0.05 
µg/g day-1). All drugs were administered by subcutaneous injection using olive oil as 
vehicle. The sham- operated group received vehicle only. All animals were fed similar 
diets and adrenalectomized animals (unreplaced group) were maintained on 0.9% NaCl. 
Treatment was of 10 days duration, commencing 24h after operation and finishing 2h 
prior to removal of tissues. Animals were killed by decapitation, blood collected for 
plasma corticosterone measurement and dorsal skin and kidneys were removed. Spleens 
were also removed and weighed. Homogenates of skin and kidney were prepared and 
assayed for 11B- hydroxysteroid dehydrogenase activity as previously described in 
Methods of this chapter. Protein content of each homogenate was 0.5 mg with NA DP 
at a final concentration of 100 M. 
4.7c Statistical analysis: 
The values are shown as mean (± SEM) for triplicate incubates from between 5 
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and 8 animals in each group. The differences among groups was tested by one factor 
analysis of variance (ANOVA) with significance set at the 5% limit. 
4.7d Results: 
Plasma corticosterone measured by radioimmunoassay was below the limit of 
detection of the assay ( <1.1 nmol/I) in all groups, except in the sham -operated (median 
24 nmol/1, range 8 - 54) and the corticosterone -replaced groups (median 4.3 nmol/1, 
range 2.3 -9). Post mortem examinations confirmed bilateral adrenalectomy in the 
respective groups except shams. 
Sham -operated (107.5± 9.6) mg and corticosterone- treated groups (102.5 ± 10.3) 
mg had similar splenic weights. Compared with shams, splenic weight was markedly 
reduced in the dexamethasone treated group (47.5 ± 2.5) mg, p <0.005. Splenic 
weight rose in the adrenalectomy (150.0± 15.3) mg p <0.05 and aldosterone- treated 
groups (165.0 ±21.8)mg, p <0.05 compared with shams. There was no significant 
difference in the change in body weight of the various groups. The changes in splenic 
weights were consistent with glucocorticoid deficiency in the adrenalectomized and 
aldosterone- treated animals and with glucocorticoid excess in the dexamethasone 
treated group. 
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The activity of kidney enzyme was similar in all five groups of animals (Figure 
4.8). This was in contrast to the findings for the skin enzyme (Figure 4.9). When 
compared with the sham- operated group, the unreplaced group and aldosterone 
replaced group exhibited significantly (p<0.05) reduced skin enzyme activity. In both 
glucocorticoid- replaced groups, skin enzyme activity was similar to that of the sham 
operated group (Figure 4.9). 
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SHAM ADX B DEX ALDO 
Figure 4.8: The regulation of kidney 11 beta -hydroxysteroid 
dehydrogenase: the effects of adrenalectomy (ADX) and 
replacement with corticosterone (B), dexamethasone (DEX) and 
aldosterone (ALDO). 
Results shown as mean ± SEM, n -8 for sham and 5 for all other 
groups. 
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* p < 0.05 
* 
SHAM ADX B DEX ALDO 
Figure 4.9: The regulation of skin 11 beta -hydroxysteroid 
dehydrogenase: the effects of adrenalectomy (ADX) and 
replacement with corticosterone (B), dexamethasone (DEX) 
and aldosterone (ALDO). 
Results shown as mean ± SEM, n =8 for sham and 5 for all other groups. 
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These findings suggest that similar to what has been demonstrated with cultured 
human skin fibroblasts in vitro ( Hammami and Siiteri, 1991), the skin enzyme in vivo 
is positively regulated by glucocorticoids (with mineralocorticoid replacement in 
adrenalectomized animals not exhibiting any influence). Unlike the findings for skin 
enzyme 11B- hydroxysteroid dehydrogenase in kidney was not regulated by 
glucocorticoids. In support of the current findings, previous workers had likewise 
described a constitutive 11B- hydroxysteroid dehydrogenase in kidney (Walker 1993; 
Smith and Funder, 1991). 
4.8 LOCALIZATION OF SKIN 11B- HYDROXYSTEROID 
DEHYDROGENASE: 
Antibodies generated against the enzyme from rat liver, in rabbits, have been 
used to localize 11B- hydroxysteroid dehydrogenase in a variety of tissues (Edwards et 
al., 1988; Phillips et al., 1989). Using antibodies to liver type protein has limitations 
however, since there are tissues in which enzyme activity can be readily detected eg. 
distal nephron, yet immunostaining for the enzyme with such antibodies may not be 
obtained (Edwards et al, 1988; Rundle et al, 1989). Bearing this shortcoming in mind 
an attempt to localise 11B- hydroxysteroid dehydrogenase in both mouse and human 
skin was undertaken. 
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Dorsal skin from freshly killed nude mice and normal human skin obtained at 
laparotomy from the anterior abdominal wall were used. Immunohistochemical 
localization of the enzyme was undertaken using an antibody (Monder and Lakshmi, 
1990) raised in rabbit against a purified hepatic microsomal preparation of rat 11 B- 
hydroxysteroid dehydrogenase. As negative controls pre -immune rabbit serum and 
inappropriate antibody (to 1- antitrypsin) were also performed. 
Tissue samples were placed immediately in Bouin's fixative for 24 - 48 h and then 
subjected to routine paraffin embedding. Sections were cut at 4,um, deparaffinised and 
then rehydrated through graded alcohols. Endogenous peroxidase activity was blocked 
by 10 min treatment with 3% hydrogen peroxide. To minimize background staining 
slides were pre- incubated with 20% donkey serum. Primary antibody, pre- immune 
serum or inappropriate antibody, at dilutions of 1:100 or 1:200, were then incubated 
with sections of tissue for 30 min at room temperature. This was followed by labelled 
avidin- biotin irnmunodetection (Guesdon et al, 1979) with biotinylated donkey 
antibody to rabbit immunoglobulin and peroxidase- conjugated streptavidin. The 
peroxidase substrate chromogen was 3, 3,- diaminobenzidine tetrachloride. The 
substrate was hydrogen peroxide. Slides were then counterstained with Mayer's 
haematoxylin and mounted in D.P.X. 
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Plate 4.1 shows positive staining for 11B- hydroxysteroid dehydrogenase in mouse 
skin. This was largely confined to the epidermis. There was no significant staining with 
pre -immune serum (Plate 4.2). 
Sections from normal human skin revealed strong positive cytoplasmic staining 
for 11B- hydroxysteroid dehydrogenase in the epidermis with the exception of the basal 
cell layer (Plate 4.3). There was moderate positivity on the luminal border of sweat 
ducts and some staining in the cytoplasm of sweat glands (Plate 4.3). For comparison, 
Plates 4.4 and 4.5 show the staining pattern with pre -immune serum and inappropriate 
antibody (a 1- antitrypsin), respectively. 
The localization of the enzyme to the epidermis, predominantly, favours the 
notion that inhibition might be achieved with topical therapy. 
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PLATE 4.1 
Immunohistochemical staining of mouse skin with antiserum to 




Immunohistochemical staining of mouse skin 




Section of human skin stained for l lß- hydroxysteriod dehydrogenase 









Section of human skin stained with inappropriate 




For the first time, skin 11B- hydroxysteroid dehydrogenase has been 
characterized and localized in an animal model. It is also the first time that the 
regulation of this enzyme has been studied in vivo. The hairless mouse seems a suitable 
model for further studies involving 11B- hydroxysteroid dehydrogenase in skin. 
Using this model, the whole skin enzyme activity differs from that of whole 
kidney in several respects. Skin 11 B- hydroxysteroid dehydrogenase activity is regulated 
by glucocorticoids whereas kidney enzyme is unaffected. The skin enzyme utilizes 
NADP preferentially. This biochemical characteristic favours the existence of 111.E -HSD, 
in skin (liver -type protein). This is further supported by immunohistochemical studies 
which have localized liver -type protein to the epidermis. 
These findings however, do not preclude the presence of other isoforms in the 
skin or indeed an isofonn unique to the skin. In particular, the absence of staining of 
the dermis with antiserum to liver -type protein and the findings of previous studies 
indicating cortisone to cortisol conversion by fibroblasts ( Hammami and Siiteri, 1989) 
indicate that dermis might well be a site of 11B -HSD, activity. Unlike the skin, kidney 
utilizes both NAD and NADP reflecting the presence of both 11B-HS DI and 11B-HS D2 
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in this organ. 
Kinetic studies and enzyme regulation experiments further indicate differences 
between skin and kidney 11B- hydroxysteroid dehydrogenase. The differences 
demonstrated in vitro are consistent with clinical experience. A patient shown to be 
deficient in kidney enzyme (Stewart et al., 1988) did not exhibit clinical cutaneous 
stigmata of glucocorticoid excess. In this patient (G.B.) the roof of an epidermal suction 
blister was incubated with 3H- cortisol, up to 15% was recovered as ;H- cortisone, 
implying presence of 11 ß- hydroxysteroid dehydrogenase activity in skin despite evidence 
for its absence in kidneys (presumably absent from distal nephron). 
Whether deficiency (or excessive activity) of the skin enzyme is important in the 
pathogenesis of skin diseases or susceptibility to glucocorticoid effects remains to be 
elucidated. The nude mouse provides a model in which these hypotheses may be tested. 
The localization of 11B- hydroxysteroid dehydrogenase to the epidermis would 
facilitate attempts to inhibit it by topical means. 
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CHAPTER 5 
POTENTIATION OF HYDROCORTISONE ACTIVITY IN SKIN 
5.1 INTRODUCTION: 
Glucocorticoids play an important role in the treatment of many skin diseases. 
Modifications of the cortisol structure have resulted in a wide variety of clinically 
efficacious agents. The more potent, however, often carry a risk of skin thinning and 
systemic toxicity (Editorial 1977 Lancet); this is not too surprising given the high 
intrinsic potency of such agents. There are theoretical advantages of targeting the 
glucocorticoid receptor by achieving high local levels of an intrinsically weak steroid. 
In this way one need not compromise local efficacy but may significantly reduce 
systemic toxicity. Thus systemic side -effects from topical glucocorticoids are well 
recognized in the setting of chronic or relapsing disease when more potent, highly 
bioavailable agents are used (Himathongkam 1978; Teelucksingh et al., 1993) but such 
effects have not been described with topical hydrocortisone in adults (Turpeinen, 1988). 
On the whole, the systemic absorption of hydrocortisone from skin is very low (Wester 
et al., 1983). 
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Human skin has the capacity to metabolize and inactivate hydrocortisone to 
cortisone (Malkinson et al., 1959, Hsia and Hao, 1966). If it was possible to inhibit skin 
metabolism of hydrocortisone then this might result in enhanced local biologic action 
with minimal systemic toxicity. Previous work had demonstrated that liquorice and its 
extracts were potent inhibitors of 11B- hydroxysteroid dehydrogenase in liver and kidney 
(Valentino etal.,1987, Monder etal., 1989). The question that follows is whether local 
inhibition of this enzyme could enhance hydrocortisone action? 
5.2 LIQUORICE: 
The latter question is particularly interesting because of what has been previously 
described with glycyrrhetinic acid and carbenoxolone, derivatives of liquorice. These 
substances had long been thought to possess glucocorticoid (anti -inflammatory) activity 
(Finney and Somers, 1958; Finney and Tarnoky, 1960; Khan etal., 1967; Parke, 1967). 
In fact, the clinical use of 2% carbenoxolone and glycyrrhetinic acid has been reported 
to benefit a variety of inflammatory disorders both in man (Csonka and Murray, 1971; 
Annan, 1957; Adamson and Tillman, 1955; Somerville, 1957; Colin -Jones, 1957) and 
animals (Halpin, 1956). It was also shown that the administration of glycyrrhetinic acid 
to normal human volunteers or patients with adrenal disease could influence ACTH (as 
evaluated by decreases in urinary excretion of 17- ketosteroids) and MSH (Louis and 
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Conn, 1956), further implying glucocorticoid -like action. The anti -inflammatory effect 
was, however, unpredictable ( Warin and Evans, 1956; Donaldson and Duthie, 1956) 
and it was noted that carbenoxolone possessed no intrinsic anti-inflammatory potency 
in adrenalectomized animals (Finney and Somers, 1958). The latter suggested that these 
substances did have a direct glucocorticoid action but that such an effect was perhaps 
mediated by reduced metabolism/clearance of endogenous glucocorticoids. To support 
this latter view, Kumagai (Kumagai et al., 1957) found that the concomitant use of 
liquorice- extract produced greater efficacy when combined with glucocorticoids in 
patients with rheumatologic diseases than when these patients were treated with 
glucocorticoids alone. To further elucidate this I turned to the animal model for the 
study of skin 11B- hydroxysteroid dehydrogenase. 
5.3 INHIBITION OF SKIN I IB- I- IYDROXYSTEROID 
DEHYDROGENASE: 
Dorsal skin obtained from freshly killed female nude mice (nu /nu, mixed genetic 
background) was homogenized in 10 nil Krebs -Ringer buffer as described in Methods. 
Incubation of homogenized skin (1.5 mg) with 3H- corticosterone was undertaken (see 
Methods, Chapter 4). To determine the possible effects of glycyrrhetinic acid on skin 
enzyme, incubations were also performed with glycyrrhetinic acid at final 
119 
concentrations ranging from 10-4 - 10-8 M. Solutions of glycyrrhetinic acid were 
prepared fresh in absolute ethanol. Control samples containing either no homogenate 
or 10 µl ethanol were compared with incubations containing glycyrrhetinic acid. 
5.3a Results: 
The in vitro experiments using skin from nude mice showed that 11 B- 
hydroxysteroid dehydrogenase activity as assessed by the conversion of corticosterone 
to dehydrocorticosterone was high (Figure 5.1). This was slightly reduced by ethanol 
alone but markedly inhibited in a dose dependent manner by all concentrations of 









* p< 0.05 
** 
1% ethanol GE 10-4M GE 10-6M GE 10-8M 
Figure 5.1: The activity of 11 beta -hydroxysteroid dehydrogenase 
in skin homogenate and the effects of ethanol and various 
concentrations of glycyrrhetinic acid (GE). 
Results shown as mean ± SEM, n =5. p values were obtained after 
comparison by ANOVA followed by paired Student's t test. 
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5.4 TOPICAL GLYCYRRHETINIC ACID ENHANCES SKIN 
VASOCONSTRICTOR ACTIVITY OF HYDROCORTISONE. 
Having demonstrated that skin 11B- hydroxysteroid dehydrogenase was 
susceptible to inhibition of glycerrhetinic acid in vitro and having found that most 
enzyme staining localized to the epidermis (Chapter 4) with little staining in the dermis, 
it was thought that it might be possible to modulate skin enzyme by topical application 
of an inhibitor. In order to determine whether enzyme inhibition might be associated 
with an altered biological effect, I turned to the skin vasoconstrictor bioassay of 
glucocorticoid activity in human subjects. 
5.4a Subjects and methods: 
Twenty three healthy volunteers who had no previous systemic exposure to 
exogenous corticosteroids participated in the study. There were 12 female and 11 male 
subjects of mean age 29 years (range 21 -50 years). The skin vasoconstrictor bioassay 
as modified by Place (1970) and described in Methodology 1, Chapter 3 was used to 
determine the potency of test substances. Two subjects were tested twice after an 
interval two months so that a total of twenty five tests were performed taking groups 
of 4 to 6 subjects at a time. Test solutions comprised hydrocortisone acetate, 
beclomethasone dipropionate, glycyrrhetinic acid and glycyrrhetinic acid with 
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hydrocortisone acetate (HCA) all made up fresh in 95% ethanol in the following 
concentrations: - 
Hydrocortisone acetate: 10, 3, 1, 0.3, 0.1 mg /ml 
Beclomethasone dipropionate: 10, 3, 1, 0.3, 0.1 ,ug /ml 
Glycyrrhetinic acid: 20 mg /ml 
Hydrocortisone acetate and glycyrrhetinic acid together: 
10 mg HCA and 20 mg GE /ml, 
3 mg HCA + 20 mg GE /ml, 
1 mg HCA + 20 mg GE /ml, 
0.3 mg HCA +20 mg GE /ml 
0.1 mg HCA + 20 mg GE /ml. 
Test substances were kept in coded vials and used within twenty four hours of 
preparation. Ten µl of each solution were applied in random order to 7x7 mm sites 
demarcated by silicone grease on the flexor aspect of the forearm. After having been 
allowed to dry the test area was occluded with polyester film (Melinex 12 ,uM, ICI) for 
16 -18 hours. The degree of blanching was assessed 1, 2, 3, and 6 hours after removal of 
the occlusive dressing and scored independently by two observers using a scale where 
0 = no blanching, 1 = mild, 2 = definite, and 3 = intense blanching. All solutions were 
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applied and test sites subsequently read using double -blind procedure. Time -effect 
curves for each test substance were plotted and area under the curve determined using 
the trapezoidal rule. 
5.4b Statistical analysis: 
Comparison between groups was by analysis of variance (AN OVA), followed 
by paired Student's t -test. Significance was set at p <0.05, and results expressed as mean 
+SEM. Linear regression analysis was used to plot the dose -response relationship. 
5.4c Results: 
The dose -response relationship of test substances on the skin vasoconstrictor 
response in normal volunteers is shown in Figure 5.2. 
Hydrocortisone acetate alone produced a flat response at the lower limit of 
detection of the assay consistent with what has been previously reported (Place et al., 
1970). The addition of glycyrrhetinic acid to hydrocortisone acetate, however, 
produced significant potentiation of cutaneous vasoconstrictor effect at concentrations 
of hydrocortisone acetate 10 mg/ml (p <0.01), 3 mg/ml (p <0.001) and 1 mg/ml 
(p <0.001). Glycyrrhetinic acid alone and ethanol alone produced no effect. 
Beclomethasone dipropionate produced a steep dose -response consistent with previous 
















Log conc. / (pg /ml) 
Fig 5.2 : 
Relation of human vasoconstrictor response (area 
under blanching curve in arbitrary units x h), to 
dose of beclomethasone dipropionate (BDP), 
hydrocortisone plus glycyrrhetinic acid (HC +GE) 
and hydrocortisone (HC) alone. 
Results shown as mean ( ±SEM), n =25. 
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5.5 CONCLUSIONS: 
1. In vitro glycyrrhetinic acid was shown to be a potent inhibitor of 
11B- hydroxysteroid dehydrogenase in skin. 
2. Immunohistochemical studies localized 1 l l;- hydroxysteroid dehydrogenase to 
the epidermis, suggesting that it may have been amenable to inhibitio n by topical 
means. 
3. When tested in vivo, glycyrrhetinic acid on its own has no biological effect on 
human skin but when combined with hydrocortisone produced an effect greater 
than hydrocortisone alone. 
4. Glycyrrhetinic acid, possibly by inhibiting metabolism of hydrocortisone in 
human skin, results in enhanced biological activity of hydrocortisone (Skin 
Vasoconstrictor Response). 
5. Previous studies have shown that the enzyme 11B- hydroxysteroid dehydrogenase 
controls access to the mineralocorticoid receptor. The current evidence, by 
virtue of the fact that the inhibition of the enzyme results in an enhanced 
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glucocorticoid response, suggests that the enzyme might also regulate access to 
the glucocorticoid receptor. 
6. Local glycyrrhetinic acid -inhibition of cortisol metabolism provides a possible 
mechanism of increasing glucocorticoid anti -inflammatory action in the skin. 
This principle of local enzyme inhibition producing enhanced glucocorticoid 
activity may well be applicable to other sites where there is local glucocorticoid 
metabolism e.g. gastrointestinal tract and bronchial tree. 
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CHAPTER 6 
MECIIANISM OF ANTI- INFLAMMATORY ACTION OF LIQUORICE 
6.1 INTRODUCTION 
Liquorice and its derivatives have long been known to possess both 
mineralocorticoid (Borst et al, 1953; Elmadjian et al., 1956) as well as glucocorticoid 
properties (Kumagai et al, 1957; Annan, 1957; Adamson and Tillman, 1955; 
Somerville, 1957; Colin- Jones, 1957; Finney and Tarnoky, 1960). The mechanism of 
these actions was poorly understood, although the presence of an intact adrenal gland 
or cortisol replacement in patients with adrenal insufficiency was known to be essential 
(Borst et al., 1953; Elmadjian et al., 1956). Glycyrrhetinic acid, the active principle in 
liquorice was shown to be a potent inhibitor of 11 B- hydroxysteroid dehydrogenase from 
liver and kidney in vitro (Valentino et al., 1987; Monder et al., 1989) and that such 
inhibition, in vivo, could explain the mineralocorticoid effects of liquorice (Stewart et 
al., 1988). 
In Chapter 5, it was demonstrated, like that from liver and kidney, skin 11B- 
hydroxysteroid dehydrogenase was also inhibited by glycyrrhetinic acid in vitro, and 
that such inhibition in vivo may have led to potentiation of skin vasoconstrictor 
response - an apparent glucocorticoid- mediated phenomenon. Thus inhibition of the 
enzyme might also account for the glucocorticoid action of liquorice. 
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6.2 LIQUORICE: AN INHIBITOR OF STEROID AND 
PROSTAGLANDIN DEHYDROGENASES. 
There is, however, structural homology between 11B- hydroxysteroid 
dehydrogenase and several other hydroxysteroid dehydrogenases, including 3a -, 1713 - 
and 20B- hydroxysteroid dehydrogenase in both prokaryotes and eukaryotes (Monder 
and White, 1992). Because of the small contribution of the latter enzymes to the 
metabolism of cortisol in human skin (Hsia, et al., 1964, 1966) it seems unlikely that 
inhibition of these enzymes could be responsible for the potentiation of hydrocortisone 
action by glycyrrhetinic acid. 
On the other hand, there is considerable structural homology between 
prostaglandin metabolizing enzymes and 11B- hydroxysteroid dehydrogenase (Baker and 
Fanestil 1991; Krook et al., 1990). On the basis of the latter there was speculation that 
the anti -inflammatory capacity and mineralocorticoid action of liquorice and its 
derivatives could be in part the result of altered prostaglandin metabolism. Indeed 
Peskar (Peskar et al., 1976) had suggested that the inhibition of metabolism of 
prostaglandin was the possible mechanism by which carbenoxolone healed peptic ulcers. 
This conclusion was drawn from the finding that gastric prostaglandin metabolism was 
inhibited by carbenoxolone at fairly high concentrations (Peskar et al., 1976; Rask- 
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Madsen et al., 1983). To determine whether the anti -inflammatory effects of liquorice 
derivatives (glycyrrhetinic acid and carbenoxolone) demonstrated in human subjects 
might arise from some influence on prostaglandin metabolism, the comparative effects 
of these liquorice- derived compounds upon the prostaglandin metabolizing enzyme, 
15- hydroxyprostaglandin dehydrogenase and 11 B- hydroxysteroid dehydrogenase was 
examined in vitro. Human placental tissue was chosen because it is a rich source of 
both 11B- hydroxysteroid dehydrogenase (Monder and White, 1992) and 
1 5-hydroxyprostaglandin dehydrogenase (Krook et al., 1990). 
6.3 METHODS: 
Chorionic homogenate (protein content 1.5 mg) was incubated with 500 ng PG E2 
and 1 mM NAD at 37° C for 15 min in a phosphate buffer containing 20% glycerol (pH 
8.4). Prostaglandin dehydrogenase activity was measured by radioimmunoassay of the 
quantity of 15 -keto PGE2 produced after transformation to its methyl oxime (this assay 
was performed by Cheng Li Nan, MRC Reproductive Biology Unit, Edinburgh). The 
experiment was completed with glycyrrhetinic acid, carbenoxolone and 
5- (4- fluorobenzoyl) 2- hydroxybenzene acetic acid (FHBA), a known prostaglandin 
dehydrogenase inhibitor, all at concentrations up to 40 M. 
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The effects of similar concentrations of the latter substances on human placental 
11B- hydroxysteroid dehydrogenase were evaluated as described for the skin 
(Methodology, Chapter 4). Briefly, 0.3 mg protein from fresh placental homogenate 
was incubated with 12 ,uM 3H- cortisol and 200 µM NAD in Krebs -Ringer buffer at 
37 °C for 1h. Steroids were extracted with ethyl acetate and separated by thin -layer 
chromatography. Activity of 11B- hydroxysteroid dehydrogenase was expressed as a 
percentage conversion percentage 3H- cortisol to 3H- cortisone. 
6.4 RESULTS: 
The results show that glycyrrhetinic acid and carbenoxolone had no effect on 
15- hydroxyprostaglandin dehydrogenase activity (Figure 6.1, top), in contrast to the 
inhibition produced by FHBA. On the other hand, FHBA had no affect on 
11B- hydroxysteroid dehydrogenase while both carbenoxolone and glycyrrhetinic acid 
produced marked inhibition (Figure 6.1, bottom). 
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Figure 6.1: The comparative effects of FHBA, glycyrrhetinic acid and 
carbenoxolone on prostaglandin dehydrogenase activity (top) and 11 




At the concentrations used in this experiment, neither glycyrrhetinic acid nor 
carbenoxolone had any effect upon 15- hydroxyprostaglandin dehydrogenase, however, 
1 lß- hydroxysteroid dehydrogenase was markedly inhibited by these compounds. 
Oral ingestion of liquorice has been shown to produce mineralocorticoid effects 
even when plasma glycyrrhetinic acid concentrations are below 2µM the lower limit of 
detection of the assay (Stewart et al., 1987). This evidence taken together with the 
above findings makes it unlikely that altered prostaglandin metabolism contributes 
substantially to either the salt -retaining or anti -inflammatory properties of liquorice and 
its derivatives. It seems likely that the long recognized anti -inflammatory action of 
liquorice is mediated by inhibition of metabolism of cortisol. 
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CHAPTER 7: VARIATION IN SENSITIVITY TO GLUCOCORTICOIDS 
7.1 BACKGROUND 
A possible shortcoming in the approach to glucocorticoid therapy has been the 
relative disregard for what has, in fact, been a long held clinical perception; that 
sensitivity to glucocorticoid therapy can be strikingly variable. It is known for example, 
that glucocorticoid regimes will be successful in preventing acute renal transplant 
rejection in only about 50% of cases (Dumble et al., 1981; Langhoff and Ladefoged, 
1987). Similar heterogeneous corticosteroid sensitivity has also been described in the 
treatment of myasthenia gravis (Willcox etal.,1989; Tindall, 1980). Though recognized 
in a number of clinical settings, the phenomenon of glucocorticoid resistance has 
probably been best documented in asthma. Thus, although most patients with asthma 
will benefit from glucocorticoids, bronchospasm in some patients proves refractory to 
such therapy (Dwyer et al., 1967; Schwartz et al., 1968; Carmichael et al., 1981). That 
this phenomenon is not confined to any particular disease state suggests that inherent 
biological factors rather than specific diseases might be dictating this. 
There are a number of possible factors that could contribute to reduced 
sensitivity to glucocorticoids: 
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(i) Severity of the disease being treated is an obvious factor. Thus patients with 
more severe disease may require larger dosages or more prolonged treatment to 
derive an optimal response. 
(ii) Differences in metabolic clearance could also contribute to such a phenomenon. 
It has been shown, for example, that the metabolic clearance rate and the volume 
of distribution of prednisolone are lower and the half -life longer in patients with 
an increased tendency to toxicity (Axelrod, 1989). Likewise, co- existing diseases 
may significantly reduce clearance. Thus patients with impaired hepatic and 
renal function will clear glucocorticoids less effectively (Axelrod 1989). In 
patients on enzyme inducing drugs like phenytoin and rifampicin, the reverse is 
seen. These patients can exhibit "resistance" (Becker et al, 1973; Edwards et al., 
1974; Lofdahl et al., 1984) to glucocorticoids because of increased metabolic 
clearance. 
(iii) Many of the anti -inflammatory actions of glucocorticoids are mediated by the 
anti -inflammatory proteins, the lipocortins or annexins (Peers et al., 1993). The 
development of antibodies to lipocortin -1 has been shown to be associated with 
attenuated responsiveness to glucocorticoid therapy in patients with rheumatoid 
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disease (Podgorski et al., 1992). 
However, there is another scenario which will not be explained by the above. 
There are those patients who seem exquisitely sensitive to development of glucocorticoid 
associated side -effects. Thus Becker (Becker 1965; Becker et ai, 1973) had observed, 
for example, that the topical administration of glucocorticoids resulted in greater rises 
of intra- ocular pressure in patients with primary open -angle glaucoma compared with 
non -glaucomatous controls. Moreover, this ocular sensitivity was paralleled by an 
increased sensitivity to adrenal suppression with dexamethasone (Becker et ai, 1973). 
Lymphocytes from such patients, likewise, exhibited greater suppression of 
phytohaemagglutinin -induced transformation under the influence of glucocorticoids 
(Becker et al, 1973). This implied, that in these patients this enhanced glucocorticoid 
sensitivity was not tissue -specific but might be a generalized phenomenon. More 
suggestive evidence for heterogeneity in response to glucocorticoid had, in fact, first 
come from animal studies. 
It has been recognized for some time now that there are marked inter -species 
differences in the response to glucocorticoids. Thus hamster, mouse, rat and rabbit are 
glucocorticoid- sensitive whereas guinea pigs, monkey and man are 
glucocorticoid- resistant species (Claman, 1972). This differentiation is based on the 
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relative ease of producing lymphoid depletion after systemic glucocorticoid exposure 
(Claman, 1972). Such differences in sensitivity can be explained by the finding that 
there are differences in affinity among glucocorticoid receptors in different species, for 
the same ligand (Kraft et al.., 1979). Interestingly, it was shown that even within a single 
species there might be differences in sensitivity and this sensitivity may be genetically 
determined. Thus, the thymus cells of mice with H2a haplotype were shown to be much 
more sensitive to the lytic action of glucocorticoids both in vivo and in vitro than those 
from mice with the H2b haplotype (Becker et al., 1976). 
Moving upwards in the animal kingdom, there are marked differences in 
glucocorticoid sensitivity among primates. New World monkeys, for example, 
marmoset and squirrel are glucocorticoid resistant compared with Old World species 
eg. chimpanzee (Lipsett et al., 1985). Despite the 10 -fold or so greater circulating levels 
of cortisol in resistant species, life expectancy, biochemistry and metabolism are similar 
to that of Old World species (Lipsett, et al., 1985). The affinity of the glucocorticoid 
receptor for dexamethasone, however, is markedly reduced in New World primates. 
Evidence that a similar situation might also exist in man came with the report by 
Vingerhoeds (Vingerhoeds et al., 1976) of a "possibly genetically determined 
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hyposensitivity to the glucocorticoid action of cortisol". In this description, two 
patients, a father and son, exhibited gross, sustained hypercortisolism without the 
clinical stigmata of Cushing's syndrome. This paradox was explained by the finding of 
qualitative abnormalities of glucocorticoid receptor in lymphocytes and skin fibroblasts 
(Chrousos et al., 1982). Since this description there have been subsequent reports 
indicating a variety of abnormalities of the glucocorticoid receptor. These include a 
decreased number of glucocorticoid receptors (lida et al., 1985), decreased binding of 
the activated receptor to DNA (Nawata et al., 1987) and decreased stability of the 
receptor at higher temperatures (Bronnegard el al., 1986). 
Interestingly, a cortisol hyperactive syndrome in which there are features of 
Cushing's syndrome associated with subnormal levels of serum cortisol, free cortisol 
and 24 -h urinary cortisol excretion, has also been described (Iida et al., 1990, 1991). 
The latter might represent the prototype of those patients who are particularly prone 
to glucocorticoid side -effects. 
Extensive studies in the evaluation of such patients and their extended kinship 
showed that there was, however, no association between the transmission of the 
condition and HLA haplotypes (Lipsett et al, 1985). This implied, unfortunately, that 
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it was not possible to utilize a very convenient marker, HLA haplotypes, to screen wider 
populations for such abnormalities. 
Further study of such inherent variability in responsiveness to glucocorticoids 
might provide insight as to how it might be possible to tailor glucocorticoid therapy to 
individual needs rather than through empiricism. The value of some clinical or 
biochemical marker that might predict the outcome to glucocorticoid therapy for 
inflammatory or neoplastic conditions would be immense. 
The skin vasoconstrictor bioassay has served as a useful method to assess 
glucocorticoid potency. Can it be utilized to define glucocorticoid sensitivity? 
7.2 RATIONALE FOR USE OF SKIN VASOCONSTRICTOR ASSAY AS 
A MARKER OF GLUCOCORTICOID SENSITIVITY 
That the skin vasoconstrictor response in an individual might reflect inherent 
glucocorticoid sensitivity is suggested from what is understood to be the mechanism of 
blanching. Although the precise mechanism of the blanching phenomenon is not known 
a number of possibilities has been proposed (Marks and Sawyer, 1986). 
Glucocorticoids are known to reduce the erythema induced by a variety of vasodilators. 
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Thus topical arachidonic acid will induce skin erythema but prior treatment of the skin 
with glucocorticoid will substantially reduce this erythematous response (Marks and 
Sawyer, 1986). Similarly, histamine characteristically induces a wheal and flare 
cutaneous response which can be subdued by prior glucocorticoid application (Marks 
and Sawyer, 1986). Glucocorticoids are known to inhibit both histamine release from 
basophils (Schleimer et al., 1981) as well as to prevent arachidonic acid release from 
membrane phospholipids (Blackwell et al, 1980). It is possible that inhibition of 
phospholipase A2 is the final common pathway to both these processes since both 
histamine as well as exogenous arachidonic acid can stimulate endogenous 
phospholipase A2 activity (Flower, 1988 b). Furthermore glucocorticoid sensitizes 
blood vessels to the vasoconstrictive influence of endogenous catecholamines (Ginsburg 
and Duff, 1958; Haigh et al., 1990), a process that can likewise be linked to inhibition 
of endogenous phospholipase A2 activity (Rascher et al., 1980). Glucocorticoids are 
known to inhibit phospholipase by way of the anti -inflammatory proteins - lipocortins 
(Flower, 1988 a,b). Direct evidence for a role for lipocortins in this vasoconstrictor 
process is, however, not currently available. Even so, this would not necessarily be 
exclusive of other mechanisms (Walker et al., 1992 c; Walker and Williams, 1992) 
especially those involving endothelium- dependent factors (Brenner et al., 1989). 
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7.3 SKIN VASOCONSTRICTION - A GLUCOCORTICOID- SPECIFIC 
PHENOMENON 
Although the precise cellular mechanism of skin blanching is not known, it does 
seem to arise as a result of interaction between glucocorticoid and glucocorticoid 
receptors in the skin vasculature (Marks et al, 1982; Kornel et al., 1982; Gaillard et al, 
1985). Thus neither progesterone, deoxycorticosterone, estradiol nor testosterone, even 
at high concentrations, induce blanching when applied on their own (Marks et al., 
1982). However, when co- applied with potent glucocorticoids, progesterone and 
deoxycorticosterone but not estradiol or testosterone antagonize the vasoconstrictor 
response in dose -dependent fashion (Marks et al., 1982). Progesterone and 
deoxycorticosterone behave as glucocorticoid antagonists in most 
glucocorticoid- responsive systems whereas estradiol and testosterone are without effects 
(Funder, 1985). 
More direct evidence to suggest that blanching is mediated by occupancy of 
glucocorticoid receptors comes from a study that showed attenuation of blanching 
responses to topical glucocorticoids following the systemic administration of RU 38486 
(Gaillard et al, 1985). This compound exhibits potent anti -glucocorticoid properties 
which correlate with strong binding to the glucocorticoid receptor leading to its 
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inactivation (Moguilewsky and Philibert, 1984). 
7.4 SKIN VASOCONSTRICTOR ASSAY IN A POPULATION: INITIAL 
STUDIES VALIDATING THE SKIN VASOCONSTRICTOR 
RESPONSE AS A POTENTIAL MARKER OF GLUCOCORTICOID 
SENSITIVITY. 
An inherent value of the skin vasoconstrictor bioassay is the built -in control of 
the subject's normal skin for comparison. Quantitative validation was therefore 
unnecessary. Initial qualitative blanching assays were therefore performed. 
7.4a Subjects and methods 
Fifty eight healthy adult subjects (mostly Caucasians) of both sexes and mean 
age 35 years (range 16 -50) were used as a pool of volunteers. All were tested initially 
with solutions ofbeclomethasone dipropionate, apotent topically active glucocorticoid 
of high topical bioavailability at concentrations of 100 and 10 ug /ml using the skin 
vasoconstrictor assay as described in Methodology 2, chapter 3. 
7.4b Results: 
A single reading of vasoconstrictor response after 16 hours of occlusion revealed 
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that 52 (90 %) had a positive response to 10 tig /ml. Fifty five (95 %) had a positive 
response to 100 ,ug /ml. Three individuals remained negative on serial testing over the 
ensuing three months. 
Serial qualitative testing of the latter three individuals over the ensuing three 
months at intervals of one month showed they remained consistently unresponsive to 
topically applied beclomethasone dipropionate. Two patients were otherwise normal 
and one had type I diabetes. 
Results very similar to these have been reported by previous assayists. Burdick 
(1974) reported 90% positive responders to fluosinolone acetonide out of 24 subjects. 
Place (1970), likewise, reported 92% responsiveness using triamcinolone acetonide. 
Both fluosinolone acetonide and triamcinolone acetonide, like beclomethasone 
dipropionate (Johansson et al., 1982) exhibit high topical activity. 
Previous users of this assay have recognized that there is "biologic- variation" in 
responsiveness, (Burdick, 1974; Barry and Woodford, 1978; Stoughton, 1992) and thus 
selected only those individuals who were good responders (Burdick, 1974). The purpose 
of these studies was to determine bioavailability and potency of topical agents however, 
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and the significance of unresponsiveness in individuals was not explored. 
A negative response could presumably arise as a result of impaired 
bioavailability across the skin -barrier. However, beclomethasone dipropionate is highly 
lipophilic and exhibits high bioavailability across the skin (Johansson et al., 1982). It 
is therefore possible that individuals who do not demonstrate a skin response with such 
an agent may have some defect involving glucocorticoid -glucocorticoid receptor 
interaction. 
7.5 EVIDENCETHAT SKIN VASOCONSTRICTION IS MEDIATED VIA 
CLASSICAL (TYPE II) GLUCOCORTICOID RECEPTORS. 
The systemic administration of a known glucocorticoid receptor blocking agent 
RU 38486, has been found to attenuate the skin blanching phenomenon (Gaillard etal., 
1985). The compound RU 38486 also blocks progesterone receptors (Kelly, 1992) but 
the application of progesterone to the skin does not result in blanching (Marks et al., 
1982). This suggested that the blanching phenomenon was the likely result of 
interaction of glucocorticoid with its receptor in skin. A negative skin response could, 
therefore, reflect some abnormality of glucocorticoid: glucocorticoid -receptor 
interaction i.e. glucocorticoid resistance. 
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It is noteworthy that route of administration of RU -38486 (and perhaps dose) 
can influence observed effects of this compound (Laue et al., 1989). Thus oral 
administration of RU -38486 failed to stimulate vasopressin release in monkeys, whereas 
intramuscular administration had produced such an effect. The inhibitory effect of 
systemic administration of this compound on skin vasoconstriction had previously been 
shown (Gaillard et al, 1985). The effect of topically applied RU -38486 on the 
blanching response was, therefore, tested. 
RU -28362 is another synthetic glucocorticoid of high potency with negligible 
affinity for renal mineralocorticoid (Type I glucocorticoid) receptors (Morris and 
Souness, 1992; Tempel et al., 1993). It was therefore also important to study the effect 
of this compound. 
7.5a Methods: 
The skin vasoconstrictor assay was conducted as described in Methodology 2 
(Chapter 3). Beclomethasone dipropionate, 10 µg/ml, was applied alone or was co- 
applied with RU- 38486, 10µg/ml, and the effect compared with RU -38486 applied 
alone. RU- 28362, 10µg/ml, was also applied alone. 
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7.5b Results: 
Six initially positive responders were tested serially over three months at monthly 
intervals. These subjects retained the ability to exhibit a blanching response to 
beclomethasone dipropionate. This pool of six subjects was used for the above tests. 
Beclomethasone dipropionate 10 µg/ml, produced intense blanching when 
applied alone. When, however, the glucocorticoid antagonist, RU 38486 (10 µg /ml), 
was co- applied with 10 µg /ml beclomethasone dipropionate solution, there was 
complete attenuation of the blanching response. RU -28362 produced intense blanching 
in all subjects tested. 
It is unlikely that suppression of blanching arose out of impaired local 
bioavailability of beclomethasone dipropionate when co- applied with RU -38486 since 
similar fmdings have been previously obtained following systemic administration of 
RU -38486 (Gaillard et al., 1985). RU -38486 applied on its own also showed no 
blanching response. 
That blanching can be attenuated by a glucocorticoid receptor blocker supports 
the central role of the glucocorticoid receptor in this process and because blanching 
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occurs with RU- 28362, a substance with little affinity for Type I glucocorticoid 
receptors, strongly supports that vasoconstriction is mediated via classic (Type II) 
glucocorticoid receptors. 
A lack of cutaneous response to topically applied glucocorticoids might also 
therefore reflect insensitivity (resistance) to glucocorticoids; representing some defect 
in type II glucocorticoid receptor number or function. 
7.6 SKIN VASOCONSTRICTOR AND ALDOSTERONE (TYPE I 
GLUCOCORTICOID) RECEPTORS_ 
Using the methods described above, aldosterone in concentrations of 10 -100 
µg /ml produced no visible blanching in three subjects who were repeatedly responsive 
to beclomethasone dipropionate. This suggested that aldosterone receptors were not 
important in producing blanching. To further support this, other evidence was 
obtained. 
Pseudohypoaldosteronism is a condition presenting in early childhood with salt 
wasting and failure to thrive and is characterized by high urinary levels of sodium 
despite hyponatraemia, hyperkalaemia and hyperreninemia occurring in the face of 
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elevated aldosterone levels indicating renal tubular insensitivity to mineralocorticoids 
(Dillon et al., 1980). Aldosterone receptor deficiency have been demonstrated in 
mononuclear leucocytes in patients with this syndrome (Armanini el al., 1985) 
suggesting that mineralocorticoid receptor deficiency is a generalized phenomenon in 
some patients. One such patient, an eighteen month old boy (A.D., a patient of 
Ninewell Hospital, Dundee) with clinical and biochemical features of this syndrome was 
tested for skin vasoconstrictor responses to beclomethasone dipropionate. 
The application of beclomethasone dipropionate (100, 30, 10, 1 µg/m1) to the 
skin of this boy resulted in blanching at all doses. 
All of this evidence points to the lack of contribution of Type I glucocorticoid 
receptors to the blanching phenomenon. 
7.7 CONCLUSIONS: 
The blanching phenomenon represents a specific glucocorticoid receptor - 
mediated effect which from the current data is mediated via classical (Type 11) 
glucocorticoid receptors. Like previous workers, I was struck by the marked 
heterogeneity in responsiveness to topically applied glucocorticoids. There is a small 
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subset of apparently normal individuals in a population who do not respond to topically 
applied glucocorticoid or those who will only respond when high topically doses are 
applied. 
Variable skin sensitivity could reflect variable glucocorticoid sensitivity. It might 
therefore be possible to apply this principle to evaluate glucocorticoid sensitivity in 
other systems where responses to glucocorticoids have been otherwise defined e.g. 
glucocorticoid resistant and sensitive asthma. 
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CHAPTER 8 THE EFFECTS OF ACUTE SYSTEMIC GLUCOCORTICOID 
EXPOSURE ON SKIN VASOCONSTRICTOR RESPONSIVENESS 
8.1 BACKGROUND 
There is abundant data regarding the reproducibility of the skin vasoconstrictor 
assay (Barry and Woodford, 1976; Smith et al, 1992). There are, however, no data on 
the behaviour of this assay in respect of systemic glucocorticoid exposure. Can systemic 
glucocorticoid exposure alter skin vasoconstrictor responsiveness to topically applied 
glucocorticoids? Since the blanching response correlates so closely with the anti - 
inflammatory actions of glucocorticoids it would be important to determine whether 
systemic exposure impacts on cutaneous responsiveness. 
Preliminary data suggest that previous glucocorticoid exposure may lead to 
altered glucocorticoid sensitivity. This comes principally from the work of Du Vivier 
(Du Vivier and Stoughton, 1975; Du Vivier, 1976). Thus acute tolerance to the 
vasoconstrictor effect of topically applied glucocorticoid has been described (Du Vivier 
and Stoughton, 1975). A glucocorticoid applied topically will cause blanching within 
6 to 8 hours. This vasoconstrictor response will then fade within the ensuing 24 -48 
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hours. With repeated applications over several days the vasoconstrictor response 
becomes no longer elicitable. If left untreated for 72 to 96 hours, the vasoconstrictor 
response will once more become elicitable. When compared with other known effects 
of glucocorticoids on the skin, tolerance to the vasoconstrictor response was not an 
isolated finding; other biological effects of glucocorticoids were similarly affected. Thus 
it was demonstrated (Singh and Singh, 1986) that suppression of histamine induced 
erythema and wheal in skin by glucocorticoids underwent tachyphylaxis with continued 
glucocorticoid use. Similarly, the initial application of glucocorticoid to mouse skin 
leads to marked inhibition of epidermal mitosis. With repeated application of 
glucocorticoid, acute tolerance to its anti -mitotic effects can also be demonstrated (Du 
Vivier, 1976). 
Evidence for the diminution of glucocorticoid sensitivity following systemic 
exposure also comes from other studies (Goulding et al., 1989; and Podgorski et al., 
1992). In these studies, patients maintained on higher dosages of oral prednisolone (> 
7.5 mg/day) for rheumatoid arthritis exhibited reduced sensitivity to subsequent 
glucocorticoid therapy. It was postulated that the generation of anti -lipocortin 
antibodies following oral administration of glucocorticoids might be responsible for 
such reduced responsiveness. 
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Glucocorticoid receptor levels in target tissues are subject to up- regulation and 
down -regulation (Smith and Shuster, 1984; Rosewicz etal., 1988). In most tissues there 
is an inverse relationship between hormone and glucocorticoid receptor levels (Reul el 
al., 1989; Frey and Frey, 1992). This might represent a possible explanation for the 
tachyphylaxis to topically applied glucocortcoids. 
It is also possible that induction of enzyme /s that metabolize glucocorticoids 
might be relevant. There is data to implicate the latter mechanism in glucocorticoid 
tachyphylaxis. Thus B lymphocytes which metabolize cortisol more rapidly than T 
lymphocytes are less sensitive to the lytic effects of glucocortcoids (Frey and Frey, 
1992). In Chapter 4 it was shown that 11 ß- hydroxysteroid dehydrogenase enzyme 
activity in skin is inducible; reduced in adrenalectomized animals and normal (compared 
with sham -operated animals) once glucocorticoids are replaced. This would lend 
support to the notion that steroid enhanced metabolism might be a mechanism of such 
tachyphylaxis in the skin. 
Whatever the mechanism it seems evident that variation in sensitivity might 
influence glucocorticoid toxicity since dosages are prescribed empirically without regard 
to such differences in individual sensitivity. Can systemic glucocorticoid exposure lead 
to an alteration in peripheral sensitivity to glucocorticoid in the manner that topical 
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therapy does? If this is the case then extinction of the vasoconstrictor response might 
serve as a guide to systemic glucocorticoid exposure. This study was designed to assess 
whether systemic exposure to low dose glucocorticoid altered the skin vasoconstrictor 
response. Since it was the eventual aim to study skin blanching in glucocorticoid 
resistant asthmatics, it was decided to carry out a detailed study in normal subjects of 
the effects of taking varying doses of inhaled glucocorticoid. Normal subjects rather 
than asthmatic patients were chosen to eliminate the possible effects of intercurrent or 
previous glucocorticoid therapy. 
8.2 SKIN VASOCONSTRICTOR RESPONSES FOLLOWING SYSTEMIC 
EXPOSURE TO GLUCOCORTICOIDS 
8.2a Methods: 
Sixteen subjects who were initially found to be positive responders were followed 
prospectively for six months. Over this period all sixteen subjects were exposed in 
random order to beclomethasone dipropionate administered via standard metered -dose 
inhaler in dosages of 0 (placebo), 400, 800, 1400 and 2000 ,ug/day in four divided doses 
for ten days. Wash -out intervals of 18 days separated treatments which were assigned 
in random order using double -blind approach in a protocol summarized in Figures 8.1 
and 8.2. 
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DAYS 10 18 10 18 10 18 
washout " washout washout 
Rx 1 Rx 2 Rx 3 
10 18 10 
L. washout `\ 
Rx 4 Rx 5 
Figure 8.1: The design of experiment to determine the effects of 
varying doses of beclomethasone dipropionate. 
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Figure 8.2: The sequence of tests to evaluate the systemic effects of BDP 
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Skin sensitivity to topically applied beclomethasone dipropionate (10, 3, 1, 0.1 
pg/'ml test solutions) was determined after 10 days of treatment at each dose as 
described in Methodology 2, (Chapter 3). Test substances were applied on the ninth day 
of treatment and readings were taken the following day after 16 h of occlusion. The 
presence or absence of blanching at each topically applied dose of beclomethasone was 
first ascertained and then graded on a four -point scale as previously described in 
Chapter 3_ 
It was important to ascertain, using other parameters, the degree of systemic 
glucocorticoid effect induced by each treatment. Because the time -course of systemic 
glucocorticoid effects are tissue- dependent (Axelrod, 1989) it was necessary to test a 
variety of glucocorticoid end -points. The following were therefore also tested; 
circulating neutrophils, bone metabolism, and intermediary metabolism. Methods of 
measurement of all these parameters are outlined in Chapter 2. Testing the 
hypothaIlan.._ axis is the traditional yardstick of both the degree of 
systemic glucocora : exposure a ,'hether the is recovery' from chronic treatment 
with such (1-larrison et :, _ _ 1 976; Feek et al., 1981). The hypothalamic- 
pituitary- adrenal axis across each treatment period was therefore also tested. 
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0900 h plasma cortisol has been used to indicate basal hypothalamic- pituitary- 
adrenal function (Mygind and Hansen, 1973; Sherman et al., 1982; Bisgaard et al., 
1988). Likewise, 24h urinary free cortisol has also been used to test basal hypothalamic - 
pituitary- adrenal function (Prahl et al., 1987, Smith and Hodson, 1983). Dynamic 
testing of this axis would provide a more sensitive index of systemic glucocorticoid 
exposure. While there are a number of ways of evaluating the hypothalamic- pituitary- 
adrenal axis by dynamic tests (Feek et al., 1981; Harrison el al., 1982; Cunningham 
1983), the short metyrapone test (Dickstein et al., 1986, 1991) represent a simple, 
convenient and sensitive way to do this (Feek et al, 1981; Holt et al., 1990). The short 
metyrapone test was performed according to the method of Dickstein (Dickstein et al., 
1986). Briefly, metyrapone 1500 mg was administered with 300 ml milk at 0600h and 
blood taken at 0800h, 1200h and 1400h. Plasma samples were analysed for cortisol and 
11- deoxycortisol by radioimmunoassay. Plasma cortisol at 0800h established the 
efficacy of the block to cortisol biosynthesis. The mean value of 11- deoxycortisol 
obtained at 1200 and 1400h was taken as a measure of pituitary- adrenal responsiveness. 
This study had the approval of the Lothian Region Ethics Committee and was 
conducted in accordance with the Declaration of Helsinki (Appendix I) as to guiding 
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medical doctors in research involving drug treatment of human subjects. 
8.2b Statistical analysis: 
The effects of each treatment was analyzed by three way analysis of variance 
(subject, dose and phase). Least squares estimates of effects relative to placebo were 
obtained with their standard error. The hypothesis of no treatment effect was tested by 
t -tests at each dose and significance set at the 5% limit. 
The proportion of patients demonstrating a positive response to various doses 
of topical beclomethasone dipropionate was compared across each treatment of 
systemically administered dose by chi -squared tests. Significance was also set at the 5% 
limit. 
8.2c Results 
(i) Skin vasoconstrictor responses: 
The mean blanching score produced by application of 10, 3, 1 and 0.1 µg/ml of 
beclomethasone dipropionate to the skin of sixteen positive responders were similar for 
placebo and all doses of inhaled beclomethasone dipropionate administered to the 
airways (Figure 8.3). Similarly, the number of individuals having a positive blanching 
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Placebo 400 800 
BDP / ug 
1400 
Figure 8.3: The mean blanching scores after placebo and 
following treatment with varying doses of beclomethasone 














-A- 400 ug 
--O-- 800 ug 
- ,k- 1400 ug 
-V- 2000 ug 
-1 0 0.48 
Log concentration of topical dose of BDP (µg /ml) 
Figure 8.4: The proportion of individuals showing a positive 
blanching response at each dose of topically applied 
beclomethasone dipropionate after placebo treatment and varying 
doses of inhaled beclomethasone dipropionate (BDP). 
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response at each of these dosages (Figure 8.4) did not differ significantly irrespective of 
the systemically administered dose. 
(ii) Hypothalamic- pituitary- adrenal effects: 
Using 0900 h plasma cortisol as an end -point ofhypothalamic- pituitary- adrenal 
effect showed that only treatment with 2000 µg/day beclomethasone dipropionate 
produced such an effect (p <0.05), (Figure 8.5). Using urinary free cortisol as such a 
marker showed that significant effects were established at doses 1400 µg/day (p <0.001) 
and 2000 µg/day p <0.001 (Figure 8.6). In comparison dynamic testing with metyrapone 
showed that even lower dosages produced significant effects on this axis: 800,ug/day 
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Figure 8.5: Effects of varying doses of beclomethasone 
dipropionate (BDP) on the hypothalamic -pituitary -adrenal axis - 
0900h PLASMA CORTISOL. 
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Figure 8.6: Effects of varying doses of beclomethasone dipropionate (BDP) 
on hypothalamic -pituitary -adrenal axis - 24h urinary free cortisol. 






















Figure 8.7: Effects of varying doses of beclomethasone 
dipropionate (BDP) on the hypothalamic -pituitary -adrenal axis - 
11-deoxycortisol response to metyrapone. 
Results shown as mean ± SEM, n =16. 
167 
(iii) Circulating neutrophils 
Glucocorticoid exposure is known to induce changes in circulating leucocytes 
(Fauci et al, 1976). In the current experiment, doses greater than 800 ,ug /day were 
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Fig. 8.8: Effects of varying doses of beclomethasone 
dipropionate (BDP) on circulating neutrophils. 
Results shown as mean ± SEM, n =16. 
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(iv) Bone metabolism: 
Glucocorticoids have many effects on bone metabolism (Baylink, 1983; Reid, 
1989) and osteoporosis is a frequent complication ofglucocorticoid therapy irrespective 
of the disease being treated (Adinoff and Hollister, 1983). Plasma osteocalcin is a 
sensitive and specific marker of bone formation in patients with a variety of metabolic 
bone diseases (Brown et al, 1984; Delmas, 1985; Reid, 1989). 
The effect of the varying dosages of beclomethasone dipropionate on plasma 
osteocalcin is shown in Figure 8.9. There was a significant reduction in plasma 










* p < 0.05 
** p < 0.005 
** 




MI Day 9 
1400 2000 
Figure 8.9: Effects of varying doses of beclomethasone 
dipropionate (BDP) on plasma osteocalcin after 5 days (0) and 
9 days (K of treatment. 
Results shown as mean ± SEM, n =16. 
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(vi) Intermediary metabolism: 
Glucocorticoids are known to influence carbohydrate metabolism (Baxter and 
Tyrrell, 1986; Melby, 1974; Kruszynska, 1987) and this can be used as a measure of 
systemic exposure. 
The effects of the various treatments on fasting blood glucose, insulin and C- 
peptide are shown in Figure 8.10. At low dosages there was no influence on these 
parameters. When used at the highest dose (2000 µg/day), however, fasting plasma 
insulin and C- peptide levels were significantly increased (p <0.05). 
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* p<0.05 
Placebo 400 800 
BDP µg 
1400 2000 
Insulin (mU /L) 
Before 
.V., After 
C- peptide (pmol /L) n Before 
After 
Glucose (mmol /L) 
Before 
After 
Figure 8.10: Effects of varying doses of beclomethasone 
dipropionate (BDP) on glucose homeostasis. 
Results shown as mean ± SEM, n =16. 
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8.3 CONCLUSIONS: 
Mean blanching score in a cohort of positive responders did not change 
significantly over a period of six months. Likewise, blanching profiles (% blanching at 
each topically applied dose) also did not change significantly. This was the case despite 
demonstrating varying degrees of systemic glucocorticoid exposure using the other 
parameters described. It is possible that the degree of glucocorticoid exposure (either 
dose or duration) was not large enough to induce such a change in the skin. 
In evaluating degree of systemic glucocorticoid effects, plasma osteocalcin was 
a particularly sensitive marker; being more readily affected than changes in circulating 
neutrophils and metyrapone testing of the hypothalamic- pituitary- adrenal axis. 
Previous work have shown that dosages of 1000 µg/day (Meeran et al, 1991) and 2000 
,ug/day (Pouw etal.,1991) can reduce circulating plasma osteocalcin levels. The current 
data shows that even lower dosages are also associated with this effect. 
Despite detecting changes in the mentioned variables, there was no apparent 
change in skin vasoconstrictor responsiveness at any dosage of treatment with 
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beclomethasone dipropionate compared with placebo treatment. Short term but 
significant systemic exposure to glucocorticoids therefore does not appear to affect skin 
vasoconstrictor responses. 
This is the first time that the skin vasoconstrictor response has been compared 
systematically with other end-points of systemicglucocorticoid effect. Although 10 -day 
systemic exposure was not associated with change in skin vasoconstrictor 
responsiveness, it is important to determine whether changes in skin vasoconstrictor 
responsiveness do occur after more prolonged or higher dose systemic exposure. 
For obvious reasons it is difficult to carry out these studies in normal subjects. 
It would be appropriate to carefully evaluate the skin vasoconstrictor response in 
patients treated chronically with glucocorticoid therapy especially if these patients could 
be evaluated for other parameters indicative of systemic glucocorticoid sensitivity. In 
this way correlation between skin responsiveness and systemic glucocorticoid sensitivity 
could be established. Glucocorticoid sensitivity in bronchial asthma provides the best 
defined and most available model in which to pursue this. 
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CHAPTER 9: TESTING SKIN VASOCONSTRICTOR RESPONSES IN 
GLUCOCORTICOID RESISTANT ASTHMA 
9.1 GLUCOCORTICOID RESISTANT ASTI -IMA 
The phenomenon of glucocorticoid resistance has probably been best studied in 
asthmatics. Schwartz demonstrated a decreased eosinopenic response to cortisol and 
an accelerated plasma cortisol clearance in patients who were clinically resistant to 
cortisol's anti - asthmatic effect (Schwartz et al., 1968). Further study of severe steroid - 
dependent asthmatics (Rose et al., 1980) suggested that altered binding, distribution and 
clearance of prednisolone were not responsible for the large requirement of these 
patients. On the basis of this finding Rose deduced that differences in severity or 
pathophysiology or that some intrinsic difference in glucocorticoid receptor sensitivity 
might be operational (Rose et al., 1980). 
Carmichael, continuing this theme studied the clinical characteristics of patients 
defined as either sensitive or resistant to glucocorticoids after therapeutic trials 
(Carmichael etal.,1981). It was found that patients who responded poorly had suffered 
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longer, had more severe airways disease and had a family history of asthma more 
commonly. In further studies of these patients, it was also found that there was an 
apparent inability of oral prednisolone to reduce the level of monocyte complement 
receptors in resistant compared to sensitive patients (Carmichael el al., 1981; Kay et al., 
1981). A further series of in vitro studies demonstrated that colony growth of 
mononuclear cells from glucocorticoid- resistant asthmatics was less susceptible to 
inhibition with glucocorticoids when compared with glucocorticoid- sensitive patients 
(Poznansky et al., 1984, 1985). More recently, monocytes from asthmatics have been 
shown to release a cytokine which primes neutrophils and eosinophils for enhanced 
leukotriene generation when subsequently stimulated by ionophore. In glucocorticoid 
sensitive asthmatics low concentrations of hydrocortisone completely inhibited the 
production of this cytokine whereas 1000 -fold higher concentrations did not suppress 
it in glucocorticoid- resistant patients (Wilkinson et al., 1989, 1990). 
Even more recently, the role of anti -lipocortin -1 antibodies has also been 
invoked as a possible explanation for glucocorticoid resistance. Many of the anti - 
inflammatory action of glucocorticoids are mediated by lipocortins and the presence of 
antibodies to lipocortin -1 has been associated with lack of effect of glucocorticoids in 
rheumatoid patients (Podgorski et al., 1992). When however, the presence of anti- 
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lipocortin antibodies in glucocorticoid- resistant asthmatics was investigated (Wilkinson 
et al, 1990) the findings were inconclusive (Busse, 1990). 
As previously described, the skin vasoconstrictor response is 
glucocorticoid- mediated. It was hypothesized that it might be possible to distinguish 
between a specific lung glucocorticoid resistance and a more generalised defect, by 
testing whether there was also abnormal responsiveness in the skin of patients whose 
disease was resistant to glucocorticoid therapy. Glucocorticoid- sensitivity in bronchial 
asthma provided the best clinically defined and the most available model in which to test 
this hypothesis. 
The aim of this experiment was therefore to determine whether skin 
responsiveness to topically applied glucocorticoid could indicate clinical sensitivity of 
asthma to systemic glucocorticoid therapy. 
9.2 METHODS 
9.2a Criteria for selection of groups: 
Asthmatic patients were drawn from the outpatients' department at the Northern 
General Hospital, Edinburgh. Informed consent was obtained from all patients and the 
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study had the approval of the Local Ethical Committee. All patients had a typical 
history of variable dyspnoea and wheeze. To be included these patients must have 
demonstrated > 20% diurnal variation in peak expiratory flow as well as > 15% 
improvement in peak expiratory flow or forced expired volume in 1 second (with 
minimum improvement of200ml) after exposure to inhaled ß2 agonists (modifications 
of previously detailed criteria, Carmichael et al, 1981). 
Patients were classified according to the following sub -groups: 
a. Mild asthmatics, n = 26. These patients had few symptoms and relatively normal 
lung function. Some of these were on inhaled B2- agonists alone while others 
were on, in addition, inhaled glucocorticoids (up to 2000 ,ug of either 
beclomethasone dipropionate or budesonide daily). This group was to serve as 
a control for possible influences of inhaled BZ agonist or inhaled glucocorticoid. 
b. Asthmatics on long term systemic glucocorticoids, n = 13. Median dose of 
prednisolone was 7.5 mg daily, with a median duration of treatment 10 years. 
These patients had mild airways obstruction and were taking long -term 
prednisolone. Most were suffering from allergic bronchopulmonary 
aspergillosis. This group was to serve as control for the possible effect of long 
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term oral glucocorticoid therapy. 
c. Asthmatics who were glucocorticoid- sensitive, n = 31. All were on regular 
inhaled glucocorticoids, range 400 -2000 µg /day, median dose was 800 ,ug /day. 
Four of these patients were also taking oral prednisolone (5 -10 mg daily), all for 
less than 5 years. 
d. Asthmatics who were glucocorticoid- resistant, n = 15. All were on regular 
inhaled glucocorticoids, range 400- 2000 µg /day. 8 were also on oral 
prednisolone, median 7.5 daily (range 5 -10) mg with, median duration of 
treatment 8 years. 
The latter two groups (c and d) were defined according to the following criteria 
(modification of previously used criteria, Carmichael et al., 1981). Asthmatics with 
significant airways obstruction (Forced expired volume in 1 second < 70% predicted for 
age and sex) seen at the outpatients' clinic underwent a two -week trial of oral 
prednisolone to determine whether their asthma was responsive to glucocorticoid. 
Before coniunencing the glucocorticoid- trial, peak expiratory flow rate was measured 
three times a day for a week while the patient continued whatever treatment that was 
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already being used. Patients were then given oral prednisolone 20 mg daily for one 
week, followed by 40 mg daily for a second week. Baseline forced expired volume was 
measured prior to commencing treatment and this was repeated at the end of each 
treatment week. The patient continued to monitor peak expiratory flow throughout 
treatment. Mean peak expiratory flow during the last two days of the pre- treatment 
week was compared with that of the last two days of each treatment week. 
Patients were deemed glucocorticoid resistant if there was failure ofinitial forced 
expiratory volume in 1 second and mean peak expiratory flow to improve by at least 15 
% after two weeks of treatment. 
For all groups the following were also noted: atopy, smoking history, family 
history of asthma, duration of asthma symptoms and highest achieved forced expiratory 
volume in the preceding two years. Atopy was defined as two or more reactions with 
a weal diameter more than 2 mm greater than the control test when skin -prick tests to 
a range of common allergens including house -dust mite, pollen, animal danders and 
Aspergillus fumigatus were performed. These data were usually extracted from the case 













































































































































































































































































































































































































































9.2b Skin vasoconstrictor bioassay 
This was performed as described in Methodology 2 (Chapter 3). Beclomethasone 
dipropionate was dissolved in 95% ethanol to concentrations between 3 and 100 µg /ml. 
Test solutions were applied in random order to the forearm of subjects whose asthma 
responsiveness was unknown to the skin tester. 
Blanching responses were evaluated qualitatively (i.e presence or absence of 
blanching) as well as quantitatively (scored O - 4) on the visual analogue scale, at each 
concentration of topically applied beclomethasone dipropionate after 16 hours of 
occlusion. 
9.2c Statistical analysis 
Chi -square tests with Yates' correction were used to compare groups for 
differences with respect to atopy, smoking, family history and proportion showing 
blanching responses at different doses of topical beclomethasone dipropionate. Two - 
sample t -tests were used for comparison of lung function and duration of asthma. 




All groups were fairly well -matched for age, sex, smoking, atopy and family 
history of asthma (Table 9.1). The duration of symptoms in the mild asthma group was, 
however, somewhat shorter and there was a smaller proportion of smokers in this 
group. 
Mean FEV, % predicted was slightly reduced in glucocorticoid- sensitive (CS) 
asthmatics (82 %) and those taking long term prednisolone (77 %). Airway obstruction 
was marked in glucocorticoid- resistant (CR) asthmatics (mean 54% predicted, range 
20 - 80 %) and significantly greater (p <0.001) than in those patients who were 
corticosteroid sensitive. 
At the start of the trial of corticosteroids, mean FEY, % predicted was 50% (95% 
confidence intervals (CI) 44 - 56 %) in CS asthmatics and 41% (95% CI 31- 51 %) in CR 
patients. Following the trial, FEV, % predicted improved to 73% (95% CI 65 - 80 %) in 
CS but was unchanged (39 %, 95% CI 29 - 49 %) in CR asthmatics. 
There were no significant differences between the patient groups with respect to 
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atopy, smoking or family history of asthma (Table 9.1). The duration of symptoms in 
the mild asthmatics was shorter (mean 12.3y, 95% CI, 7.6 -17y) than in the other groups 
(p<0.01). There were no significant differences between these groups though a trend 
(p= 0.063) towards longer duration of asthma was observed in CR patients (mean 32.9y, 
95% CI 24.9- 40.9y) compared with CS patients (mean 23.2y, 95% CI 16.5- 29.5y). 
However, within the latter group those who required two weeks of prednisolone to show 
improved airway calibre (n =10) had suffered from asthma longer (mean 33y, 95% CI 
18.5- 47.5y) than those who responded (n =21) after one week (mean 18.5y, 95% CI 12.2 - 
24.8y; p <0.05). 
Figure 9.1 depicts the proportion of individuals from each group showing a 
positive blanching response to cutaneous beclomethasone dipropionate at any given 
concentration. Patients with glucocorticoid resistant asthma showed blanching that 
was significantly lower at all concentrations of beclomethasone dipropionate (p <0.02 
at 30 µg/ml, p <0.001 at 10 ¡g/ml, p <0.01 at 3/.2g/ml) except 100 jug/mi. The blanching 
curves for mild asthmatics, glucocorticoid sensitive and the prednisolone groups were 
quite similar. 
Figure 9.2 illustrates the intensity of blanching at each cutaneous concentration 
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in the different groups. There was a linear relationship between mean blanching score 
and topical dose of glucocorticoid. Compared with the glucocorticoid sensitive group 
the dose -response relationship for the glucocorticoid resistant group was shifted 
markedly to the right with significantly reduced blanching scores at all doses (p <0.001 
at 3 pg/ml, p <0.001 at 10 µg /ml, p <0.05 at 30 ,ug/ml) except 100 ,ug/ml. The dose - 
response relationships for glucocorticoid responsive and prednisolone treated patients 
were very similar with no significant difference in blanching scores at any dose. 
Likewise there was no significant differences in the response between mild asthmatics 
and glucocorticoid responsive patients. Interestingly, the dose -response curve for the 
prednisolone treated group was also shifted to the right compared with mild asthmatics 
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Fig 9.1 : 
Proportion of asthmatics showing any degree 
of blanching to beclomethasone dipropionate (BDP). 
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MA Mild asthma 
P Asthma - long term prednisolone 
CS Glucocorticoid sensitive asthma 
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Fig 9.2 : 
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Intensity of Cutaneous Vasoconstrictor Response 
to Beclomethasone Dipropionate (BDP) in Asthmatics 
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9.3 CONCLUSIONS 
The skin vasoconstrictor response was reduced (both qualitatively and 
quantitatively) in patients fulfilling criteria for glucocorticoid resistant asthma. These 
patients had more severe airways disease, responded poorly to systemic glucocorticoid 
therapy and tended to have a longer history of asthma. The latter factors might also 
imply that they had greater lifetime exposure to glucocorticoids which, because of the 
cross -sectional nature of the study was difficult to determine. 
Some of these patients would have previously been studied using other tests to 
evaluate glucocorticoid sensitivity (Poznansky et al, 1984, 1985; and Kay et al., 1981). 
Leucocytes from these patients were found to exhibit reduced sensitivity to the effects 
of glucocorticoids. These data suggest that in glucocorticoid resistant asthmatics there 
is a generalized insensitivity to glucocorticoids which has been previously detected in 
circulating leucocytes of patients and for the first time in their skin as well. 
There was some indication that the prolonged use of oral prednisolone might 
have attenuated skin vasoconstrictor responsiveness. Thus, there was an apparent shift 
of the blanching curve to the right i.e. reduced skin sensitivity in asthmatics on long 
term prednisolone compared with mild asthmatics. This was however, only a trend as 
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the differences between those on prednisolone and mild asthmatics were not uniformly 
significant. Indeed, there is apparent ordering of the blanching intensity curves for mild 
asthma, glucocorticoid sensitive, prednisolone- treated and glucocorticoid resistant 
asthmatics from left to right. This is interesting, since previous glucocorticoid use has 
also been associated with reduced clinical responsiveness in other settings. Thus it has 
been shown that previous therapy with glucocorticoids was associated with reduced 
clinical and leucocyte responsiveness in rheumatoid patients (Podgorski et al, 1992). 
Even more supportive of this hypothesis is the findings from a study by Linder (Linder 
el al, 1993) who upon my suggestion tested skin vasoconstrictor responsiveness in 
various groups of elderly patients. These workers found that compared with healthy 
elderly, age- matched patients receiving prednisolone for up to one year exhibited 
reduced blanching responses. 
The skin vasoconstrictor response may be used to predict systemic sensitivity to 
glucocorticoid therapy. It would be important to test this hypothesis in other situations 
ofglucocorticoid resistance eg. familial glucocorticoid resistance syndromes (Chrousos 
et al., 1982). Apparent glucocorticoid resistance has also been described in depression 
(Whalley et al, 1986) and anorexia nervosa (Kontula et al, 1982). It would be 
interesting to test skin sensitivity in these clinical situations. 
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Whereas the cause of reduced skin responsiveness (and indeed reduced asthma 
responsiveness) to glucocorticoids remain speculative, the current data and that of 
Linder et al., (1993) suggests that previous systemic glucocorticoid exposure might be 
relevant. 
192 
CHAPTER 10: CONCLUSIONS AND FURTHER WORK 
193 
CHAPTER 10: CONCLUSIONS AND FURTHER WORK 
The interplay between glucocorticoids and the skin have long been recognised 
at both pharmacological and biochemical levels. Most importantly, a number of 
cutaneous diseases, both inflammatory and non -inflammatory, is amenable to treatment 
with glucocorticoids, the introduction of which revolutionized the practice of 
dermatology (Stoughton and Cornell, 1988). Secondly, skin blanching, the 
pharmacodynamic response to topically applied glucocorticoids, has been utilized for 
over thirty years to predict efficacy (and potency) of new topical glucocorticoids. 
Finally, the ability of the skin to metabolise cortisol has been fairly well documented 
(Malkinson et al, 1959; Hsia eta'., 1964; Hammami and Siiteri, 1991) even though the 
biological significance of this metabolic process is speculative. In this work I have 
explored the latter two facets of the interaction between glucocorticoids and the skin. 
METABOLISM OF CORTISOL BY SKIN: 
It is known that the metabolic fate of cortisol can be diverse including products 
of both A -ring reduction as well as side chain oxidation (Bodor, 1988), but 
C -11B- dehydrogenation has been shown to be most crucial (Brownie, 1992). The latter 
process is mediated by 11B- hydroxysteroid dehydrogenase (Monder and Shackleton, 
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1984), an enzyme with vital physiologic functions in many tissues (Monder and White, 
1992). In skin 11B- hydroxysteroid dehydrogenase is not only active but is also the 
dominant metabolic pathway (Hsia et a1, 1964) for cortisol. The spin -offs from this 
aspect of the current work are two -fold. Firstly, an animal model suitable to the study 
of this enzyme in skin has been developed eliminating the technical and other practical 
difficulties inherent in studies with human skin. Using this model, it might therefore 
now be possible to study the biological impact of this enzyme upon skin integrity. The 
use of inhibitors and enhancers, for example, might well illustrate such effects. 
Glycyrrhetinic acid, for example, was shown to be an effective inhibitor of 
11B- hydroxysteroid dehydrogenase activity both in vivo (Chapter 5) and in vitro 
(Chapters 5, 6,) I have also derived data (not shown) that 11 B- hydroxysteroid activity 
is enhanced, in vitro, in the presence of dithranol (1,8- dihydroxy- 9[10H]- anthracenone), 
a compound known to be efficacious in psoriasis. Important lessons might be learnt 
from study of inhibition or enhancement of enzyme activity using glycyrrhetinic acid or 
dithranol in the animal mode. 
There are preliminary data from a number of quarters which suggest that altered 
enzyme activity / change in glucocorticoid flux might be relevant to the pathogenesis 
of skin disease. To begin with, "stress" is a frequent precipitant of many dermatoses 
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(Fitzpatrick et al, 1987). Stress is known to activate the hypothalamic- pituitary- adrenal 
axis, the consequences of which have been a source of great debate (Selye, 1946; Ingle, 
1952; Schayer, 1964, 1967; Munck et al., 1984). More recently, Walker (Walker et al., 
1992 a) added a further dimension to this when it was demonstrated that there was 
defective 11B- hydroxysteroid dehydrogenase (11B HSD) activity in clinical situations 
associated with ACTH excess. Thus, during stress these effects on the hypothalmic- 
pituitary- adrenal-cortisol-11B HSD axis could possibly influence terminal metabolism 
of cortisol and impact upon pathogenesis of skin disease. The following points would 
support such a view. Alcohol, for example, is a known risk factor for psoriasis 
(Poikolainen eta!, 1990) and alcohol was shown in this work (Chapter 6) to inhibit skin 
11B- hydroxysteroid dehydrogenase. Likewise, the hypothesis of alteration in skin 
11B- hydroxysteroid dehydrogenase activity in dermatoses would be supported by the 
findings of Buhles (Buhles et al., 1987) which revealed that despite normal circulating 
cortisol levels, urinary metabolites of cortisol was markedly diminished in untreated 
patients with eczema and psoriasis compared with normal individuals. As a preliminary 
step in testing this hypothesis I evaluated psoriatic and eczematous skin for 
11B- hydroxysteroid dehydrogenase using immunohistochemistry as described for 
normal skin in Chapter 6. It was found that because of the increased thickness of the 
epidermis in both eczema and psoriasis, that immunostaining for 11B- hydroxysteroid 
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dehydrogenase appeared increased (data not shown). This may not be contrary to the 
foregoing, however, since bioactivity and not immunoactivity in the diseased state is 
what might prove relevant. It is possible that the enhanced immunostaining in disease 
states could represent the product of variant mRNA species without the potential to 
produce active 11B- hydroxysteroid dehydrogenase, a situation known to exist in other 
organ systems (Brown et al., 1993). The current work provides the basis for further 
exploration of the role of skin 11B- hydroxysteroid dehydrogenase for which the nude 
mouse model seems appropriate. 
An even more significant consequence of the current work was the finding of 
potentially novel means of targeting glucocorticoid therapy. It was shown that by 
combining hydrocortisone, an intrinsically weak glucocorticoid, with glycyrrhetinic acid 
the action of hydrocortisone was enhanced in producing skin blanching, the classic 
bioassay of glucocorticoid efficacy. The ideal drug should have a high therapeutic index 
i.e. one with a low risk of adverse effects compared with any given desired effect (Bodor, 
1988). A major objective of topical glucocorticoid therapy has been to enhance 
therapeutic activity but the use of high potency agents have led to a concomitant risk 
of systemic toxicity (Editorial Lancet, 1973, 1977). Indeed, hypothalamic - 
pituitary- adrenal axis suppression has been shown to occur with most topical 
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glucocorticoids in current use and to be proportional to the potency of the formulation 
(Stoughton and Cornell, 1988). Such effects have not been described with topical 
hydrocortisone (Turpeinen, 1988) except in the isolated group of the very young with 
severe and extensive disease (Turpeinen et al., 1986). On the whole, the systemic 
absorption of hydrocortisone from human skin is low (Wester et al., 1983). The 
increased biologic effect observed when hydrocortisone is co- applied with glycyrrhetinic 
acid could be due to enhanced topical bioavailability but Walker (Walker et al., 1992 
c, 1993) has demonstrated similar enhancement of hydrocortisone action even after 
systemic administration of liquorice (active principle of which is glycyrrhetinic acid). 
Nonetheless, increased skin blanching implies increased access to the dermal vasculature 
(Barry and Woodford, 1978) and perhaps the systemic circulation but given the weak 
intrinsic activity of hydrocortisone and its short half -life it seems plausible that this 
particular combination might prove to be associated with less risk than currently 
available potent agents. This principle of local inhibition of cortisol to derive an 
enhanced site specific action might also be applicable to other sites where 11 ß- 
hydroxysteroid dehydrogenase is active, for example, tracheobronchial tree and 
gastrointestinal tract. The nude mouse would be an attractive model to test whether 
such local inhibition of cortisol metabolism is indeed devoid of systemic effects. Du 
Vivier (Du Vivier et al., 1978) had previously used this model for this purpose using 
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epidermal DNA synthesis remote from the area of application as an end -point to 
evaluate systemic effects. 
Finally, study of skin 11B- hydroxysteroid dehydrogenase in the nude mouse 
model indicates biochemical characteristics which suggest that a distinct isoform exists 
in skin. This would explain why patients with deficient renal 1113- hydroxysteroid 
dehydrogenase do not exhibit skin signs. 
11B- hydroxysteroid dehydrogenase: Protector of the glucocorticoid receptor? 
There is strong association between the anti- inflammatory activity of 
glucocorticoids which results from gene activation (Blackwell eta!, 1982; Tsurufuji and 
Ohuchi, 1989) and blanching. In addition, it usually takes about 6 hours before 
blanching becomes manifest. Such a definite time lag is generally seen in whole animal 
experiments for the manifestations of anti -inflammatory effects of glucocorticoids 
(Tsurufuji and Ohuchi, 1989). Moreover, blanching is inducible by active 
glucocorticoids, blocked by glucocorticoid antagonists (Marks et al., 1982; Gaillard et 
al.., 1985), and from the current work, arises when glucocorticoids interact with classical 
(type II) glucocorticoid receptors. Thus the skin blanching response most likely depends 
upon receptor activation as well as transcriptional and translational events presumably 
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arising in the blood vessels of skin. That the concomitant use of glycyrrhetinic acid, an 
inhibitor of 11 B- hydroxysteroid dehydrogenase, led to an enhanced blanching response 
induced by hydrocortisone suggests that 11B- hydroxysteroid dehydrogenase might 
normally act to protect the glucocorticoid receptor from cortisol exposure, thereby 
limiting glucocorticoid responsive gene activation. There are data from a number of 
other sources to support the conclusions from the current work that 11 B- hydroxysteroid 
dehydrogenase might be a protector of the glucocorticoid receptor. The wide tissue 
distribution of this enzyme has long invoked such a teleological argument (Monder and 
Shackleton, 1984; Monder and White, 1992). From experimental studies too, there are 
supportive data. Thus, glucocorticoids are known to adversely affect testicular function 
(Phillips et al., 1989). Ontogenic studies in the rat have suggested that 
11B- hydroxysteroid dehydrogenase of Leydig cells protects against the deleterious 
effects of glucocorticoid excess in the testis, an organ where glucocorticoid receptors 
abound (Phillips etal., 1989). Similarly, if the foetus is exposed to glucocorticoid excess, 
there are adverse influences on birth- weight (Reinisch et al., 1978). The foetus is 
normally protected from the exponential increases in maternal glucocorticoid levels as 
pregnancy progresses (Burke and Roulet, 1970; Rees et al., 1975) by the placental 
11B-hydro xysteroid dehydrogenase barrier. When this glucocorticoid barrier is lacking 
e.g by administering dexamethasone (which is not metabolized by 11 B- hydroxysteroid 
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dehydrogenase) offspring with low birth -weight are produced (Benediktsson et al, 1993; 
Edwards et al., 1993). Similarly, the findings in the colon, also a site of 
11ß- hydroxysteroid dehydrogenase activity, that glucocorticoid responsive gene 
expression could be derepressed by liquorice derivatives (Fuller and Verity, 1990) 
provides more supportive evidence for the protective role of this enzyme over the 
glucocorticoid receptor. In addition, the halogenation of the C-9- a position of cortisol 
is known to produce agents resistant to the metabolic action of l lß- hydroxysteroid 
dehydrogenase (Oelkers et al, 1994). When cortisol is converted to 9- a- flurocortisol it 
has been found that not only is its mineralocorticoid action potentiated (due to 
increased type I receptor activation) but that in addition there is a 10 -fold increase of 
glucocorticoid (anti -inflammatory) action (Szefler, 1989; Oelkers eta!, 1994) providing 
further proof for the influence of this enzyme on glucocorticoid- mediated effects. 
Moreover, a detailed localization study of llß- hydroxysteroid dehydrogenase gene 
expression (and enzyme activity) in various rat tissues and the presence of 
glucocorticoid receptors in those tissues revealed close co- localization (Whorwood et 
al, 1992). 
Thus the conclusion from the current work that 11 B- hydroxysteroid 
dehydrogenase might influence access to the glucocorticoid receptor receives support 
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in the literature. 
An explanation of the glucocorticoid- activity of liquorice. 
Since the 1940's the literature has been replete with references to the 
mineralocorticoid properties ofliquorice and its derivatives (reviewed in Edwards 1991; 
Farese et al, 1991). It was thought for a long time that liquorice produced its 
mineralocorticoid actions via direct interaction of its active principle, glycyrrhetinic 
acid, with mineralocorticoid receptors. This hypothesis was incorrect for two reasons. 
Firstly, glycyrrhetinic acid had 1 /100 the affinity of aldosterone for mineralocorticoid 
receptors (Arriza et al., 1987). Secondly, liquorice and its derivatives did not display 
such properties unless the adrenals were intact or cortisol was replaced when there was 
adrenal insufficiency (Borst et al, 1953; Elmadjian et al.., 1956). Recent work (Stewart 
et al, 1987; Edwards et al., 1988) have shed new light on this subject and it is now 
known that liquorice mediates its mineralocorticoid action via inhibition of the cortisol 
metabolism by 11B- hydroxysteroid dehydrogenase. Cortisol has been shown to have 
similar affinity to aldosterone for mineralocorticoid receptors, in vitro (Arriza et al., 
1987). By inhibiting 11 B- hydroxysteroid dehydrogenase, high levels of a cortisol are 
generated locally with the result that mineralocorticoid receptors become activated in 
excess. 
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Although mineralocorticoid properties were first recognised, liquorice was some 
time later also shown to possess glucocorticoid activity (Kumagai et al., 1957; Finney 
and Somers, 1958; Finney and Tarnoky, 1960; Fletcher et al., 1967). Using a variety of 
models of inflammation, glycyrrhetinic acid was shown to consistently demonstrate 
anti -inflammatory activity (Finney and Somers, 1958). When it came to clinical trials 
in man, the results were less predictable ( Warin and Evans, 1956, Donaldson and 
Duthie, 1956). Within recent times there has been renewed interest in this area 
following a series of reports which suggests a role for traditional Chinese herbal 
remedies in treating skin diseases (Sheehan et al., 1992; Harper et a!, 1990; Galloway 
et al., 1991). Although the active ingredient /s is not known, glycyrrhetinic acid was 
found to be a component of such decoctions (Galloway et a!, 1991). 
Despite the foregoing, the mechanism of the anti -inflammatory actions of 
liquorice has remained speculative. The similarity in chemical structure between 
glycyrrhetinic acid and hydrocortisone was notable (Finney and Somers, 1958) but as 
was the case with mineralocorticoid actions, an intact adrenal (Khan and Sullivan, 
1967) or exogenous cortisol (Kumagai et al., 1957) was also important for 
glucocorticoid activity. 
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In this work, the hypothesis that the anti -inflammatory action of liquorice 
resided in the inhibition of cortisol metabolism was tested. The liquorice /glucocorticoid 
interaction was elucidated using the classic bioassay of glucocorticoid action - skin 
vasoconstrictor bioassay. The results showed that glycyrrhetinic acid was ineffective on 
its own but in the presence of hydrocortisone the glucocorticoid effect was potentiated. 
In vitro skin 11 B- hydroxysteroid dehydrogenase was shown to be markedly inhibited 
by glycyrrhetinic acid. 
There has been speculation that glycyrrhetinic acid could mediate 
anti -inflammatory activity by mechanisms related to altered prostaglandin metabolism 
(Peskar, 1976; Baker and Fanestil, 1991); mechanisms independent of glucocorticoid 
influences (Baker and Fanestil, 1991). It is known that there is structural homology 
between some steroid metabolising and prostaglandin metabolising enzymes (Baker and 
Fanestil, 1991; Monder and White, 1992), so that direct effects on prostaglandin 
metabolism are indeed possible. When, however, the inhibitory effects of glycyrrhetinic 
upon 11B- hydroxysteroid dehydrogenase (cortisol metabolism) and 
15- hydroxyprostaglandin dehydrogenase (most structurally homologous to the steroid 
metabolising dehydrogenase above), were compared, there was no apparent inhibition 
of the prostaglandin dehydrogenase at any concentration used in the experiment 
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whereas there was marked inhibition of steroid metabolism (ID 
So = 5x10 
-6 M). 
However, this data relate purely to a lack of effect on prostaglandin degradation but 
effects on synthesis are still possible. The latter possibility has in fact, been previously 
investigated (Inoue et al., 1986) and it was found that even at high concentrations 
glycyrrhizin, glycyrrhetinic acid and carbenoxolone produced little or no effect on either 
prostaglandin or leukotriene production, implying lack of any significant effect on 
synthetic pathways. 
There are other important biological effects of glycyrrhetinic acid apart from its 
glucocorticoid -like action, e.g. bacteriostatic (Benigni and Franco, 1958) and anti -viral 
properties (Pompei et ai, 1979; Inoue et al, 1986) but it does seem that the long 
recognised anti -inflammatory action of glycyrrhetinic acid accrues from inhibition of 
cortisol metabolism, a mechanism similar to that explaining its mineralocorticoid action 
(Edwards et al., 1988). 
SKIN VASOCONSTRICTOR ACTIVITY OF GLUCOCORTICOIDS 
Glucocorticoids when applied topically on human skin undergo absorption 
resulting in apparent vasoconstriction (Shah et al 1989) in the dermal vascular bed 
(Barry and Woodford 1978) to produce skin blanching. Formore than thirty years, this 
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blanching effect has been used as ameasure ofpercutaneous bioavailability and potency 
of glucocorticoids from topical formulations and has proven invaluable in selecting 
optimum formulations from the skin vasoconstrictor bioassay (Barry and Woodford 
1976, 1978, 1986). In the current work this bioassay was utilised for this traditional 
purpose and in the conventional manner to evaluate the effects of liquorice derivatives 
on hydrocortisone action but in addition, it was also tested for a novel purpose - to 
ascertain glucocorticoid sensitivity. 
While the precise mechanism of blanching has not been fully elucidated, the use 
of aglucocorticoid receptor blocking agent was known to ablate the blanching response 
(Gaillard et al 1985). Blanching is therefore the likely pharmacodynamic response of 
glucocorticoid- receptor interaction and subsequent gene activation. It was an 
hypothesis to be tested in the current work that skin blanching might be possible marker 
ofsuch interaction and could therefore be used to indicate sensitivity to glucocorticoids. 
The finding of reduced skin blanching in asthmatics whose airways responsiveness to 
systemic glucocorticoid therapy was reduced and of higher blanching scores in 
asthmatics whose disease was amenable to glucocorticoid therapy supports this 
hypothesis. The heterogeneity of skin blanching responses in a population (Burdick 
1974, Stoughton 1992) might therefore be a reflection of the mechanism whereby some 
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patients respond to or develop side -effects from glucocorticoids more readily when 
comparable doses are used (Axelrod 1989). 
It is noteworthy that there is a small subset of individuals who fail to blanch 
despite the application of high concentrations of highly bioavailable glucocorticoids. 
It is tempting to suggest that these individuals may have some form of 
glucocorticoid- resistance syndrome which has been well characterised in lower primates 
(Lipsett et al 1985) and though initially assumed to be rare in humans (Malchoff et al 
1990), may, in fact, be more common in man than previously thought (Lamberts et al 
1992). Indeed there might be grades of glucocorticoid resistance that are subtle. 
Whereas in its most extreme form glucocorticoid resistance is characterised by 
hypertension and hypokalaemic alkalosis secondary to mineralocorticoid excess 
(Vingerhoeds et al 1976) there is some evidence that hypertension without biochemical 
features of mineralocorticoid excess can also occur in this syndrome (Lamberts et al 
1992). It is interesting that, using the skin vasoconstrictor assay, Walker demonstrated 
that in patients with essential hypertension, blanching responses were more intense 
compared with normal control subjects (Walker 1993). This implies that increased 
sensitivity of the vasculature to circulating glucocorticoids might be contributory to the 
hypertensive process and that the skin vasoconstrictor response reflects this. It seems 
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that 11B- hydroxysteroid dehydrogenase activity might not be relevant to this 
supersensitivity however, since plasma half -life or (11 a -3H) cortisol, a measure of 11 B- 
hydroxysteroid dehydrogenase activity, was not different from normal controls (Walker 
1993). This increased sensitivity in hypertensives was also non -specific for 
glucocorticoids and was shown to occur both with cortisol (which is metabolised by 
11ß- hydroxysteroid dehydrogenase) and beclomethasone dipropionate - a 
glucocorticoid with a protected C -11 -0H group (Walker 1993, Oelkers et al 1994). 
It would be interesting to utilise the skin vasoconstrictor bioassay in order to 
determine whether glucocorticoid receptor structure /function might be abnormal in 
common clinical situations. Such studies might help to explain why persistent 
hypercortisolaemia in not always associated with clinical features of Cushing's 
syndrome. Thus increased activity of the hypothalamic -pituitary- adrenal axis is found 
in a substantial proportion of patients with primary depression (Schiesser et al 1979, 
Schlechte et al 1985, Whalley et al 1986), anorexia nervosa (Kontula et al 1980,1982) 
and in pregnancy (Rees et al 1975), yet clinical stigmata of Cushing's syndrome are 
lacking. Altered glucocorticoid sensitivity has been demonstrated both in the ability to 
suppress serum cortisol levels and in the ability of dexamethasone to suppress 
lymphoproliferative responses in depressed patients (Lowy et al 1984). Reduced levels 
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of glucocorticoid receptors have been found in mononuclear cells from patients with 
both depression (Whalley et al 1986) and anorexia nervosa (Kontula et al 1982). Using 
the skin vasoconstrictor assay it might be possible to determine in a variety of such 
clinical states whether abnormal glucocorticoid action /sensitivity might be contributory 
to the pathophysiology and whether altered glucocorticoid sensitivity might be 
contributory to decompensated states in pregnancy eg. pregnancy induced hypertension 
and gestational diabetes. 
In an attempt to rank the blanching response against traditional markers of 
glucocorticoid action skin vasoconstrictor response was evaluated following varying 
degrees of systemic glucocorticoid exposure and compared with the observed effects of 
such treatments on the hypothalamic- pituitary- adrenal axis, intermediary and bone 
metabolism and hematopoietic effects. The results showed that, at least in the short 
term, changes in the skin blanching responsiveness were not sensitive to systemic 
glucocorticoid exposure. This is not too surprising given the number of factors which 
are known to influence the precision of the skin bioassay and the high level of variance 
inherent in the assay. It is because of this high variance that skin blanching responses 
might be inadequate to define sensitivity in individuals though group effects (as in 
glucocorticoid resistant asthma) may be readily identified. With refinement, 
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particularly if less subjective means of evaluating blanching are developed (Shah et al 
1989) then the sensitivity of the assay might improve sufficiently to overcome this 
problem. Another inherent weakness of the assay is its sigmoidal dose -response 
relationship. Thus it has been shown (and reproduced in this work) that increasing 
concentrations of the same glucocorticoid in the same vehicle will produce an increasing 
blanching effect (McKenzie and Stoughton 1962) but with larger amounts of 
glucocorticoids further increase in the blanching effect may not occur despite 10 -fold 
increase in concentration (Stoughton 1987, Stoughton and Wullich 1989). Hence the 
flattening of the dose -response curve could mask real differences in sensitivity. 
However, the absence of blanching at high doses of topically applied glucocorticoids 
indicate, with high specificity, lack of glucocorticoid responsiveness. 
It is possible that intrinsic abnormalities of glucocorticoid receptor number or 
function (Chrousos et al 1982, Iida et al 1985, Bronnegard et al 1986, Nawata et al 1987) 
could dictate an individuals response to glucocorticoid therapy. It also seems that 
altered responsiveness can arise as a result of previous glucocorticoid exposure. Thus, 
in the cross -sectional study of skin vasoconstrictor responsiveness in asthmatic patients 
there emerged an ordering of the results which suggests that previous glucocorticoid 
therapy might have influenced skin vasoconstrictor responsiveness. The question 
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therefore arises as to whether in the subset of asthmatics who proved refractory to 
anti -asthma effect of glucocorticoids might represent a group who might have been 
selected out by their own long term use of glucocorticoids. Alternatively, it is possible 
that these individuals exhibited tachyphylaxis to glucocorticoid therapy. The first 
reported tachyphylaxis to glucocorticoids was observed using the skin vasoconstrictor 
assay (Du Vivier and Stoughton 1975). It is not just blanching that undergoes this 
tachyphylactic phenomenon. Indeed tachyphylaxis to glucocorticoids has also been 
shown for DNA synthesis which is readily suppressed in both normal and diseased skin 
following application of topical glucocorticoids. Continuous glucocorticoid application 
over ensuing days will lead to subsequent increase in DNA synthesis above normal 
levels even while glucocorticoid is still being applied (Du Vivier et al 1982). Similarly, 
the histamine induced "wheal and flare" response in skin that is normally suppressed by 
glucocorticoids will undergo tachyphylaxis with continued use of glucocorticoid (Singh 
and Singh 1986). Whether systemic glucocorticoid therapy is associated with similar 
induction of tachyphylaxis is speculative but the findings from the study of asthmatics 
undertaken in this work encourages this form of speculation. 
There are however, data from the literature to support such a view. Thus 
basophils from patients, receiving long term glucocorticoid therapy for connective tissue 
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diseases and asthma, were found unresponsive to the effects of dexamethasone in 
inhibiting histamine release when these cells were subsequently challenged in vitro by 
anti -IgE ( Lampi et al 1985). Similarly, patients treated with higher doses of 
glucocorticoids for rheumatic diseases have been shown to exhibit reduced clinical 
responses when subsequently challenged with glucocorticoid (Podgorski et al 1992). 
These data suggest that tachyphylaxis to the anti -inflammatory actions of systemic 
glucocorticoid therapy can in fact, occur. This does not necessarily imply that all effects 
of glucocorticoids exhibit tachyphylaxis to the same degree or in the same time period. 
Thus, the biological responses to glucocorticoids are highly variable due to differential 
responsiveness of individual genes to the hormone (Chrousos et al 1988) and least 
sensitive genes will therefore require a higher duration of treatment to become fully 
induced. Because of this differential responsiveness, it is possible that with chronic 
glucocorticoid use adverse effects may continue to be effected despite tachyphylaxis to 
anti -inflammatory actions. If tachyphylaxis to the beneficial effects of glucocorticoids 
ensues then it would be appropriate to withdraw glucocorticoid therapy periodically - 
at a rate governed by clinical status (Dixon and Christy 1980). A clinical or biochemical 
marker of tachyphylaxis to the anti-inflammatory actions of glucocorticoids would be 
of immense value in guiding the clinician. Skin blanching response to glucocorticoids 
correlates closely with anti -inflammatory action (Cornell and Stoughton 1985). 
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Blanching might therefore serve this function. It might prove useful to screen, 
sequentially, patients who are embarking on chronic glucocorticoid therapy to 
determine whether tachyphylaxis to the blanching response (anti -inflammatory) occurs 
and when this occurs to reduce glucocorticoid exposure. Indeed using the skin 
vasoconstrictor assay Linder, (Linder et al 1993) found evidence for diminution of skin 
vasoconstrictor responses following prolonged systemic glucocorticoid therapy. When 
this is observed it might be appropriate to suggest "drug holidays" from systemic 
glucocorticoid therapy thereby reducing risks inherent with such therapy. This 
approach has previously been suggested for optimizing therapy with topically applied 
glucocorticoids (Du Vivier 1976). 
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GLOSSARY OF TERMS AND ABBREVIATIONS USED: 
ACTH Adrenocorticotrophic hormone 
11ß -HSD The enzyme 11B- hydroxysteroid dehydrogenase 
B Corticosterone 
BDP Beclomethasone dipropionate 
BLANCHING: The change in colour of the human skin in 
response to topically applied glucocorticoids. The 
colour change presumably occurs on the basis of 
vasoconstriction in the dermal vascular bed. 







These are steroid receptors which have high (Type 
affinity for the synthetic glucocorticoid 
dexamethasone compared with the naturally 
occurring glucocorticoids, cortisol and 
corticosterone. The affinity of steroids for these 
receptors parallels their anti -inflammatory 




A plastic resin 
Forced expiratory volume in 1 second as a 
percentage of forced vital capacity 
FHBA 5- (4- fluorobenzoyl) 2- hydroxybenzene acetic acid 
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GE Glycyrrhetinic acid 
HC Hydrocortisone 
HC1 Hydrochloric acid 
H2O Water (deionized and glass distilled) 
KBQ Kilo Becquerel 
KCI Potassium chloride 
KH2PO4 Monopotassium phosphate 
M Molar concentration 
MSH Melanocyte stimulating hormone 
mg Milligram 




Na H CO; 
These are steroid receptors which exhibit much 
lower affinity for dexamethasone and very high 
affinity for corticosterone. These receptors have 
similar affinity for corticosterone and aldosterone. 
In vivo, although circulating corticosterone levels 
are higher than aldosterone, these receptors 
selectively bind to aldosterone. Recent evidence 
have shown that this occurs because corticosterone 
is denied access to these receptors, in vivo, by the 
enzyme l lß- hydroxysteroid dehydrogenase which 





NAD Oxidized nicotinamide adenine dinucleotide 











The most abundant non -collagenous protein of 
bone. It is synthesized by osteoblasts and has 
been found to be a specific and sensitive marker of 
bone turnover in patients with various metabolic 
bone diseases. 
15- hydroxy prostaglandin dehydrogenase 
Percentage 
Ribonucleic acid 
This tested the hypothalamic- pituitary- adrenal 
axis by the 11- deoxycortisol response to 
metyrapone blockage of cortisol synthesis 
Tris (hydroxymethly) methylamine 
microgram 
less than 
weight per volume 
250 
THE WORLD MEDICAL ASSOCIATION, INC. 
13 Chemin du Levant 
01210 Ferney- Voltaire, France 
DECLARATION OF HELSINKI 
Recommendations guiding medical doctors in biomedical research involving 
human subjects. 
Adopted by the 18th World Medical Assembly, Helsinki, Finland, 1964 and as 
revised by the 29th World Medical Assembly, Tokyo, Japan, 1975 and by the 
35th World Medical Assembly, Venice, 1983. 
INTRODUCTION 
It is the mission of the medical doctor to safeguard the health of the 
people. His or her knowledge and conscience are dedicated to the fulfilment 
of this mission. 
The Declaration of Geneva of the World Medical Association binds the 
physician with the words, "The health of my patient will be my first 
consideration ", and the International Code of Medical Ethics declares that, 
"A physician shall act only in the patient's interest when providing medical 
care which might have the effect of weakening the physical and mental 
condition of the patient'. 
The purpose of biomedical research involving human subjects must be to 
improve diagnostic, therapeutic and prophylactic procedures and the 
understanding of the aetiology and pathogenesis of disease_ 
In current medical practice most diagnostic, therapeutic or prophylactic 
procedures involve hazards. This applies especially to biomedical 
research. 
Medical progress is based on research which ultimately must rest in part on 
experimentation involving human subjects. 
In the field of biomedical research, a fundamental distinction must be 
recognised between medical research in which the aim is essentially 
diagnostic or therapeutic for a patient, and medical research, the essential 
object of which is purely scientific and without implying direct diagnostic 
or therapeutic value to the person subjected to the research. 
Special caution must be exercised in the conduct of research which may 
affect the environment, and the welfare of animals used -for research must bE 
respected. 
Because it is essential that the results of laboratory experiments be 
ppïied to human beings zc further scientific knowledge and to ticlp 
suffering humanity, the World Medical Association has prepared he followin( 
liberty to abstain from participation in the study and that he or 
she is free to withdraw his or her consent to participation at 
any tine. The physician should then obtain the subject's 
freely -given informed consent, preferably in writing. 
10. When obtaining informed consent for the research project the 
physician should be particularly cautious if the subject is in a 
dependent relationship to him or her or may consent under duress. 
In that case the informed consent should be obtained by a 
physician who is not engaged in the investigation and who is 
completely independent of this official relationship. 
11. In case of legal incompetence, informed consent should be 
obtained from the legal guardian in accordance with national 
legislation. Where physical or mental incapacity makes it 
impossible to obtain informed consent, or when the subject is a 
minor, permission from the responsible relative replaces that of 
the subject in accordance with national legislation. 
Whenever the minor child is in fact able to give a consent, the 
minor's consent must be obtained in addition to the consent 
of the minor's legal guardian. 
12. The research protocol should always contain a statement of the 
ethical considerations involved and should indicate that the 
principles enunciated in the present Declaration are complied 
with. 
II. Medical Research Combined with Professional Care (Clinical Research) 
1. In the treatment of the sick person, the physician must be free 
to use a new diagnostic and therapeutic measure, if in his or her 
judgement it offers hope of saving life, re- establishing health 
or alleviating suffering. 
2 The potential benefits, hazards and discomfort of a new method 
should be weighed against the advantages of the best current 
diagnostic and therapeutic methods. 
In any medical study, every patient - including those of a 
control group, if any - should be assured of the best proven 
diagnostic and therapeutic method. 
The refusal of the patient to participate in a study must never 
interfere with the physician -patient relationship. 
5. If the physician considers it essential not to obtain informed 
consent, the specific reasons for this proposal should be stated 
in the experimental protocol for transmission to the independent 
committee (1.2). 
6. The physician can combine medical research with professional 
care, the objective being the acquisition of new medical 
knowledge, only to the extent that medical research is justified 
by its potential diagnostic or therapeut c value for the 
patient. 
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ndations as a guide to every physician in biomedical research 
ng human subjects. They should be kept under review in the future. 
be stressed that the standards as drafted are only a guide to 
ans all over the world. Physicians are not relieved from criminal, 
Lnd ethical responsibilities under the laws of their own countries. 
Sasic Principles 
1. Biomedical research involving human subjects must conform to 
generally accepted scientific principles and should be based on 
adequately performed laboratory and animal experimentation and on 
a thorough knowledge of the scientific literature. 
2. The design and performance of each experimental procedure 
involving human subjects should be clearly formulated in an 
experimental protocol which should be transmitted to a specially 
appointed independent committee for consideration, comment and 
guidance. 
3. Biomedical research involving human subjects should be conducted 
only by scientifically qualified persons and under the 
supervision of a clinically competent medical person. The 
responsibility for the human subject must always rest with a 
medically -qualified person-and never rest on the subject of the 
research, even though the subject has given his or her consent. 
4. Biomedical research involving human subjects cannot legitimately 
be carried out unless the importance of the objective is in 
proportion to the inherent risk to the subject. 
5. Every biomedical research project involving human subjects should 
be preceded by careful assessment of predictable risks in 
comparison with foreseeable benefits to the subject or to others. 
Concern for the interests of the subject must always prevail over 
the interests of science and society. 
. The right of the research subject to safeguard his or her 
integrity must always be respected. Every precaution should be 
taken to respect the privacy of the subject and to minimise the 
impact of the study on the subject's physical and mental 
integrity and on the personality of the subject. 
7 Physicians should abstain from engaging in research projects 
involving human subjects unless they are satisfied that the 
hazards involved are believed to be predictable. Physicians 
should cease any investigation if the hazards are found to 
outweigh the potential benefits. 
8. In publication of the results of his or her research, the 
physician is obliged to preserve the accuracy of the results. 
Reports of experimentation not in accordance with the principles 
laid down in this Declaration should not be accepted for 
publication. 
9 In any research on human beings, each potential subject must be 
adequately informed of the aims, methods, anticipated benefits 
and potential hazards of the study and the discomfort it may 
entail. He or she should be informed that he or she is at 
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. Non -Therapeutic Biomedical Research Involving Human Subjects 
(Non -Clinical Biomedical Research) 
1. In the purely scientific application for medical research carried 
out on a human being, it is the duty of the physician to remain 
the protector of the life and health of that person on whom 
biomedical research is being carried out. 
2. The subjects should be volunteers - either healthy persons or 
patients for whom the experimental design is not related to the 
patient's illness. 
3. The investigator or the investigating team should discontinue 
the research if in his /her or their judgement it may, if 
continued, be harmful to the individual. 
4. In research on man, the interest of science and society should 
never take precedence over considerations related to the 
well -being of the subject. 
tober 1983 
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activity in skin by glycyrrhetinic acid. Lancet 1990; 335; 
1060 -1063; 
(2) Edwards, C.R.W. and Teelucksingh, S. Glycyrrhetinic acid 
and potentiation of hydrocortisone activity in skin. Lancet 
1990; 336; 322 -323 (letter); 
(3) Teelucksingh, S. and Edwards, C.R.W. Potentiation of 
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Potentiation of hydrocortisone activity in skin by 
glycyrrhetinic acid 
S. TEELUCKSINGH A. D. R. MACKIE D. BURT M. A. MCINTYRE 
L. BRETT C. R. W. EDWARDS 
The enzyme 113- hydroxysteroid dehydrogenase 
(11(3- OHSD), which catalyses the conversion of 
cortisol to the inactive steroid cortisone in man 
(and corticosterone to 11 -dehydrocorticosterone 
in rodents), was demonstrated by immunohisto- 
chemistry in skin biopsy samples from healthy 
volunteers and from patients with psoriasis and 
eczema. In -vitro studies confirmed the presence of 
the enzyme in skin from nude mice and showed 
that it is inhibited by glycyrrhetinic acid, the major 
active component of liquorice. By means of the 
skin vasoconstrictor assay, glycyrrhetinic acid was 
shown to potentiate the action of hydrocortisone. 
This work suggests a novel means of targeting 
glucocorticoid therapy. 
Lancer 1990: 335: 1060 -63. 
Introduction 
Corticostcroids arc important in the treatment of many skin 
disorders. Modifications of the steroid structure have 
produced a wide variety of clinically effective agents; 
however, many of the more potent agents carry a risk of skin 
thinning and systemic toxicity.' Even agents with a high 
ratio of local to systemic activity used in the lung' 
(cg, beclomethasonc dipropionate) for the treatment of 
asthma have systemic effects within recommended dose 
regimens. 3-5 Theoretically, targeting the glucocorticoid 
receptor by achieving high local levels of an intrinsically 
weak steroid need not compromise local efficacy but may 
reduce the risks of systemic toxic effects. Local inhibition of 
metabolism of a weak steroid such as hydrocortisone offers 
this prospect. The skin has the capacity to metabolise 
cortisol to cortisoneó7 by means of 113- hydroxysteroid 
dehydrogenase (11(3 -OHSD). We have previously shown 
that glycyrrhetinic acid, a constituent of liquorice, is a potent 
inhibitor of this enzyme system.E-9 The aim of this study was 
to assess how effectively glucocorticoid receptors in human 
skin could be targeted by inhibition of metabolism of 
cortisol. The in -vitro part of the study on skin metabolism of 
glucocorticoid and its inhibition by glycyrrhetinic acid used 
skin from the nude mouse, which has previously been used 
as a model system for investigation of the effects of topical 
glucocorticoid therapy.'° 
Subjects and methods 
We studied 23 healthy volunteers with no previous eaposure to 
exogenous cotvcostcroids -12 women and II men of mean age 
29 years (range 21 -50 years). The Stoughton -McKenzie 
vasoconstrictor assay" as modified by Place" was used to determine 
the potency of test substances. 2 subjects were tested twice with an 
interval of 2 months, so a total of 25 tests wcrc donc on groups of 4-6 
subjects at a time. The test solutions were hydrocortisone acetate (at 
concentrations of 0 I , (33, 1 0, 3 0, and I O mg /ml), bcclotnethasonc 
dipropionatc (0 I , 03, 1 0, 3 0, and 10 jig /ml), glycyrrhetinic acid 
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(20 mernI), and a mixture of glycyrrhetinic acid (20 rngJml) and 
hydrocortisone acetate at the above concentrations. All solutions 
were freshly made up in 95% ethanol in coded vials and were used 
within 24 h of preparation. 10 pl volumes were applied in random 
order to 7 x 7 RIM sites outlined by silicone grease on the flexor 
aspect of the forearm. After it had been allowed to dry, the test area 
was covered with polyester film ('Mclinex' 12 pin: ICI, UK) for 
16-18 h. The dcgt«. of blanching was assessed I, 2, 3, and 6 h after 
removal of the occlusive dressing and scored independently by two 
observers on a scale of 0 = none, 1 = mild, 2 = definite, and 
3 = intense blanching. All solutions wcrc applied and test sites read 
blind. Time-effect curves were plotted for cads test substance and 
the area under the curve was determined by the trapezoidal rule. 
For the in -vitro studies dorsal skin from freshly killed female 
nude mice (nu /nu, mixed genetic background) was homogenised 
('Ystral' homogetiscr. Scottish Scientific Instruments Centre Ltd) 
in 10 ml Krebs -Ringer buffer surrounded by ice, with 20 s bursts of 
homogenisation and 30 s cooling intervals. Homogenates were spun 
at 750 g, 4'C for 5 min, and the supernatants wcrc assayed for 
protein concentration (Bio-Rad' protein assay kit). The 
homogenates wcrc diluted with Krebs -Ringer buffer to yield the 
same protein content per wet weight of skin. 400 pd volumes were 
incubated with shaking at 37'C for 60 min with 12 nmol /I tritiated 
corticostcronc of specific activity 82 Ci /mmol (Amcrsham 
International) in 600 pl Krcbs -Ringer with 0.2% glucose and 0.2% 
bovine scrum albumin. Control samples containing either no 
homogenate or 10 pl ethanol were compared with incubations 
containing glycyrrhetinic acid, freshly made up in absolute ethanol, 
in final concentrations of 100 µmod /I, 1 pmol /I, and 001 µmod /I. 
'After centrifugation, corti osteroids wcrc extracted from the 
supernatant with ethyl acetate. 3H- corticostcrone was separated 
from'H- 11 -dchydrocortieosterone by thin -layer chromatography 
in a system of chloroform /95% ethanol (92/8). The percentage 
conversion of corticosteronc to 11- dehydrocorticostcronc was 
determined. 
lmmunohistochemieal studies used the IgG (racoon of a rabbit 
antiserum (56 -125) against purified rat liver l Ill- OHSD." As 
negative controls preimrmuune rabbit scrum and inappropriate 
primary antibody (to al- antitrypsin) were included. Normal 
human skin was obtained at laparotomy from the anterior 
abdominal wall and punch biopsy samples wcrc taken from lesions 
of patients with psoriasis and c¢cma. The tissue samples wcrc 
placed immediately in Bouin's fixative for 24-48 h, then subjected 
to routine paraffin embedding. Sections wcrc cut at 4 pm, 
deparaffunised, and rchydrated through graded alcohols. 
Endogenous peroxidase activity was blocked by 10 min treatment 
with 3% hydrogen peroxide, and to minimise background staining 
slides were prcincubated with 20% donkey scrum. They were then 
incubated in primary antibody, prcimmunc scrum, or 
inappropriate antibody at dilutions of 1 to 100 or 200 for 30 min at 
room temperature. This step was followed by labelled avidin -biotin 
imrmunodctcction" with biotinylatcd donkey antibody to rabbit 
immunoglobulin and peroxidase-conjugated sucpuvidin. The 
peroxidasc substrate was 3,3'- diaminobavidine tetrachloride. The 
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slides were counterstained in Mayer's haematoxylin and mounted 
in DPX. 
The groups were compared by analysis of variance (ANOVA), 
followed by a paired or unpaired Student's t test as appropriate. 
Significance was taken asp < 0.05, and results are expressed as mean 
and SEM. Linear regression analysis was used to plot the 
dose -response relation. 
Results 
The dose -response relations of test substances on the skin 
vasoconstrictor response in normal volunteers are shown in 
fig 1. Hydrocortisone acetate alone produced a flat response 
at the lower limit of detection of the assay. The addition of 
glycyrrhetinic acid, however, produced significant 
potentiation of the cutaneous vasoconstrictor effect at 
hydrocortisone acetate concentrations of 10 mg /ml 
(p <0.01), 3 mg /ml (p <0.001), and 1 mg /ml (p <0.001). 
Glycyrrhetinic acid alone and ethanol alone had no effect. 
The high 11 ß -OHSD activity in skin from nude mice 
(mean [n = 5] percentage conversion of 3H- corticosterone to 
3H -11- dehydrocorticosterone 49.0 [SEM 1.3] %) was 
slightly reduced by ethanol alone (39.0 [0.7]%;p< 0.05) but 
was greatly inhibited in a dose -dependent way by all 
concentrations of glycyrrhetinic acid (100 µcool /1= 0 [0] %, 
p <0.0001; 1 µcool /1 =4.1 [0.5] %, p <0.0001; 0.01 µcool/ 
1= 31.8 [1.5]%, p < 
Sections from normal human skin showed strong positive 
cytoplasmic staining for 11 fi -OHSD in the epidermis, with 
the exception of the basal cell layer (fig 2a). The luminal 
border of the sweat ducts stained moderately and there was 
some staining in the cytoplasm of sweat glands. There was 
no significant staining with either preimmune rabbit serum 
(fig 2b) or the inappropriate primary antibody (not shown). 
The distribution of the enzyme was similar in psoriatic and 
eczematous skin, although the enzyme seemed to be present 
in greater amounts (fig 2c and d). Mouse skin stained less 
intensely but all layers of the epidermis were positive (fig 3a) 
in comparison with normal human skin. The preimmune 
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Fig 1- Relation of human vasoconstrictor response (area under 
blanching curve in arbitrary units Y h) and dose of 
beclomethasone dipropionate, hydrocortisone plus 
glycyrrhetinic acid, and hydrocortisone alone. 
Hydrocortisone acetate 
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Fig 2- Localisation of 113 -OHSD. 
a= normal human skin stained for 113 -OHSD: b= normal skin with 
preimmune serum; c = psoriatic skin; d = eczematous skin. 
Discussion 
The anti -inflammatory activity of glycyrrhetinic acid has 
long been suspected.1536 Its chemical structure is similar to 
that of hydrocortisone but the mechanism of its anti - 
inflammatory action was not clear." We found that 
glycyrrhetinic acid is a potent inhibitor of 1113 -OHSD in 
kidney and liver"-'" and postulated that its anti -inflammatory 
activity is not a direct effect but is the expression of reduced 
conversion of cortisol to its biologically inactive product 
cortisone. 
The skin's capacity to metabolise cortisol was shown 
some time ago. 6.7 The fact that cortisone is the major 
metabolite shows that 1113 -OHSD is active in skin. It is 
difficult to study human skin in vitro because of problems 
with its homogenisation.19 The skin of nude mice is 
comparable to human skin as a physicochemical barrier to 
many drugs, including corticosteroids,'° hut unlike human 
skin it yields a consistent homogenate. With this tissuue we 
1 062 
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Fig 3- Localisation of 11 ß -OHS° in skin of nude mouse. 
a = stained for i i Il -OH SD: b = preimmune serum control 
have confirmed the presence of 11(3 -OHSD in skin and have 
shown that, as in kidney, glycyrrhetinic acid is a potent 
inhibitor of the enzyme. 
Our immunohistochemieal data localise the enzyme to the 
epidermis and confirm that enzyme activity is retained in 
diseased skin. This anatomical disposition makes it 
potentially suitable to modulation by topical therapy To 
evaluate whether in -vitro inhibition could be produced in 
vivo, the classic bioassay" of glucocorticoid anti - 
inflammatory activity was used. Despite its limitations,20 the 
Stoughton -McKenzie assay provides a reliable index of 
glucocorticoid potency." Our findings in human heutg, 
confirm that hydrocortisone alone is a weak anti - 
inflammatory agent. The addition of 2% glycyrrhetinic 
acid, however, greatly potentiated its activity. The fall -off at 
a hydrocortisone concentration of 10 mg/ml may relate to 
lower bioavailabiliry, since at this concentration the mixture 
has exceeded its solubility limit and is in suspension. 
Liquorice extracts have long been used for medicinal 
purposes. Glycyrrhetinic acid, the active principle, and its 
derivatives (eg, carbenoxolone) have proven therapeutic 
value.22 Used as 2% topical preparations these agents are 
beneficial in several inflammatory cutaneous disorders.2' 21 
However, carbenoxolone has no intrinsic anti -inflammatory 
potency in adrenalectomised animals.15 In our volunteers 
glycyrrhetinic acid alone applied overnight had no effect, 
possibly because of low endogenous cortisol levels. 
combination of hydrocortisone with glycyrrhetinic acid had 
a substantial effect. These findings support out hypothesis 
that the anti -inflammatory action of glycyrrhetinic acid is 
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mediated by cortisol which, in the presence of glycyrrhetinic 
acid, is protected from metabolism to inactive cortisone. 
The long -term application of topical corticosteroids by 
patients with skin disease, especially if an extensive area is 
affected, may lead to systemic glucocorticoid toxic 
effects.2829 A possible advantage of applying hydrocortisone, 
an intrinsically weak glucocortiooid, with glycyrrhetinic acid 
is that the enhanced local glucocorticoid activity could have 
lesser systemic effects. Glycyrrhetinic acid has limited 
solubility and its inhibitory effect on cortisol metabolism is 
likely to be confined to its site of application. 
Our previous studies have shown that 11(3 -OHSD has an 
important role in the protection of the non -specific 
mineralocorticoid receptor in tissues such as the kidney and 
salivary glands.30 Our latest findings suggest that 11 [I- 
OHSD may also modulate the access of glucocorticoids to 
the glucocorticoid receptor. The principle of local enzyme 
inhibition producing enhanced glucocorticoid activity may 
well be applicable to other sites where 11(3 -OHSD is 
present -eg, the lung. 
We thank our colleagues who acted as volunteers; Pauline Burnet and Mary 
Norman for their help with the bioassay; Dr Fouad Habib, Dr Manin 
Waterfall, and Ms Susan Stubbs for technical advice; Ms Louise Anderson, 
Ms Alison Ritchie, and Mr Donald Hay of the Animal Unit for their help; Ms 
Susan Rae and Mrs Barbara Beattie for preparing the typescript; and Dr Carl 
Monder (Population Council, New York, USA) for antiserum to I10- 
OHSD. S. T. was a Trinidad and Tobago Commonwealth Scholar under the 
auspices of the Association of Commonwealth Universities. 
REFERENCES 
I. Editorial. The hazardous jungle of topical steroids. Lancer 1977, u 
487-88. 
2 Brausand R, Thalen A, Ruempke K, Kallstrom L, Grusstad F 
Development of new glucocorticostcroids with a very high ratio 
between topical and systemic activities. in: Clark TJH, Mygtnd N, 
Selroos O, eds. Conicosteroid treatment in allergic airway disease Pro- 
Symp, Copenhagen, October 1981. Ens J Respir Dis 1982, 63 ' suppl 
122): 62 -73. 
I. Stead RJ, Cooke NJ Adverse eOecis of inhaled conicostennds H. t I .: 7 
1989; 298: 403-04 
4 Wyatt R, Waschek J , Weinbeigci M, Sherman 13 Effects nl Inhaled 
beelomethasonc dipropionate and alternate -day predniwnc ,n 
pituitary- adrenal function in children with chronic asthma . \' I: i-.. 7 
Med 1978; 299: 1387 -92 
5 Rhoades Rg, Forbes FF. Clinically apparent adrenal suppression s ih 
beclomethasone (400 meg'day) inhalation J Allergy Om hnnnool 
1980;65:218 
6 Malkinson FD, Lee hl \C', Luiukus,e I In vitro studies of adrenal netud 
metabolism in the stun J Itn-eri I):,ni,n,d 1959, 32: 101 -07 
7 ltsia SI., Hao YI. Metabolic translunnatiuns of c,,nisol 4 1 "' I .o 
human skin. Liin.hrnniiry 1966, 5: 1469 -74 
8 Stewart PM, Valentino R, Wallace AM, Burt D, Shackletun CHI-. 
Edwards CRW. Mincraloconicord activity of liquorice Illt 
hydroxysteroid deh drogcnase deficiency comes of age Laru,i 1987. o 
821 -24 
9, Valentino R, Stewart I'M, Bun D, Edwards CRW. Liquorice uilubn. 
11(i- hydroxysteroid dehydrogenasc in the rat. ,J F _ r d u c n n o l 1987. 1 1 1 
(suppl): 260 
10 Du Vivier A, Marshall RC, Brookes L.G. An animal model for evaluating 
the local and systemic effects of topically applied conirosterotds ,ar 
epidermal DNA synthesis N, J Dennmoi 1978; 98: 209 -15 
11 McKenzie AW, Stoughton RB Methods for companng lerutaneo . 
absorption of steroids Arch i)crnuaral 1962; 86: 608-10 
12. l'lace VA, Velasque/ JG, Burdick Kit. Precise evaluation cal ogncalls 
applied conicos,eroid potenc-y Modification of the Stoughton 
McKenzie assay Arc/, Der -moral 1970; 101: 531 -37 
13 Phillips DM , I .akshmi V, tvinndcr C. ConiRriternld I I JI- dt'lr' dr,ge'na H' 
in rat testis. lätdo,- nn,d.Av 1989, 125: 2(19 16. 
14 Guesdon JI., Tcninck T. Arrancas S 'Ilic use 01 aeid:n ti,. a in 
usrcraniun in unnmtunxnrvn,:rtit rt-chniques 7 Ih,n,.fir.n r',:'..."". 
1979, 27: 1 1 11 So 
15 Finney 1(513, Son,ers t;l l.hr ant,- umflanniai,',s atinu. ..I 
VOL 335- THE LANCET 1063 
glycyrrhctinic acid and derivatives. J Pharm Pharmacol 1958; 10: 
613 -20. 
16. Finney RSH, Tamoky AL. The pharmacological properties of 
glycyrrhctinic add hydrogen suednate (disodium salt). J Pharm 
Pharmacol 1960; 12: 49-58. 
17. Khan MH, Sullivan FM. The pharmacology of arbc noxolone sodium. 
In_ Robson JM, Sullivan FM, cds. A symposium of nrbenoxolonc 
sodium. London: Butterworth, 1976: 5-13. 
18. Monder C, Ste-N./art PM, Lakshmi V, Valentino R, Burt D, Edwards 
CRW. Licorice inhibits oorticosteroid 1l13- dchydrogenase- of rat 
kidney and liver: in vivo and in vitro studies. Endoainolgy 1989; 125: 
1046 -53. 
19. Voigt W, Fernandez EP, Hsia SI_ Transformation of testosterone into 
1713- hydroxy- 5a- andr9stanedid 3-one by microsomal preparations of 
human skin. J Biol Chan 1970; 245: 5594 -99. 
20. Burdick KH. Various vagaries of vasoconstriction. Arch Dermarol 1974; 
110: 238 -42. 
21. Barry BW, Woodford R_ Activity and bioavailability of topical steroids. 
In vivo /in vitro correlations for the vasoconstrictor test J Clin 
Pharmacol 1978; 3:: 43-65. 
22. Anon. Carbenoxolone sodium. In: Martindale The extra 
pharmacopoeia, 29th cd. London: Pharmaceutical Press, 1989: 1080- 
81. 
23. Csonka GW, Murray M. Clinical evaluation of arbenoxolone in 
balanitis. Br J Vener Dis 1971; 47: 179-81. 
24. Annan AG. Hydrocortisone and glycyrrhainic acid. Br Med J 1957; i: 
1242. 
25. Adamson AC, Tillamn WG. Hydrocortisone. Br Med J 1955; ii: 1501. 
26. Somerville J. Glycyrrhetinic add_ Br Med H 1957; i: 282-83. 
27. Colin -Joncs E. Glycyrrhetinic acid. Br Med J 1957; i: 161. 
28. Garden JM, Freinkel RK. Systemic absorption of topical steroids. 
Metabolic effass as an index of mild hypercortisolism. Arch Dermarol 
1986; 122: 1007 -10. 
29.Ohman EM, Rogers S, Mozan FO, McKenna TJ. Adrenal suppression 
following low -dose topical dobctasol proprioratc. J Roy Soc Med 1987; 
80: 422 -24. 
30. Edwards CRW, Stewart PM, Burt D, et al. Localisation of 1111 - 
hydroxyste oid dchydroge nase: tissue -specific protector of the 
mineralocarticoid reuc stor. Lancer 1988; ii: 986-89. 
BOOKSHELF 
Principles and Practice of Pediatrics 
Edited by F. A. Oski, C D. DeAngelis, R. D. Fcigin, and J. B. 
Warshaw. Philadelphia: Lippincott_ 1990. Pp 2000. S95. ISBN 
0- 397507070. 
In size alone Dr Oski and his co- editors have produced an 
impressive book. It weighs over 3 kg, runs to 2000 pages, 
and boasts 261 contributors. Assuming that each of the 
contributors was given a free copy, one might initially 
wonder whether there are any paediatricians left to buy it, 
but in chapter 2 we are told that in 1985 there were 35 617 
paediatricians in the United States (there are about 750 in 
Britain). It is written by Americans for Americans: one 
chapter is entitled Getting Started in the Real World: How 
to Set up Your Private Practice. 
Lippincott's glossy advertising brochure boasts that they 
"give you 5 books in one ", but some paediatricians may 
prefer to acquire their books as and when they need them 
rather than bulk -buying a volume that puts considerable 
strain on the bookshelf as well as the back. The five sections 
include General Pediatrics, The Fetus and Newborn, 
Ambulatory Pediatrics, the Sick or Hospitalized Patient, 
and a section curiously titled Important Things You Forget 
to Remember. To evaluate it as a reference book for an 
experienced paediatrician I looked up some recent cases 
where I needed to get more information. For Menke's 
disease, Blount's disease, CHARGE syndrome, and 
mitotdlondrial cytopathy the book gave concise and useful 
information. Unfortunately, Joubert's syndrome was noted 
only in passing. Eight marks out of ten. How did it perform 
as a text for junior paediatricians working for their 
examinations? I was impressed with the extensive 
background information on history taking, examination 
skills, paediatric pharmacology, molecular genetic, and the 
special needs of children with chronic illnesses. Ten out of 
ten. In the preface Dr Oski suggests that the book is 
designed to meet the needs of the medical student, but I 
cannot recommend it for British undergraduate use-two 
260 
out of ten. Is it a good practical guide to diagnosis and 
treatment for the busy intern or registrar? There are several 
excellent sections including lists of differential diagnoses of 
common symptoms, normal laboratory values for different 
age -groups, and a well illustrated section on paediatric 
procedures. Nine out of ten. 
This good and comprehensive text is excellent value for 
money and I strongly recommend it. For the second edition 
I would advise the publishers to put the colour plates in the 
text rather than at the front (to save the reader leafing 
backwards-.and forwards) and to divide it into two volumes, 
since its spine will not survive four years if the book is used as 
much as it should be. 
University Department of Paediatrics 
and Child Health. 
General Infirmary. 
Leeds LS2 9NS. UK MALCOLM LEVENE 
Modern Coronary Care 
Edited by G. S. Francis and J. S. Alpert. Boston: Little, 
Brown /Edinburgh: Churchill Livingstone. 1990. Pp 797. 
(70.00. ISBN 0- 316291595. 
Eighty years ago Dr James Herrick was asked to sec a patient 
with severe chest pain. The doctor thought the diagnosis 
was myocardial infarction, but then, in a response familiar to 
all of us, he spent a restless night wondering whether he had 
made the right decision. The patient died, necropsy 
confirmed the diagnosis, and the syndrome of myocardial 
infarction began its modem career as a recognisable disease. 
Eighty years on we are still discovering fundamental aspects 
of this fascinating condition -it was only ten years ago that 
the central role of coronary thrombosis, as postulated by 
Herrick, was finally proven, opening the way to a decade of 
thrombolysis. Francis and Alpen have attempted to pull 
together the major themes that have dominated coronary 
care and to present an up- to-date summary of current 
thoughts and management. The book is a series of reviews 
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SERUM HBV DNA' DURING AND AFTER TNF TREATMENT 
TNF dose (pg m') Post TNF 
Patient 0 10-15 100 2 wk 8 -12 wk 
I, severe CAH 
cirrhosis 4 o 0 0 
2, mild CAH 307 241 574 1062 213 
3, mild CAH 228 157 124 606 412 
4, mild CAH cirrhosis 17 4 12 II 0 
5, moderate CAH 0 0 190 396 0 
6, CPH /C11í 1323 961 1504 934 
pg per 40 pl. 
CAH =chronic active hepatitis. CPH =chronic persistent hepatitis. CLH_ thermic 
lobular hepatitis 
received no specific antiviral therapy for at least twelve months. All 
were HBsAg, HBeAg, and HBV DNA positive. Patient 5 (table) 
proved to be HBV DNA negative on day 0 of the trial, before 
receiving rTNF. With one exception treatment began with daily 30 
min infusion of rTNF in 100 ml of 4% albumin for 5 days. Later 
rTNF was given in a bolus over IO min on a day -case basis, thrice 
weekly. In patient I (table) therapy began as IO 31g m' 
intramuscularly but was discontinued after three doses because of 
reactions; 40 days later rTNF was given intravenously. Two 
patients began on a dose of 10 pg/m1, and four on 15 pg/m', for 2 
weeks, and if no important toxicity was seen the dose was increased. 
The dose levels were 10, 15,30,60,80, and 100 gem'. Paracetamol 
500 mg was given before each infusion. 
Five of the six patients completed 9 or more weeks of treatment. 
An initial fall in serum HBV DNA was seen in the five who were 
HEW DNA positive at the start of the trial (median values after 14 
days fell to 68% of pretreatment values [range 0 -78 %j, table). In 
patient 6 rTNF was discontinued after 3 days, with no further 
treatment, but his HBV DNA returned to previous values within 28 
days after an initial fall CO 71% of pretreatment levels. In patient 1 
serum HBV DNA fell to zero after the intramuscular injections, was 
low on three.occasions during or shortly after intravenous therapy, 
and was undetectable over the subsequent 6 months. The 
remaining four patients completed treatment to the maximum dose 
of 100 pgJm2. Patients 2 and 5, however, had recurrent rigors at 
doses over 30 pg/m2. They were given indomethacin 25 mg 30 min 
before each injection, and symptoms disappeared. In three of these 
patients, after an initial fall in I- BV DNA, an upward trend was 
noted throughout the trial; this trend was most dramatic in patient 5 
whose serum HBV DNA became strongly positive at doses over 30 
pg/m2. After cessation of treatment HBV DNA rose strikingly in 
three patients, falling again towards pretreatment values after 2 -3 
months. HBsAg titres broadly paralleled changes in HBV DNA. 
No change in HBeAg/Ab status was seen. After 5-12 months of 
follow -up HBV DNA had returned to pretreatment values an 
patients 2, 3, and 6. HBV DNA remained negative in patients I and 
5, and in patient 4 it was detectable intermittently (range 0-7 pg per 
40 pl). Unfortunately, however, the progression of liver disease was 
not halted in patient I and he had successful liver transplantation 6 
months after completing TNF treatment. All patients had a dose 
related increase in serum gamma glutamyltransferase (GGT) 
(median 58 -128 IU) during treatment. Serum aspartate 
transaminase (AST) rose in three of the four who received higher 
doses of rTNF. AST doubled in patients 2 and 5 with rTNF over 
30 pg/m2 in parallel with the rise in HBV DNA; values fell when 
treatment was discontinued. No serious clinical toxicity was seen. 
With 10-15 µg/m2 doses of rTNF a reduction in senun HBV 
DNA was seen, suggesting that rTNF was initially exerting an 
antiviral action against HBV. rTNF doses of over 30 µg/m2 (or 
longer treatment with rTNF) were associated in two patients with 
enhanced viral replication and raised HBV DNA and HBsAg. 
Higher doses ofTNF may be immunosuppressive -TN F is known 
to induce cortisone release.' Alternatively, TNF may directly 
enhance viral replication. Treatment of HUT -78 cells with TNF 
reduces the subsequent replication of HIV,' but when HIV is 
cultured in MOLT -4 cells TNF enhances viral replication.' The 
induction of other cytokines may also modulate the actions of TN F; 
for example IL -1 has been shown CO inhibit the antiviral action of 
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TNF against encephalomyocarditis varus cultured in fibroblasts 
and to inhibit the release of interferon beta from these cells.. .lie 
concomitant rise in HBV DNA and AST while on trratinunt 
suggests that the increase in viral replication may have ,,curl 
accompanied by increased lysis of hepatocytes. 
This study has shown that long -term outpatient treatment with 
(1-NF is possible. There was little evidence of systemic toxicity 
despite the presence of very high peak plasma TNF. This finding is 
noteworthy in view of the postulated toxicity of TNF in septic 
shock, which is associated with much lower scrum TNF.' 
None of our patients seroconverted to HBeAb despite the initial 
reduction in HBV DNA. A synergistic antiviral effect has been 
shown between TNF and interferon alpha in vitro studies." fhe 
addition of I FN -a as a more potent direct antiviral agent or a I' ter 
duration of therapy might result in complete viral clearance 13y 
simulating natural patterns of cytokine production the effectiveness 
of therapy for chronic HBV infection might be enhanced. 
We thank Dr R. Bown, Dr 8. McDougall, Dr A. Forbes, and Dr J I. 
'fhirkenlc for their help. N.S. is supported by the Wellcome Trust and 
J.Y.N.L. by the Crouchcr Foundation. 
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Glycyrrhetinic acid and potentiation of 
hydrocortisone activity in skin 
Sii, -We were somewhat surprised by Dr MacKenzie and 
colleagues' (June 23, p 1534) comments on our report (Mai 31, 
p 1060) demonstrating potentiation of hydrocortisone active\ In 
skin by glycyrrhetinic acid (GE), the active component of liqui ice 
They say that similar potentiation was reported in the 1951" by 
Borst and colleagues' and that we failed to mention this. They also 
refer CO a paper by Elmadjian et al' showing synergistic effects of 
hydrocortisone and liquorice extracts in two adrenalectomised 
patients. We were aware of both these papers and had cited than in 
our previous Lancet repon demonstrating the inhibition of 
11 fl- hydroxysteroid dehydrogenase (I l (3 -OHSD) by liquorice.' 
This report and those by Borst, Elmadjian, and their colleagues 
related to the mineralocorticoid -like actions of liquorice-Mc 
so-called deoxycortone -like effects -and demonstrated sodium 
retention and potassium loss when liquorice was given either with 
cortisone or hydrocortisone or when the adrenals were intact. It was 
not possible to draw any conclusions about the effect of liquorice on 
glucocorticoid action. Indeed Borst et al suggested that it did not 
have such an effect, as judged by the failure of liquorice to reduce the 
eosinophil count in healthy subjects or to improve the joint 
symptoms in rheumatic patients.' The aim of our recent repon was 
to examine the liquorice /glucocorticoid interaction in a well 
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toated glucocorticoid bioassay' ̀ - namely, the skin 
,Constrictor assay. Our results showed that GE could indeed 
cd.ance glucocorticoid activity in addition to its well known 
ri¡ncralocortjcoid -like effect, and thus explain Kumagai and 
co- workers' clinical observations. They showed that in two 
paoicllts, one with rheumatic fever and the other with lupus 
dyt.hcmatosus, there was potentiation and prolongation of the effect 
of ACTH and hydrocortisone by glycyrrhizine. 
Department of Medicine. 
western General Hospital, 
Edinburgh EH4 2XU. UK 
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Pre -eclampsia and HLA -DR4 
SIR; I )r Hoff and colleagues (March 17, p 661) report results from 
I population study that seem to indicate a negative association 
between 1-1LA -DR4 and pre-eclampsia/eclampsia, mild pre - 
edarnpsia, and pregnancy -induced hypertension. This is in striking 
contrast to an earlier report of a positive association between 
pre-cclampsia and DR4- Hoff et al cannot explain the discrepancy. 
They pooled two populations, on the grounds that the direction of 
the association between disease state and DR4 was the same in both. 
However, the two populations have very different gene frequencies 
of DR4 (0.057 blacks, 0.158 whites)' and they also differ in types of 
pregtt-tcy hypertension. The criterion for validly combining two 
popcl.:lnrs is that the marker gene frequencies are not different In 
Ibis csc they are very different Since a larger proportion of black 
than of whites are affected by the disease, the proportion of each race 
in the disease and control groups is different, and the frequency of 
DR5 would be expected to be lower in the disease group. The 
control group should have the same proportions of blacks and 
:yhnrs ,c the disease group 
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Phis letter has been shown to Dr Hoff, whose reply follows. 
-En L. 
S1R,- i )r Wilton and Dr Cooper are correct to note that pooling 
two different racial populations which have different distributions 
of sou.:- variables can lead to misleading results on statistical 
analysts Race can be a confounding factor but our statistical 
findings cannot be so easily dismissed. They come from a large 
historical cohort instead of a case -control study. The :ewer 
frequency of DR4 among women with the hypertensive disorders of 
Pregnancy is observed consistently in both races. We did analyse 
Our pooled data by the stratified chi -square method with 
stratilicati.in by race. Stnitiftcatjon eliminates biased comparisons 
that remelt from confounders such as race. The significance lock 
were similar to those derived from the pulled analyses 
Pc'lu I. tit lalws'.nuoes 
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Rectal gluten challenge and diagnosis of 
coeliac disease 
SiR, -Dr Loft and colleagues (June 2, p 1293) report the possibility 
of diagnosis of coeliac disease (CD) by direct gluten challenge of 
rectal mucosa. 
Dobbins and Rubin' were the first to describe the appearance of 
mild alterations in the rectal mucosa of coeliac patients when they 
were locally challenged with gluten. These alterations, which were 
greatest at 8 h post -challenge, consisted of polymorphonuclear 
infiltration of lamina propria and surface epithelium and depletion 
of goblet cells. These findings did not receive much attention until 
lately. Austin and Dobbins' and I and my colleagues' in 1988, as 
well as Loft and colleagues' elegant studies,` (and June 2) provide 
new and interesting data. Unfortunately, these groups of workers 
used different techniques for gluten challenge and timing for 
post -challenge biopsy; these differences might have caused the 
conflicting results about the number of post -challenge (versus 
pre -challenge) intraepithelial lymphocytes (IEL) and the degree of 
cellular infiltration of the lamina propria. Some results in these 
audits were, however, in accord -such as the absence of an increase 
in post- challenge mitotic crypt cell activity" and the significant 
increase in post- challenge mucosal thickness," which proved to be 
due, in pan , to extravascular deposition o fibrinogen.' The results of 
these studies strongly suggest that the rectal mucosa of coeliac 
patients is sensitive to gluten, in contrast with previous 
assumptions. 
Hott useful are these findings for the individual in need of a 
definite diagnosis of CD? Loft et al, who used computerised image 
analysis for IEL counts, regard rectal gluten challenge as a reliable 
test for the diagnosis of CD. We,' however, with the longs[ and 
probably the most aggressive rectal gluten challenge, found no 
difference between pre-challenge and post- challenge IEL counts, 
by the simple and widely used technique of counting 500 successive 
surface epithelial cells and expression of the results as percentages of 
epithelial cells. 
Thus, although there is evidence for sensitivity of rectal mucosa 
of coeliac patients to gluten, the practical usefulness of this finding 
remains unclear. 
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Possible locus for polycystic kidney disease 
on chromosome 2 
SIR. .Aut.00mal dominant polycystic kidne disease I ADPKD,I is 
one of the commoner mendelian disorders. Linkage analysis has 
mapped the disease gene (PKD1) to the short arm of chromosome 
Ili.' but several laboratories have identified families in which the 
disease gene segregates independently of PKDJ markers.` - As part 
of a European Community programme on the prevention of 
inherited polycystic kidney disease (protect leader Dr M. H. 
Hreuning. Leiden) an effort is being made to map the gene 1PKD2) 
in a large Danish family with this "unlinked" ADPKD ' Family 
members. whose gene carrier status has been established clinically 
and or b. ultrasonography (over the age of 35), have been typed 
with the highly polymorphic DNA markers \1SI, MS31 , MS43a, 
and 1 "NH' -I" The MS probes were purchased from (.ellmtark, 
UK, and í'NI12,1 (root Promega, USA Mier radioactive labelling 
they Ns err hybridised euissecuti'ely tyt 'Hylxtnd N' filters 
;Antershanl Internanon:it) containing Ilya digested bt 
14athnneri 1 he data were :utal%sett wuh the 'LINK At ;1:. 
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Iccumulation of labelled liposomes was seen in inflamed scar tissue 
n I patient with suspected recurrence of malignant melanoma 
;groin), and in a benign thyroid cyst of a patient with an 
arupharyngeal carcinoma. (Thin needle aspiration of cyst fluid and 
measurement of activity in a probe scintillation counter 2 weeks 
after injection of liposomes showed over twenty-fold greater activity 
in the cyst fluid than in a simultaneously drawn blood sample.) 
In a patient with suspected recurrence of malignant melanoma 
the liposome scan was negative, in agreement with other imaging 
methods and the clinical course ( "true negative "). Images of 
tumours were best seen 24 h and more after injection of liposomes; 
early images showed very low or no uptake of labelled liposomes. 
The distribution of liposomes (uptake in liver, spleen, bone 
marrow, and blood) showed considerable interindividual variation, 
which did not seem to correlate with radiolabelling efficiency. 
The overall specificity of liposome scanning in our study was 
59 %, specificity 25% (which is due to the selection of patients), and 
diagnostic accuracy 58 %. When confined to patients with 
oropharyngeal carcinomas, the sensitivity of liposome scanning was 
67 %, without a definable value for specificity. These values arc low 
compared with the results of others," which may result from the 
relatively low number of patients and their selection. As was 
observed before,'s late images (24 h, 48 h, and later) seem to give the 
best diagnostic information. We saw a high number of "false 
negatives" in patients who were treated by chemotherapy at the 
time of liposome scanning (8/10 rumour lesions). The effect of 
chemotherapy and other forms of antitumour therapy on the uptake 
of liposomes in tumour tissues will be the subject of further 
investigations. The therapeutic use of liposomes (loaded with 
chemotherapeutic agents) will depend on the results of these 
studies. 
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Potentiation of hydrocortisone activity in 
skin by glycerrhetinic acid 
SIR, -Dr Tcelucksingh and colleagues (May 5, p 1060) describe a 
response to topical hydrocortisone in skin, in which cutaneous 
blanching due to this steroid is apparently enhanced by co- 
application of glycerrhetinic acid, a compound closely related to 
carbenoxolone. This enhancement is attributed to inhibition in 
the skin of metabolism of cortisol by 1113- hydroxystcroid 
dehydrogenase. Teelucksingh et al suggest that this is a novel means 
of targeting glucocorticoid therapy. 
The potential merit of this approach depends upon the 
assumption that suppression of inactivation of hydrocortisone and 
consequent increase in tissue hydrocortisone is not accompanied by 
increased systemic absorption, exposing the patient in some 
circumstances to real risk of steroid toxicity.' However, this remains 
an unsupported assumption because systemic absorption of 
hydrocortisone in the presence of glycerrhetinic acid was not 
measured, and without this information Teelucksingh et al cannot 
claim to have dissociated increased local efficacy from increased 
systemic toxicity. The problem of increased kcal steroid toxicity ti 
also not addressed. 
Single or repeated co-application of glycerrhetinic acid with 
hydrocortisone might have increased percutaneous absorption of 
hydrocortisone. The increased blanching may thus have been 
wholly independent of any action on enzymatic metabolism, which 
was not measured in their study on human skin. These difficulties 
highlight the crucial importance of evaluating systemic 
hydrocortisone absorption in a study of this type. 
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'.'This letter has been shown to Dr Teelucksingh and Professor 
Edwards, whose reply follows. -Et). L. 
SIR, -ln our paper we showed that combining hydrocortisone, an 
intrinsically weak glucocorticoid, with an inhibitor of its enrym:uic 
metabolism enhances the action of hydrocortisone in pro du. ing 
skin blanching, the classic bioassay of glucocorticoid eflii -y. 
Professor Greaves is concerned about the possible risks of 
hydrocortisone toxicity due to increased systemic absorption. 
Systemic side- effects from topical glucucorticoid therapy are well 
recognised in the setting of chronic or relapsing disease when more 
potent, highly bioavailable topical agents arc used.' Such effects 
have not been described with topical hydroconisoner except in the 
very young with severe disease.' On the whole the systemic 
absorption of hydrocortisone from human skin is very low.''( he 
increased biological effect of hydrocortisone when co- applied with 
glycyrrhetinic acid implies increased access no the der'.11al 
vasculatures and perhaps the systemic circulation -but in view of 
the weak intrinsic action of hydrocortisone and its short half -life we 
proposed that this particular combination might prove to be 
associated with less risk than currently available potent agents. 
Greaves also suggests that glycyrrhctinic acid might increase 
percutaneous absorption of hydrocortisone independent of 
inhibition of enzymatic catabolism. Our study did not address this 
point. We demonstrated 1 1(3- hydroxysteroid dehydrogenase in 
human epidermis and showed that glycyrrhetinic acid is a potent 
inhibitor of this in 'vitro. We postulated that by inhibiting the 
metabolism of hydrocortisone in the epidermis, glycyrrhetinic acid 
was allowing greater access of hydrocortisone to glucocorticoid 
receptors in the dermis and hence the augmented biological action. 
The findings of Fuller and Verity' are in keeping with our 
hypothesis. They showed that in the colon, also a site of 
I I ß- hydroxysteroid dehydrogenase activity, corticosteroid 
responsive gene expression was enhanced by carbenoxolone (the 
hemisuccinate derivative of glycyrrhetinic acid). These findings 
therefore support our view that this enzyme protects not only the 
mincralocorticoid receptor' but also the glucocorticoid receptor. 
Department of Medicine. 
University of Edinburgh. 
Western General Hospital. 
Edinburgh EH4 2XU. UK 
263 
S. TEI:I.UC:KSINGII 
C. R. W. EUWAKUs 
I. Editorial. "Ilse hazardous jungle of topical steroids. Loire, 1977; ii: 487 -88. 
z. Tdrpcinen M. Influence of age and severity of dermatitis on the pr canoe 
absorption of hydrocortisone in children. Be J Derward 1988; 118: 517 -22. 
). Turpcincn M, Salo OP, L eisti S. ElTccm of percoanoan absorption dhydrnu,n sore 
un adrenncortiol responsiveness in infants with sever skin disease Br J Ikr.rur.t 
1986;115:475-84. 
I Wester RC. Bocks DA, Maibad, HI. In vivo percvtano,uy atwrptr.n I 
hydrocortisone in psoriatic patients and normal volunteers. J Am Acud 
1983; 8: 645-47. 
i Harry BW,Wodfdrd R. Activity and bidnvaifabili,y of capital sten+ds. In viw,;in v.tn, 
urrebtions for the vasoconstrictor test. J Our Phan 1978; 3:43 -55. 
6 I'ulkr PJ, Verity K. Colonic sodium- potassium adenosine triphosphate ,obonn gow' 
expression: dnutgeny and regulation by adrerva,wtr-at tcnnd 
1990; 127: 32 -38. 
7 Edwards C lEW, Stcw-an I'M. Hun U, n al. Ls-aóaatn u1 I lIt- hvJr.nia,nyJ 
dc-hydrogenasc -tissue specific protector of thr mmcral..owuowJ r.crpt.,r I ....: r 
I98tt. ir. 9146-H9 
576 THE LANCET 
and meningitis can be excluded. An osmotic diuretic should 
be available if LP is to be donc. 
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Cutaneous vasoconstrictor response to 
glucocorticoids in asthma 
PETER H. BROWN SURUJPAL TEELUCKSINC;H 
SIMON P. MATUSIEWICZ ANDREW P. GREENING 
GRAHAM K. CROMPTON CHRISTOPHER R. W. EnwARDS 
The aim of the study was to find out whether 
asthma patients whose airways obstruction is 
sensitive (CS) or resistant (CR) to corticosterord 
treatment also differ in their cutaneous 
vasoconstrictor response to a potent topical 
glucocorticoid. Corticosteroid resistance was 
defined by failure of forced expiratory volume in 1 s 
(FEV,) and peak expiratory flow rate to improve by at 
least 15% after a 2 -week trial of corticosteroids 
(prednisolone 20 mg daily for 1 week, then 40 mg 
daily for 1 week) despite more than 15% 
improvement with inhaled beta agonists. 
Beclomethasone dipropionate in concentrations of 
3 µg /ml, 10 µg /ml, 30 pg /mI, and 100 .sg /ml was 
applied to forearm skin: the site was occluded under 
plastic and the degree of blanching assessed after 
18 h. CS asthmatic subjects (n = 31), asthma 
patients with mild airways obstruction (n = 26). 
asthma patients taking long term prednisolone 
(n =: 13). and healthy volunteers showed similar 
vasoconstrictor responses In CR asthmatic subjects 
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(n = 15), the response (expressed in terms of either 
blanching intensity or the proportion of patients 
showing a positive response) was significantly lower 
than that in the CS group at concentrations of 3 
ig /ml (p < 0.01), 10 pg /ml (p < 0.01 ), and 30 
pg /m1 (p <0.05). but not at 100 pg /ml. This 
resistance to glucocorticolds in the skin. together 
with reported evidence of glucocorticoid resistance 
in peripheral blood leucocytes. suggests a general 
defect in the ability of tissues to respond to 
glucocorticoids in CR asthma 
Lancet 1991. 337 576 80 
Introduction 
Most patterns with chronic asthma respond well to 
inhaled corticosteroid therapy, and acute exacerbations of 
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their disease respond to treatment with systemic 
corticosteroids. A minority of asthmatic patients, although 
they derive substantial benefit from bronchodilators, show 
little response to corticosteroids_' Corticosteroid- resistant 
(CR) patients, in comparison with those who arc 
corticosteroid sensitive (CS), are more likely to have had 
asthma for longer than 5 years, to have a family history of 
asthma, and to experience symptoms at night) 
A series of in -vitro studies of peripheral blood 
mononuclear cells2-4 suggested that corticosteroid resistance 
was associated with a defect in monocyte responsiveness to 
glucocorticoids. Monocytes from asthmatic patients release 
a polypeptide which primes neutrophils and eosinophils for 
enhanced leulcotriene generation when subsequently 
stimulated by ionophore.54 In CS asthmatic patients release 
of this cytokine is blocked by low concentrations of 
hydrocortisone (10-8 molli), whereas in CR patients much 
higher concentrations (up to 10-4 molli) do not suppress 
release.sh Studies of peripheral blood lymphocytes have also 
shown differences between CS and CR asthmatic patients. 
The degree of activation of T lymphocytes (as assessed by 
increased HLA DR and interleukin-2 receptor expression) 
is greater and higher concentrations of dexamethasone are 
required to suppress in -vitro proliferative responses to 
phytohaemagglutinin and to suppress interleukin -2 and 
interferon -gamma release in CR than in CS asthmatic 
patients (unpublished data). 
The evidence of reduced responsiveness of airways 
obstruction and peripheral blood cell function to 
corticosteroids in CR asthmatic patients suggests that they 
may have a general defect in the ability of their cells to 
respond to glucocorticoids. It might therefore be possible to 
show a reduced response to corticosteroids in other tissue 
sites. Glucocorticoids such as beclomethasone dipropionate 
and budesonide benefit most patients with asthma because 
of their high topical potency but low systemic effect. The 
topical potency of a glucocorticoid can be determined by the 
degree of blanching produced when it is applied to the skin. 
This cutaneous vasoconstrictor response has been used to 
compare topical potencies of different glucocorticoids for 
many years.' However, healthy volunteers are normally 
used in such comparisons, and cutaneous responses of 
patients with systemic diseases for which glucocorticoids are 
used therapeutically have not been reported. We have 
studied the vasoconstrictor response to beclomethasone 
dipropionate of patients with asthma and compared CS and 
CR patients. 
Patients and methods 
"f-he vasoconstrictor response was studied in a group of healthy 
volunteers and tic groups of asthmatic pauents ;.table). Healthy 
subjects were recruited from hospital staff, none of whom were 
taking any form of corticosteroid therapy. All patients with asthma 
had a history of variable dyspnoca and wheeze, more than 20% 
diurnal variation in peak expiratory flow (PEF), and more than 15% 
improvement in PEF or FEV, (minimum improvement 200 ml) in 
response to inhaled beta-2- agonists. Atopic status, smoking history, 
family history of asthma, number of years with symptoms, and 
highest achieved FEV, in the preceding 2 years were recorded. 
Atopy was defined, by means of skinprick tests to a range of 
allergens including housedust mite, grass pollens, animal dandcrs, 
and Aspergillus /wnigatus, as two or more reactions with a weal 
diameter more than 2 mm greater than the control test. 
Patients with mild asthma had fcw symptoms and normal lung 
function One group of such patients (n - 121 were taking 
intermittent inhaled beta agonists as sole therapy; patients (n = 141 
in the ether group were also taking regular inhaled corticostemids 
265 
(up to 2 mg beclomethasone dipropionate or budesonide daily) All 
of 46 patients with asthma, whether sensitive (CS; n = 31) or 
resistant ((.R; n = 15) to corticosteroids, were taking inhaled 
conicostcroids. 8 CR patients were also taking long -term 
prednisolone (median 7.5 (range 5-10) mg daily; median duration 
of therapy 8 years), compared with only 4 CS patients. To control 
for possible influences of long -tern systemic corticosteroid therapy, 
another group of asthmatic patients taking long -term prednisolone 
was studied. These patients either had mild airways obstruction 
(most were taking prednisolone for allergic bronchopulmonary 
aspergillosis) or their response to prednisolone had not been 
formally assessed. Their median dose of prednisolone (7 mg daily) 
and median duration of treatment (10 years) were similar to those of 
the CR patients taking prednisolone. 
Patients with airways obstruction (FEV, below 70% predicted) 
in the outpatient clinic underwent a 2 -week trial of oral 
prednisolone to determine the corticosteroid responsiveness of their 
asthma. Before treatment started, PEF was monitored three times 
daily for a week. In addition to their usual treatment, patients then 
took 20 mg prednisolone daily for 1 week, followed by 40 mg daily 
for a second week. FEV, was measured before treatment started and 
at the end of each treatment week; PEF monitoring continued 
throughout the trial. Mean PEF during the last 2 days of the 
baseline week was compared with that during the last 2 days of each 
of the treatment weeks. Cortoosteroid resistance was defined as 
failure of initial FEV, and mean peak flow to improve by at least 
15% after 2 weeks of treatment. This design allowed CS patients to 
be subdivided into those who were more responsive (more than 
15% improvement in lung function after 1 week) or less responsive 
(more than 15% improvement seen only after longer duration or 
higher dose) to prednisolone. 
Beclomethasone dipropionate was dissolved in 95% ethanol to 
concentrations between 1 ig /ml and 100 pg /ml. Solutions were 
stored at 4C and used within 2 weeks of preparation. Preliminary 
tests established that there was no change in topical potency over 
this time. The vasoconstrictor assay was a modification of the 
method of McKenzie and Stoughton.' The subject's forearm was 
shaved if necessary and test sites were outlined by application of 
double -sided adhesive tape in which holes, 2 cm in diameter, had 
been cut. Test concentrations of beclomethasone dipropionatc were 
applied to the skin. 10 pl to each site. After evaporation of the 
diluent, the sites wrre covered with plastic film ('Saran' wrap or 
polythene) to enhance percutaneous absorption of glucocorticoid ' 
Prelimirìary experiments in healthy volunteers confirmed that 
blanching was greatest 16-18 h after application of glucocoricoid 
Solutions were therefore applied in the afternoon, the sites were 
occluded overnight, and the adhesive tape and plastic film removed 
the next morning. The degree of blanching was assessed 2 h later; 
this step allowed any tape - related erythema to resolve. Assessment 
was made under standard fluorescent lighting conditions b a 
trained observer who was unaware of the steroid responsiveness of 
the patient's asthma. Blanching was graded according to a 5 point 
scale: (l = normal skin, I = faint blanching, 2 = obvious blanching, 
3 = intense blanching, and 4 = intense blanching extending beyond 
the area to which solution had been applied. In patients who 
underwent a conicosterotü trial, skin testing was done heft,' of 
several weeks or months after the trial. 
Initially, the vasoconstrictor response was assessed in young, 
healthy volunteers, with concentrations of 0 fig ml, 1 ttg'ml. 3 
itgjml, and 10 µgt ml. Asthmatic patients were then tested with these 
concentrations. Subjects in whom no blanching was detectable were 
retested with concentrations of 10 µg /ml, 20 µg /ml, 30 rig ¡ml, and 
100 sg /ml. Latterly, concentrations of 3 ttg /rml, I O leg mI, 3(1 pg,ml, 
and 100 pg;ml were used. 
All subjects gave informed consent and the study was approved 
by the Lothian Region Ethics Cormminee 
The numbers of patients in the study groups who showed 
detectable blanching at each concentration were compared h 
means of chi- square tests with Yates' correction 'Ihis test was also 
used to compare groups for copy, smoking, and I moil htstnr 
Lung function data were expressed as percent predicted li,r age, 
height. anti sec 'l ,wu- siumplc i tests were used tot comparisons of 













Asthma: long-term prednrsolone 
CS asthma v -^--^^-+-- 
CR asthma 
3 10 30 100 
Log BOP concentration (ug /ml) 
Fig 1- Proportion of asthmatic adults showing any degree of 
cutaneous vasoconstrictor response to beclomethasone 
dipropionate (BDP)- 
Xa tests for CR vs CS: 5p< 0-02; tp <0 01; Ip <0.0O1. 
lung function and duration of asthma and Mann -Whitney U tests 
for intensity of blanching in response to a given concentration of 
beclomethasone dipropionate 
Results 
A concentration of 3 pg/ml beclomethasone dipropionate 
produced blanching in most healthy volunteers. 10 pg/ml 
produced detectable blanching in 52 (90%) of 58 volunteers. 
Absence of blanching was reproducible at this concentration 
in the remaining 6 when they were retested with 10 pg/ml, 
20 pg/ml, 30 pg/ml, and 100 pg/ml. 3 of these subjects 
repeatedly showed no blanching with any concentration. 
16 healthy subjects who showed a positive response 
underwent repeat tests each month for 6 months. 15 (94 %) 
showed consistent responses to beclomethasone 
dipropionate concentrations of 10 pg /ml or higher; 1 subject 
had five positive responses and one negative response to 10 
pg /ml. At 3 pg/m1 consistently positive responses were 
obtained in 14 (88%) subjects. 
The vasoconstrictor response was similar in the patients 
with mild asthma whether they were taking intermittent 
bronchodilators or inhaled corticosteroids. These groups 
were therefore combined for expression of results. In the CS 
asthma group, there was no difference in blanching between 
patients whose airways obstruction improved after I week of 
prednisolone and those who responded after 2 weeks. The 
proportion of patients who showed any degree of blanching 
at each concentration of beclomethasone dipropionate was 
similar in the mild asthma, CS, and long -term prcdnisolonc 
groups and in healthy subjects. The proportion of CR 
patients who showed blanching was significantly lower at all 
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3 10 30 
Log BOP concentration (ug /m1) 
Fig 2- Intensity of cutaneous vasoconstrictor response 
beclomethasone dipropionate (BOP) in asthmatic adults. 
Error bars indicate 95% confidence limits. 
100 
to 
Virtually all subjects showed a dose -related 
vasoconstrictor response to beclomethasone dipropionate 
(fig 2). There was no significant difference at any 
concentration between the CS group and the mild asthma or 
long -term prednisolonc group. In comparison with the mild 
and CS asthmatic groups, median blanching intensity was 
significantly lower in CR patients at 3 pg/ml (p <0-001), 10 
pg /ml (p <0.001), 30 pg /ml (p <O-05), but not at 100 pg/ml. 
In comparison with the prednisolone group, blanching in 
the CR group was significantly lower (p <0 -01) only at 10 
pg /ml, though the differences at 3 pg /mI (p = 0-08) and 30 
pg /ml (p = 0.13) approached significance. The prednisolone 
and mild asthma groups differed significantly only at a 
concentration of 30 pg /ml (p <0.01). 
Mean FEV, (% predicted) was slightly low in CS 
asthmatic subjects (82% [95% Cl 77,87d/á)) and in chose 
taking long -term prednisolone (77d/á[58- 97 %J). Airways 
obstruction was severe in the CR asthmatic group (54%, 
range 20 -80%); the difference between the CS and CR 
groups was highly significant (p < 0-001). 
Ar the start of the trial of corticostcroids, mean FEV,% 
predicted was 50á/o (95% CI 44 -56%) in the CS group and 
41% (31 -51%) in CR patients. After the trial, FEV,% 
predicted improved to 73% (65 -80%) in the CS group but 
it was unchanged (39% [29-49%j) in the CR group 
There were no significant differences among the patient 
groups as regards atopy, smoking, or family history of 
asthma (table). The duration of symptoms in the mild 
asthma group was shorter (mean 12.3 [95d/á CI 76-17 01 
years) than in the other groups (p < 0.01). There were no 
significant differences among these groups in the duration of 
asthma, though the difference between CR and CS patients 




in yr M/F 
Mean FEV, 
(95% CI) as % 
predicted 
No ( %) 
current 
smokers 
No ( %) 
atonic 





(range) to yt 
Mild asthma 
Inhaled (f0 agonist alone 12 430(21 -63) 715 94 (87-101) I (8% t 8167 %, 5(42%1 II 7(1-50) 
Inhaled steroid 14 44 I ;19-723 4'10 91 (82 -101) I r 7% I IO 7, % - 8 157% t 13 2 (2 
30' 
Asthma 
1..ong -term predmsokwu 13 54 7 ;29 -71) 518 77 (58 -97) 3 121% I 9 169% 4 r iI % I 29 H (8 55, 
CS 31 49I(18 -69) 151b 82(77 .87) gí26%, 25,81%. 14145% 232(1 -541 
CR 15 456 (27-69) S.7 54(441,4) 4.7%1 11 71% 7 147% 3 ?913 37 
Normal subteen 5S 352(19.511) t3,25 
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approached significance (p = 0 063). However, within the 
CS group the 10 patients who required 2 weeks of 
prednisolone to show an improvement in airway calibre had 
had asthma longer than the 21 who responded to I week's 
prednisolone (33.3 (18.5 -47.51 vs 18-5 [12.2 -24.8) years; 
p <0-05). 
Discussion 
Glucocorticoids applied to skin undergo percutaneous 
absorption and influence the dermal vasculature to produce 
blanching. Different glucocorticoids vary greatly in their 
ability to provoke a vasoconstrictor response; 
beclomethasone dipropionate9 and budesonide10 are the 
most potent of the glucocorticoids in clinical use. A high 
degree of blanching reflects high topical anti -inflammatory 
potency'(° This study shows that the vasoconstrictor 
response to beclomethasone dipropionate is lower in asthma 
patients whose airways obstruction is resistant to a short 
course of oral corticosteroid than in CS patients. 
Bioassay of topical corticosteroid formulations by the 
vasoconstrictor response is sensitive, precise, and 
reproducible.83' Variation in the degree of blanching occurs 
among subjects,'" but it has been assumed to be due to 
differences in absorption through the skin. Responses in an 
individual do, however, seem to be consistent from assay to 
assay.' Blanching may be detectable a few hours after 
application of glucocorticoid and some investigators assess 
the response at 6-7 h.83` The maximum response usually 
occurs around 18 h.8 Although response can be assessed 
more precisely by means of several assessments at different 
times,83o a single reading at around 18 h is satisfactory."-" 
A trained eye is required to detect minor degrees of 
blanching, and the arm must be carefully inspected under 
standard lighting conditions. Although interobserver 
agreement on blanching scores seems good, the use of a 
subjective method of assessment has been criticised." An 
objective method might be preferable, but such techniques 
as reflectance spectrophotometry, doppler laser, or 
thermography have not been proven superior." 
In our study, long -term treatment with inhaled 
beclomethasone dipropionate or budesonide (in either low 
or high doses) did not affect the vasoconstrictor response. In 
patients taking long -term prednisolone, there was a 
tendency for the blanching dose -response curve to be 
shifted to the right but there was no difference in the 
proportion of patients who showed no blanching between 
this group and the mild asthma and CS groups. The CR 
asthma group tended to have more severe symptoms than 
patients in the other groups However, their reduced skin 
IL-spouse is unlike( to he .file io gtcatcr use .a beta .Igonist 
drugs, which have relaxant effects on vascular smooth 
muscle. We have not observed reduced skin blanching in 
patients receiving regular nebulised salbutamol in high 
doses for exacerbations of asthma. Treatment with other 
drugs, such as xanthine derivatives, did not differ between 
CS and CR patients. It is possible that the lifetime dose of 
prednisolone was higher in CR patients, but it is impossible 
to estimate this exposure accurately. 
The CR asthma patients showed evidence of a degree of 
fixed airways obstruction; the best recorded I=EV, in the 2 
years before the study was only S4°i, predicted (range 
20- 80 "/.) Nevertheless. variation in ITV, tvithin a patient 
was great in many cases, and all of the patients showed a 
response to beta agonisis Our ohser anon that the 
blanching response is preserved in patients with ;wine 
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asthma suggest that the reduced response in CR asthmatic 
subjects is not related to the degree of airways obstruction at 
the time of skin testing. In some CR patients, severe asthma 
symptoms persisted despite treatment with long -term 
prednisolone, and as a result attempts to withdraw such 
treatment were infrequent and unsuccessful. It is possible 
that any element of corticosteroid responsiveness in these 
patients was being fully utilised at the time of their 
corticosteroid trials. 
The mechanism of skin blanching in response to topically 
applied glucocorticoid is unknown. Although this response 
has been used as a means of comparing the potency of topical 
corticosteroid preparations for many years, the relation 
between blanching and the mechanisms by which 
glucocorticoids exert their anti -inflammatory effects is not 
clear. There is a good correlation between blanching activity 
and clinical efficacy in the treatment of psoriasis." Marks 
and Sawyer1' found that prior application of glucocorticoid 
to skin reduced the erythema resulting from subsequent 
application of arachidonic acid and histamine and postulated 
that inhibition of phospholipase A2 activity might be 
involved in the mechanism of blanching. Glucocorticoids 
induce lipocortin 1, which inhibits the activity of 
phospholipase A2. "38 Concentrations of antibody to 
lipocortin do not differ between CS and CR asthma 
patients,t9 though Busse° suggested the possibility of a type 
2 error in that study. Glucocorticoids also increase the 
sensitivity of vascular smooth muscle to the vasoconstrictor 
effects of noradrenaline, an effect reversed by infusions of 
arachidonic acid and prostacyclin.2' Although this effect 
could explain the blanching response, there are many other 
mediators of vascular tone which may themselves be 
affected by glucocorticoids.22 
Although the mechanism of blanching is unknown, the 
response seems to be mediated through the glucocorticoid 
receptor, since blanching can he abolished by oral 
administration of the glucocon'coid receptor antagonist RU 
486.2' We .have observed that prior application of this 
compound to the skin prevents the vasoconstrictor response 
to beclomethasone dipropionate. Budesonide has sery high 
affinity for the glucocorticoid receptor' and for a given 
concentration produces the greatest degree of blanching 9 
Glucocorticoids are used in many inflammaton 
disorders, and individual patients show differing responses 
to treatment Relative corticosteroid resistance is not 
confined to asthma and, although variation in response m:l 
be due to differences in severity of the underlying disease 
process, it could also be explained by congenital or acquired 
defects in the ability of cells to respond to endogenous or 
exogenous gluet'.,vncotds Further investigation ,d skui 
resistance to glucocorticoid action may help explain ti li 
some patients with asthma, or other disorders treated with 
glucocorticoids, show a poor response to such therapy 
P. H. B thanks Allen and Hanhurys Ltd and Astra Pharmaceuticals fog 
financial suppon ti i ,vas 'I'nnidad and Tobago Commonwealth medical 
scholar under the auspices of the Association of Commonwealth Universities 
We thank Dr R. A Elton (Dcparunrnt of Medical Statistics. Umccrsits of 
Edinburgh) for his helpful advice 
267 
REFERENCES 
I (annichacl J ,I'at,rson I(:.r)ry (',(:ronron,( ;K,Ka% Alt .( ;rani I\VIt 
Cnn icostvrotd i c,stanc. ut <-honu< asthma Mr Aire 7 1081 'S'. 
1,11') ') 
2 Kat Ali. Oct, l' (_uni. haul I. ( ,run I \Cit t.,ituosicnn. t i, .r.t.uu 
asthma and nnn,, s% it , oml,lemeni uv rinot. (Im1 , f.1 I 1'i>Si 
44: 576 Kit 
580 THE LANCET 
3. Poznansky C, Gordon ACH, Douglas JG, Krajewski AS, Wyllie AH, 
Grant IWB. Resistance to mcthylprcdnisolonc in cultures of blood 
mononuclear cells from glucocorticoid- resistant asthmatic patients. 
Clin Sci 1984; 67: 639 -45. 
4. Poznansky MC, Gordon ACH, Grant IWB, Wyllie AH. A cellular 
abnormality in glucocorticoid resistant asthma. Clin Exp tmmunol 
1985; 61: 135-42. 
5. Wilkinson JRW, Crea AEG, Clark TJH, Lee TH. Identification and 
characterisation of a monocyte -derived ncutrophil- activating factor in 
conicosteroid- resistant bronchial asthma. J Clin Invest 1989; 84: 
1930-41. 
6. Wilkinson JRW, Crea AEG, Clark TJH, Lee TH. Enhanced generation 
of a novel cytokine by monocytes in corticosteroid- resistant bronchial 
asthma. Am Rev Respir Dis 1990; 141: A876 (abstr). 
7. McKenzie AW, Stoughton RB. Method for comparing percutaneous 
absorption of steroids. Arch Dermarol 1962; 86: 608 -10. 
8. Barry B, Woodford R. Activity and bioavailability of topical steroids: in 
vivo /in vitro correlations for the vasoconstrictor test. J Clin Pharntacol 
1978; 3: 43-65. 
9. Hams DM. Some properties of beclomethasone dipropionate and related 
steroids. Posrgrad Med J 1975; 5l (suppl 4): 20-25. 
10. Johansson S -A, Andersson K -E, Brattsand R, Gruvstad E, Hedner P. 
Topical and systemic potencies of budesonide and beclomethasone 
diproprionate in man. Eur J Clin Pharmawl 1982; 22: 523 -29. 
11. Place VA, Velazquez JG, Burdick K. Precise evaluation of topically 
applied corticosteroid potency. Arch Dermarol 1970; 101: 305-07. 
12. Burdidt K. Various vagaries of vasoconstriction. Arch Dermatol 1974; 
110: 238-42. 
13. Shah VP, Peck CC, Skelly JP. "Vasoconstriction" -skin blanching -assay 
for gluoocorticoids-a critique. Arch Derrnarol 1989; 125: I558-61. 
VOL 337: MARCH 9, 1991 
14. Gibson JR, Kirsch JM. Relative peen es of topical steroids Br J 
Dennatol 1986; 114: 638 -39. 
15. Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and 
clinical activity in psoriasis. Arch Dermaral 1985; 121: 63-67. 
16. Marks R, Sawyer M. Glucocortucnid- induced vasoconstriction in human 
skin. Arch Dermatol 1986; 122: 881 -83. 
17. Peers SH, Flower RJ. The role of lipoconin in conicusteroid actions. 
Am Rev Respir Dis 1990; 141: SI8 -21. 
18. Goulding NJ, Godolphin JL, Sharland PR, et al. Anti- inflammatory 
lipocortin 1 production by peripheral blood leucocytes in response to 
hydrocortisone. Lance 1990; is 1416 -18. 
19. Wilkinson JRW, Podgorski MR, Godolphin J L, Gouldusg NJ, Lee lH. 
Bronchial asthma is not associated with autoantibodics to lipucurtin- I . 
Clin Exp Allergy 1990; 20: 189 -92. 
20. Busse WW. Corticosteroid resistance in asthma: a clinical hurdle and 
mystery. Clin Exp Allergy 1990; 20: 125 -26. 
21. Rascher W, Dietz R, Schomig A, Burkan G, Gross F. Reversal of 
corticosteronc- induced supersensitisity of vascular smooth muscle to 
noradrenaline by arachidonic acid and prostacvclin Eur J PhunnacoI 
198(1; 68: 267 -73. 
22. Brenner B, Troy JL, Ballerman BJ. Endothelium dependent vascular 
responses. Mediators and mechanisms J Clin mires, 1989, 84: 
1373 -78. 
23. Gaillard RC, Pufet D, Riondel AM, Saurat J -H RU 486 inhibits 
peripheral effects of glucuconicoids in humans. J Chin Endo rinol 
Metab 1985; 61: 1009 -11. 
24. Dahlberg E, Thalen A, Brausand R, et al Correlation between chemical 
structure, receptor binding and biologial activity of some novel, high 
active 16 17 -acetal- substituted glucuconicoids Aid Phannaco! 1984; 
25: 70-78. 
Surfactant apoprotein -A concentration in sputum 
for diagnosis of pulmonary alveolar proteinosis 
TOHRU MASUDA SANAS SHIMURA HIDETADA SASAKI 
TAMOTSU TAKISHIMA 
Pulmonary alveolar proteinosis (PAP), a disease 
characterised by accumulation of surfactant in 
alveoli, is diagnosed on the basis of invasive biopsy 
procedures. We have measured apoprotein A 
(SP -A) concentrations in sputum to see if this is 
useful for the diagnosis of PAP. Sputum samples 
from three patients with PAP and twenty patients 
with other pulmonary disease were assayed using 
monoclonal antibodies to SP -A. SP -A 
concentrations were 400 times higher in patients 
with PAP than in the controls, suggestions that this 
measurement is useful for the diagnosis of PAP, 
especially where lung biopsy is contraindicated. 
Lancet 1991: 337: 580-82. 
Introduction 
Pulmonary alveolar proteinosis (PAP) is a rare disease of 
unknown aetiology that is characterised by accumulation of 
surfactant materials in alveoli. Impaired alveolar clearance 
of surfactant due to abnormal function of alveolar 
macrophages has been implicated.' The definitive 
diagnosis rests on histological findings after open -chest or 
transbronchial lung biopsy. Diagnosis by microscopic or 
chemical analysis of fluid from bronchoalveolar lavage' 
(which is also an invasive procedure) has yet to be 
established. Surfactant- associated 35 kD protein (surfactant 
apoprotein A or SP -A) is the predominant phospholipid- 
associated glycoprotein in pulmonary surfactant and is 
specific for lung surfactant." Accumulated surfactant in 
alveoli in PAP contains abundant SP -A. Monoclonal 
antibodies to SP -A' have been used to measure surfactant 
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concentration in amniotic fluid for the diagnosis of 
respiratory- distress syndrome." " We have used them to 
assay SP -A concentrations in sputum from patients with 
PAP. 
Material and methods 
Samples 
Over the past 3 years we have seen three patients with PAP 
diagnosed by transbronchial biopsy (table t). They had excrtional 
dspnoea and hypoxaemia but had no history indicating secondar 
alveolar proteinosis.12 They all expectorated sputum, especially in 
the early morning, before treatment with lung lavage. Ahei lavage, 
symptoms and laboratory and chest X -ray findings improved and 
they expectorated little or no sputum. 'Ten sputum samples (0 5-2 
ml) were collected on different mornings before transbrunchtal 
biopsy or lung lavage; care was taken to avoid mixing saliva with 
sputum. As control material single mucuid and mucopurulent 
sputum samples from twenty patients with other pulmonary 
diseases (eleven males, mean age 59 ISE 71 years) were collected 
The control patients had chronic bronchitis, bronchial asthma, 
chronic pulmonary emphysema, idiopathic pulmonary fibrosis, 
pneumonia, or lung carcinoma. These thirty sputum samples plus 
five saliva samples from the PAP patients and a brundioslveislar 
lavage fluid sample from patient 2 in table were assayed for SP -A 
concentration. 
0.5 ml of sample and 2 ml of 10 mmol.l "tris" HCI buffer i pH 7 4) 
containing 1 mmol'I ED-IA was homogenised for I min in an 
ice -cold bath (ultradisperser model- LK -21; Yamato.'l'okyu:. The 
homogenate was diluted by 013":,, sodium dtdcce I sulphate Spy 
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transferrable dements that do not resemble conventional plasrnidss 
have been isolated from these TriR/MuR S aureus transdpients, 
and attempts to done the resistance are underway. There is no 
cross- resistance to propamidinc, berzalkonium chloride, cetrimide, 
hoxadilorophane, chlorhexidine acetate, chlorhexidine gluoonate, 
or 9- arninoacridine. Our initial experiments indicate that the 
presence ofTriR does not influence the rate of kill after 30 s to 2 min 
of exposure to tridosan. Similar experiments have suggested that 
the same is true for MRSA with low -level chiorhexidine resistance.' 
However, the possibility of a rise in MIC to tridosan should be 
considered if eradication of MRSA is difficult with this agent, and 
we would be grateful if such strains were sent to the division of 
hospital infection for further study. 
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Central Public Health laboratory. 
London NW9 5HT. UK 
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Liquorice 
SIR, -Dr Baker and Dr Fanestil (Feb 16, p 428) point out the 
structural homology between the prostaglandin metabolising 
enzyme, 15-hydroxyprostaglandin dehydrogenase (PGDH) and 
11 ß- hydroxysteroid dehydrogenase (111- 0HSD), which converts 
cortisol to its inactive product cortisone. We have previously shown 
that liquorice derivatives are potent inhibitors of 11(3 -0HSD. Baker 
and Fanestil speculate that by inhibiting PGDH, liquorice might, in 
pan, exert its biological effects through prostaglandins. Their 
suggestion is based on data from Peskar et al' who showed inhibition 
of gastric prostaglandin metabolism by high concentrations of 
rarbenoxolonc. 
Liquorice and its derivatives possess both mineralocorticoid and 
glucocorticoid properties. The mechanism of these actions was 
poorly understood, although the presence of an intact adrenal gland 
or cortisol replacement in patients with adrenal insufficiency was 
known to be essential." We found that glycyrrhetinic acid, the 
active component of liquorice, is a potent inhibitor of l 11-0 H SD in 
vitro; in -vivo studies showed that this inhibition could account for 
both the mineralocorucoid and glucocorticoid effects of liquorice.'-' 
To assess whether altered prostaglandin metabolism, as suggested 
by Baker and Fanestil, might contribute to these biological actions, 
we examined the effects of glycyrrhetinic acid and carbetoxolonc on 
PGDH and 11 3-OHSD activity in vitro. Human placental tissue 
was chosen because it is a rich source of both 1113 -0HSD and 
PGDH. 
Chorionic homogenate (protein content 1.5 mg) was incubated 
with 500 ng POE. and 1 mmol/l NAD at 37'C for 15 min in a 
phosphate buffer containing 20% glycerol (pH 8.4). PGDH activity 
was measured by radioimmunoassay of the quantity of 15 -kcto- 
PGE2 produced after transformation to its methyl oxime. The 
experiment was completed with glycyrrhetinic acid, carbenoxolone, 
and 5 -(4- fluorobenzoyl)2- hydroxybenzene acetic add (FHBA), a 
known PGDH inhibitor. Substances were tested at concentrations 
up to 40 pmolll. The effects of similar concentrations of these 
substances on human placental 1113 -0HSD were evaluated as 
previously described.' Briefly, 0-3 mg protein from fresh placental 
homogenate was incubated with 12 mmol/l 'H-cortisol and 200 
µmot /l NAD in Krebs -Ringer buffer at 37'C for 1 h. Steroids were 
extracted with ethyl acetate and separated by thin -layer 
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Effects of liquorice on enzymes of prostaglandin and steroid 
metabolism. 
Upper. effects of glycynhetinic acid, carbenoxolone. and F1-18A on 
15-hydroxyprostaglandin dehydrogenase activity expressed as percentage 
of control: lower. effects of the same substances on 116- hydroxysterofd 
dehydrogenase. , glycyrrhetinic acid.'J. carbenoxolone: O. IIißA. 
percentage conversion of 'H- cortisol to 'H- cortisone. The results 
show that glycyrrhetinic acid and carbenoxolonc had no effect on 
PGDH activity, in contrast to the inhibition produced by FHBA 
(figure, upper). FHBA had no effect on Il0-0HSD activity 
whereas carbenoxolonc and glycyrrhetinic acid were inhibitory 
(figure, lower). 
Liquorice ingestion has been shown to produce mineralocortiooid 
effects even when plasma glycyrrhetinic acid concentrations are 
below 2 pmol /l, the lower limit of detection of the assay.' This 
evidence, together with the current findings, makes it unlikely that 
altered prostaglandin metabolism contributes to the salt- retaining or 
anti-inflammatory actions of liquorice and its derivatives. 
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comparing them with cyclosporin both for cflicac -y and side-effects 
(notably nephrotoxiciry, which is not exclusive to cyclosporin) arc 
needed before we can say whether their therapeutic indices are 
indeed better than that for cyclosporin. In vitro minimum active 
concentrations do not by themselves define the therapeutic index. 
Furthermore new agents may still can-y the risk of over= 
immunosuppression and will not solve a major problem 
encountered with all these agents in most patients-namely, disease 
relapse after cessation of treatment. The answer may come from 
new approaches fully discussed at the Paris meeting-namely, 
monoclonal antibodies, autoantigen peptide therapy, T cell 
vaccination, and so on. Inumunointervention is not just a matter of 
selecting the best immunosuppressive drug but searching for the 
bat strategy that allows us to slow down or stop the autoimmune 
process in a non -toxic, disease-specific, and long -term fashion. 
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Assessment of the mitochondrial respiratory 
chain 
SIR, -Trounce et al' have suggested mitochondria) respiratory 
failure as a possible cause of ageing in man. However, the frequent 
scatter of control data and their overlap with those of patients limits 
the ability of clinicians to reach a reliable diagnosis of respiratory 
chain deficiencies (figure, left)." However, we have recently 
observed that a constant ratio of respiratory enzyme activities is a 
consistent feature of oxidative phosphorylation, irrespective of the 
tissue tested. This finding may be because a balanced proportion of 
each enzyme complex is required for npttmum function of the 
respiratory chain. Our observation prompted us to present enzyme 
activities as ratios rather than absolute values. 
150 750 350 950 0 
COX (nmolimtn pet mg protein ) COX SCCR taw 
Mitochondria! enzyme activities as both absolute values and 
ratios. 
1 . = patients. I i = controls 
We studied 7 patients (A -G) and 34 controls for cytochrome c 
oxidase (COX) activity, succinatc -cy ochrome a reductase (SCCR) 
activity, and COX /SCCR activity ratios in mitochondria isolated 
from skeletal muscle. While normal COX activities were scattered 
over almost two orders of magnitude, the COX /SCCR activity 
ratios showed a normal distribution with a narrow range of values 
(mean [SDI 2.9 (0.6); range 2-4). Under these conditions, patients 
whose absolute COX values were in the low normal range could be 
unambiguously diagnosed as COX deficient (figure, right). 
Although this approach does not hold for generalised enzyme 
defects, it does improve the ability to recognise and quantify 
localised deficiencies in the mitochondria) respiratory chain. 
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Inhaled corticosteroids, bone formation. and 
osteocalcin 
SIR, -Inhaled cortieosteroids arc now a part of the trament of 
asthma. Low dosages of beclomethasone dipropionate (BDP), 
devoid of effects upon the hypothalamic- pituitary- adrenal axis, can 
control asthma.' However, there is concern now that higher 
dosages arc in use. A finding of lowered serum osteocalcin in 
individuals inhaling BDP 2000 pg daily' suggests that high -dose 
therapy might be associated with adverse effects upon bone. As pan 
of a larger study evaluating the systemic effects of inhaled BDP we 
measured osteecilcin across treatments using doses of BDP within 
the currently recommended therapeutic range (400 -2000 pg daily). 
We studied 16 healthy adult volunteers. using it randomised 
double- blind, placebo -controlled crossovel design to evaluate she 
systemic effects of 100, 200, 350, and 500 pg BDP administered by 
standard metered -dose inhaler every 6 h for IO days Wash -out 
intervals of 18 days separated each treatment period. Plasma lot 
osteocalcin measurement was collected on a fasting specimen take: 
within 30 min of 0900 h 4 days before starting treatment ;ut.i 
repeated at the beginning of the fifth and ninth days of each 
vestment period. Plasma osteocalcin was measured by an in -house 
radioimmunoassay and each individual's samples were assayed in 
the same batch. The difference from pre -treatment concentration ai 
both days of testing during treatment was analysed b a three -way 
analysis of variance with factors subject, dose, and phase. The 
hypothesis of no-treatment effect was tested by a two sided r -test a! 
each dose. 
During dosing with placebo plasma osteocalcin remained 
constant. During treatment with BDP there was a significant fall 
relative to placebo even at the lowest dose of 400 pg daily on 
treatment day 5. This effect was dose- dependent up to 1400 pg with 
a plateau thereafter (figure). With more prolonged tramcnt the 
plateau occurred at an even lower dose so that at day 9 of trament 
plasma osteocalcin was lowered to the same extent by 80O, 1400, and 
2000 pg dosages (figure). 
Osteoporosis is a sequel to chronic systemic glucucurticold 
therapy. This occurs primarily as a result of reduced bone formation 
which is reflected by reduced osteocalcin values in patients on such 
therapy.' The finding of reduced osteocalcin in adults inhaling 131)1' 
2000 jig daily is not too surprising because at such high dose 
systemic gluccortieuid effects can be expected We have now 
shown that BDP even at a dose of 4(X) 1,g per day is also associated 
....lib reduced osteocalcin values 'Phis r:mcs the pot:sththty that even 
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2000 
Plasma osteocalcin values, expressed as change from baseline . 
low dosages of this inhaled corticosteroid might reduce bone 
formation. 
Whether inhaled corticostcroids do adversely affect growth in 
asthmatic children remains a contentious issue.' It has been 
assumed that paediatric dosages of BDP are unlikely to have such an 
effect.' Whereas the clinical relevance of our current findings are yet 
to be established, it is important to note that we have demonstrated 
reduced bone formation in adults at what may be regarded a 
standard paediatric dose of BDP 400 )rg daily. 
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Revaccination against hepatitis B 
SIR, -Dr Coursaget and colleagues (May 18, p 1 180) suggest a 
cumbersome approach to the scheduling of HBV vaccine boosters. 
The thought of such a procedure is enough to discourage policy 
ma;:crs in developing countries, where the need for HBV vaccine is 
gre.nest, from embarking on a national HBV vaccine immunisation 
priti rarnrnc. 
Coursaget et al assume that boosters will be necessary for HBV 
vaccine. There is no evidence for such a conclusion. Indeed, 
long -term follow -up, at least for 7 years, did not reveal any 
development of severe hepatitis or carrier states in high -risk 
homosexuals, even after loss of circulating anti- I -IBs.' Thus 
immunological memory persists in the absence of antibody after 
immunisation. Because of the long incubation period in HBV 
infection it is probable that immunological memory will result in a 
pr. -rapt and strong anarnnestic response after exposure, and that 
at!. will provide protection against serious disease, though not 
against reinfection.' 
Certainly continued surveillance is needed to evaluate dais 
hypothesis, particularly in populations immunised at birth or in 
infancy. If such surveillance eventually reveals a need for boosters it would be more practical, in most parts of the world, to administer 
these at a fixed age cg, at entry to school-than to individualise the 
time of boosting based on quantification of individual immune 
responses. 
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SIR, -Dr Coursaget and colleagues' mathematical model for 
antibody kinetics after hepatitis B vaccination is based on anti -I-Ms 
titres measured at the time of booster vaccination, and does not 
require anti-HBs measurement 1 month later. This model could 
provide an estimate of the duration of protection in vaccination 
campaigns in which post -booster antibody measurements were not 
possible or were not planned for. In industrialised countries, 
however, post -booster anti-HBs titres are often available, and a less 
complex formula is desirable to more easily estimate the duration of 
protection in individuals. 
TABLE I- ANTI -HBs CONCENTRATIONS (POST -BOOSTER TO 
AT- BOOSTER RATIO) WITH RESPECT TO AT- BOOSTER TITRES 
(MONTH 0) 
Anti -HBs at booster (mo 0) 
Anti -HBs ratio (SD) 
(mo 1 /mo 0) IU/1 No GMT (IU /1) 
10-99 28 40 197 (23-1700) 
100-999 94 256 I11(20-614) 
1000-9999 17 2180 20 (8-50) 
GMT = geornel..c mean titre 
Our data" obtained from anti -HBs measurements at boostei 
vaccination 1 month later (n = 139) (table I) and up to 4 years later 
(n = 53, 4 aritì -HBs measurements in each) (table n) indicate that 
the anti -HBs increase from at- booster to post -booster titres and the 
decline later on can be described by two formulas: 
I: titre at 1 month post booster = 1700 x titre at booster° as 
2: otre of sample = titre at 1 month post booster x time since 
booster (in months) -139. 
Our formulae differ from that of Coursaget et al in that the 
exponent to are at booster (formula I) is slightly lower and the 
correction factor in formula 1 is five times higher than theirs 
(1700 x 30 days/month = 51 000 vs 10 000). These variables will be 
determined by the vaccination scheme and dosage, age, immune 
status, or various random factors and would have to be established 
for each immunisation protocol. 
However, reliance on a constant decline of titre after the I -month 
post -booster anti-1-Ms measurement would eliminate the 
uncertainties associated with the effects of booster vaccination. We 
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TABLE II- ANTI -HBs CONCENTRATIONS AT BOOSTER AND UP TO 
4 YEARS AFTERWARDS 




GMT (IU /I) 
vaccination mo) 
(mo 0) No at booster 1 17 25 37 49 
10-99 12 45 10 839 861 571 522 292 
100 -999 34 233 33 266 2972 1746 1330 925 
1000 -9999 7 2748 79 068 4316 3428 2799 2051 
Anubodr dechne .n sample taken later than 1 month post booste, rs independent of 
hue 1 month POSI booste, but ,5 inversely proportional to I.me (months) since 
booste. vaccination Only vacc.nee5 io, whom all 5 samples we,e avd.tdble to, 
anti HOs htiahon were included 
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Preliminary study indicated that two forms of Crohn's disease exist: 
tiçocortin- depleted, non -perforating type, and lipocortin- 
tnaintarned, perforating type. If these arc indeed different clinical 
fours of Crohn's disease several implications follow. Therapeutic 
trials for prophylaxis against postoperative recurrence should be 
targeted specifically to the high -risk population. The pathogenetic 
Pathway accounting for the observed clinical and pathological 
differences should be analysed with respect to the natural history of 
this disease. Olaison et al indicate one of the directions in which 
clinicians should go to gain further knowkdge about this complex 
disease- 
second Department of Surgery. 
Hy,ogo College of Medicine. 
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Efficacy of quinine -tetracycline for acute 
uncomplicated falciparum malaria in 
Thailand 
SIR,- Several studies in Thailand during 1972 -73 showed that 
the efficacy of short courses of quinine could be improved when 
tetracycline was also used." Quinine was given for 1 -3 days and 
tetracycline for 3-10 days. Although treatment with both drugs for 
3 days provided satisfactory cure rates until about 1980, since that 
time combined treatment with quinine and tetracycline for 7 days 
has become standard hospital treatment for adults in Thailand.' At 
the Bangkok Hospital for Tropical Diseases the cure rate of quinine 
plus tetracycline was 99-5% in 1981 -84' and 100% in 1987,s since 
when there have been no reports of these cure rates in Thailand. 
During 1990-91, the response to treatment with quinine and 
tetracycline was evaluated in 76 adults with acute uncomplicated 
falciparum malaria at that hospital. 
All patients had symptoms and the geometric mean asexual 
parasite count before treatment was 16 2681µ1 (range 
1020 -179 760). Each patient was treated orally with quinine 
sulphate 600 mg given every 8 h and tetracycline 250 mg every 6 h 
for 7 days. 70 patients were followed in hospital for 28 days. 6 
patients dropped out for reasons not related to drug administration. 
Within 48 h after treatment 85% of patients showed clinical 
improvement and malaria symptoms had subsided. The mean fever 
clearance time was 68 h. 
Parasite counts were done every 12 h during parasitaemia and 
then once daily for 28 days. After starting treatment, 24 patients had 
at least one parasite count higher than the initial count. The parasite 
clearance time was 89 h. 63 of 70 (90%) patients followed for 28 days 
in hospital were cured. 6 patients had recrudescences of their 
infections between 17 and 28 days after treatment (RI responses). 
These patients were successfully treated with either mefloquinc 
alone or sequential treatment with sodium artesunate (a derivative 
of artemisinin) and mefloquine. 1 patient remained parasitaemic 
after 7 days and was thought to have an RII response to treatment. 
This patient had parasitaemia of 24 900/111 before treatment, 470/µl 
oar day 7, and was negative on day 8 without further treatment 
However, he had a recrudescence of falciparum infection 46 days 
after treatment even though after discharge he remained in Bangkok 
What there is no malaria transmission. He was successfully treated 
with a sequential course of artesunate and mcfloquine. 
45 patients (59%) had nausea and 30 (39%) had vomiting (1-6 h 
after dosing) during the first 48 h of treatment; these symptoms 
usually coincided with peak in fever. All patients had symptoms of 
tind3onism that started on the second day and persisted throughout 
treatment. Parasitological response was compared between the 6 
Patients who had RI responses and the 63 patients who were cured. 
The initial parasite counts before treatment and fever clearance 
titres between the two groups was similar, but parasite clearance 
times of the patients whose infections subsequently recrudesced 
were significantly longer than those who were cured (120 h vs 86 h; 
369 
p = 0.01). Parasites from 8 patients were tested in vitro for quinine 
susceptibility with a microdilution radioisotope method.' The mean 
50% inhibitory concentration (IC,o) for pretreatment isolates 
successfully treated with quinine -tetracycline was 183.8 ng/ml 
(n = 5); although the mean ICw from RI failures was higher 
(233-2 ng/ml, n =3), the difference was not significant. 
These results indicate that a 7-day regimen of quinine and 
tetracycline is still satisfactory for multidnrg- resistant falciparum 
malaria in Thailand. However, a gradual increasing recrudescence 
rate and in vitro findings suggest that quinine-tetracycline is under 
increasing pressure and the failure rate may soon rise beyond 10 %. 
New drugs or drug combinations are urgently needed to combat the 
rising parasite resistance in Thailand and other areas of the world 
where resistance is increasing. 
Bangkok Hospital for Tropical Diseases. 
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Beclomethasone and osteocalcin 
SIR, -Wes have described previously (July 6, p 60) a substantial 
decrease in plasma osteocalcin (a marker of bone formation) in 
healthy volunteers after inhalation of beclomethasone 400 µg daily 
for 5 days. Peretz and Bourdoux (Nov 23, p 1340) subsequently 
reported their studies in which no change in osteocalcin was seen in 
10 volunteers given inhaled beclomethasone for a week (1000 pg 
daily). These researchers described our results as questionable. 
Perca and Bourdolix used a commercial radioimmunoassay for 
the measurement of scrum ostcocalcin ('INCSTAR', Stillwater, 
Minnesota, USA). We measured plasma ostcocalcin by an in -house 
radioimmunoassay with an antibody raised in rabbits against 
purified bovine ostcocalcin (reference range 2 -12 pg/l;interassay 
coefficient of variation 12%). Ostcocalcin was purified and the 
radioimmunosassay set up as Price and Nishimoto described.' 
Plasma osteocalcin concentrations can vary greatly depending upon 
the antibody used in the assay,' so it is not appropriate to compare 
changes in osteocalcin concentrations measured by different assays, 
as Peretz and Bourdoux have done. The more valid comparison is 
between beclomethasone treatment and placebo treatment with the 
same assay for the measurement of ostcocalcin. Our study design 
was randomised, placebo -controlled, double -blind cross -over 
(more rigorous than that of Peretz and Bourdoux), and all samples 
from a specific subject were run in the same batch. We were able to 
EFFECTS OF INCREASING DOSES OF INHALED 
BECLAMETHASONE DIPROPRIONATE ON PLASMA 
CONCENTRATIONS OF OSTEOCALCIN 
Daily dose (Ng) Baseline Day 5 Day 9 
Placebo 8-9 (2-7) 8-9 (3-4) 8 -0 (3'4) 
400 8.9(3.1) 7.8(2.9)' 7-2(3.1) 
800 9.4 (5) 7.4 (3.4)' 6-6 (2.9)' 
1400 9.6 (3.5) 6-2 (2.6)1 6-2 (2.9)' 
2000 9.1 (3-5) 6.4 (2.7)1 5 -0 (1.8)' 
Statistical comparison is against baseline value loi each dose Values ° mean (SD) 
(pg /1) - p<0.05 l'p<0001 t =p<0005 
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show a dose-dependent coot's ut leelumed)asone on plasma 
osteacalcin [nun .100 - 0lXt toe daily with no changes on the various 
placebo washout periods between. Support lior our data contes from 
Moruo and collrlgues'' observations, presented at the 1991 
American 'Mimic Association meeting, which showed that I(XX) pg 
of beclomethas one reduced circulating oste oalcin concentrations. 
It is always difficult to give all infirmation in a short letter, hut 
Pcretr-. and &urd ux sain to have missed our details of sampling 
conditions (fasting samples taken within 30 min of 0900 h). The 
table shows the absolute values for osteocalcin concentrations. In 
the figure in our previous publication osteoalcin at 0 dose of 
becloxncthauonc (placele>t was expressed as a change in ostcocalcin 
between days 5 or g and the pretreatment (or day 0) osteoalcin 
concentration- -this explains the different starting points. 
Controversy is valuable in scientific research, but we agree with 
Peretr and Buurdoux about the need for long -term clinical studies. 
Department of Mechc.oe 
Western General Hospital 
Ednburgh EH4 7XU Ux 
Fisons Pharmaceuticals 
Loughborough 
Department of C6nrcat Che.- .she 
Royal Inhrra.tv 
Ed.ntxugh 
PALI. L. PAt>rtt:Lt> 
SURUJI'.ü. TI:HLti(:KSINGH 
Kr.vIt, J. GouGH 
PHILIP HOLT 
L.\Il.:\ THU 
I. I'rae l':\. Ntshm°x. SI: RaJt.v.wnwt.ossay for the eitamin-K dependent protein of 
tone and ns disco. e.^,, m ;Jasnu I ̀ .t: X.ui :1:aJ Sal USA 1980; 77: 2234-38. 
? Power MJ. («,Jns Ir. l'.t1re8l'I' RaJ4.rnmW%.ueuv,xtY.tlttR'-ak VtN1d1pohlitnal 
artel nwn.d.rul.r.ti'o.lit r':rr.::nr. Io.s': tS: 14454-li 
1 Meerart K. Ilait.-r.ie. A. iturn: I. Suter I(. IFhcrts.n K. Oral and inhaled 
anre.sstcn.r.b ,v(yre..:.,te formation z1.« R.c Hnpir Ih'. I991: 143: A62i. 
Bone -density measurement 
StR, -The first issue of l:lJ:ctige Health Care, a bulletin 
sponsored by the UK Department of Health, is on population - 
based bone screening (Jan 18, p 174). This publication raises several 
issues of concern to clinicians. The report, from the School of Public 
Health in Leeds, looked for published evidence in support of 
population screening to prevent fractures in elderly women. The 
conclusion that screening is not justified at present seems non - 
controversial- indeed the consensus is such that we wonder why 
and by whom the studs was commissioned. The Leeds group 
claims that UK health authorities arc under pressure to introduce 
population -based screening, but we know of no group, lay or 
professional , that is trying to do this. Unfortunately, coverage of this 
repon in the by and medical press has suggested that bone- density 
measurement itself is not worthwhile but the report did not purport 
to examine the non -screening, clinical use of bone densitometry. 
Some of the controversy raised by Effective Health Care is due to 
inappropriate terminology. "Population -based screening" is clear 
but the use of "screening" when referring to opportunistic 
measurement of hone mineral density (BtMD) is more difficult. 
National Health Service hospitals that have HMD equipment are in 
a position to respond to doctors who ask for this investigation for 
their patients. .Ile clinical indications for this have been published 
in the USA,' and an equivalent document for the UK would be 
welcome. The repon concludes that there have been no scientific 
trials to assess population screening, but does not mention trials in 
Hull and in Aberdeen that began in 1990. Had the authors of the 
report contacted these two centres they would not have stated that 
the uptake of screening will be low, since in Hull and in Aberdeen 
uptake is 75% or more. 
Thc report relics heavily on "grey literature" not published in 
referred journals, and it is disturbing that the final (and correct) 
conclusion that population screening is presently unwarranted 
should have been misinterpreted by some commentators as calling 
into question the value of BMD measurement. Four large 
prospective, epidemiological studies show that a low BMD predicts 
fracture risk' r- indeed it is a stronger risk factor for future fracture 
than is hypertension for fatal stroke in the elderly° or cholesterol for 
ischacmic hear disease.' BMD is not the only risk factor for 
fractures associated with osteoporosis, but it is a very important 
factor and one that can be measured rapidly and precisely. BMD 
merits further examination in prospective trials to establish its plat, 
in the screening for, and prevention of, osteoporosis. 
"Effective health care- means sound clinical practice backed -up 
by sound clinical trials. As a publication Effective Health Care ought 
therefore to provide a comprehensive, non -selective review ut 
published work and research in progress. Health authorities, in their 
purchasing role, could do with guidance on the value of BMD 
measurement in clinical practice, as opposed to screening, but the 
first issue of Effective Health Car: does not provide it. 
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StR, -We would like to express our concerns, and those of the 
British Menopause Society Council, about Effective Health Cares 
repon on screening for osteoporosis.' This bulletin, commissioned 
by the UK Department of Health, has been distributed to 
purchasing managers within the National Health Service, who will 
no doubt regard it as official. Many will conclude that bone 
densitometry is of or value 
osteoporosis. This is incorrect, and the view that screening is of little 
value can also be challenged. 
The report makes the same mistake as Law, Wald, and Meade 
did, in a paper on which it draws heavily).- namely, the overlap in 
bone density between women with and without fracture is relatively 
small, and thus measurement is of no use. A woman with low bone 
mineral density (BMD) who is fracture -free at the time of 
assessment replosents a false positive. Such a woman who has 
escaped a fracture over, for example, a 5 -year period but will have a 
fracture during the next 5 years cannot realistically be considered as 
a false positive. Similar overlaps exist for blood pressure in those 
who have or have not had a stroke. Does that mean 
we should abandon blood- pressure measurement? The conclusion 
that the specificity and sensitivity of BMD measurement are low is 
flawed because their figures refer to hip fracture and not to other 
baseline A B 
Bone mineral content in distal radius (BMC) expressed as % 
initial value. 
N = 242 healthy postmenopausal women al baseline. followed for 1 2 
years. Group A (n = 68) received a mean 5.4 years HRT followed by no 
treatment Group B In = 1 77) received no treatment Values as mean 
(SE) p <0001 
